[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2149
1. Sun B, Li S, Yang L, Damodaran T, Desai D, Diehl AM, Alzate O, Koeberl DD: Activation of glycolysis and apoptosis in glycogen storage disease type Ia. Mol Genet Metab; 2009 Aug;97(4):267-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of glycolysis and apoptosis in glycogen storage disease type Ia.
  • The deficiency of glucose-6-phosphatase (G6Pase) underlies glycogen storage disease type Ia (GSD-Ia, von Gierke disease; MIM 232200), an autosomal recessive disorder of metabolism associated with life-threatening hypoglycemia, growth retardation, renal failure, hepatic adenomas, and hepatocellular carcinoma.
  • Liver involvement includes the massive accumulation of glycogen and lipids due to accumulated glucose-6-phosphate and glycolytic intermediates.
  • Proteomic analysis revealed elevations in glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and other enzymes involved in glycolysis.
  • The moonlighting role of GAPDH includes increasing apoptosis, which was demonstrated by increased TUNEL assay positivity and caspase 3 activation in the murine GSD-Ia liver.
  • These analyses of hepatic involvement in GSD-Ia mice have implicated the induction of apoptosis in the pathobiology of GSD-Ia.
  • [MeSH-major] Apoptosis / genetics. Glycogen Storage Disease Type I / physiopathology. Glycolysis / genetics
  • [MeSH-minor] Animals. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Liver / pathology. Mice

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19419892.001).
  • [ISSN] 1096-7206
  • [Journal-full-title] Molecular genetics and metabolism
  • [ISO-abbreviation] Mol. Genet. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


2. Shibata H, Yamakoshi H, Sato A, Ohori H, Kakudo Y, Kudo C, Takahashi Y, Watanabe M, Takano H, Ishioka C, Noda T, Iwabuchi Y: Newly synthesized curcumin analog has improved potential to prevent colorectal carcinogenesis in vivo. Cancer Sci; 2009 May;100(5):956-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • No adverse reactions were observed, judging from body weight or biochemical data concerning liver and renal damage.
  • It was demonstrated that the number of beta-catenin-positive adenoma cells in Apc(580D/+) mice fed GO-Y030 was reduced.
  • [MeSH-major] Benzene Derivatives / chemical synthesis. Benzene Derivatives / pharmacology. Cell Transformation, Neoplastic / pathology. Colorectal Neoplasms / pathology. Colorectal Neoplasms / prevention & control. Curcumin / chemical synthesis. Curcumin / pharmacology. Ketones / chemical synthesis. Ketones / pharmacology
  • [MeSH-minor] Adenoma / metabolism. Adenoma / pathology. Animals. Disease Models, Animal. Genetic Predisposition to Disease. Mice. Molecular Structure. Survival Rate. beta Catenin / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19445025.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1,5-bis(3,5-bis(methoxymethoxy)phenyl)penta-1,4-dien-3-one; 0 / Benzene Derivatives; 0 / Ketones; 0 / beta Catenin; IT942ZTH98 / Curcumin
  •  go-up   go-down


3. Abdel-Hamid MK, Abdel-Hafez AA, El-Koussi NA, Mahfouz NM, Innocenti A, Supuran CT: Design, synthesis, and docking studies of new 1,3,4-thiadiazole-2-thione derivatives with carbonic anhydrase inhibitory activity. Bioorg Med Chem; 2007 Nov 15;15(22):6975-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A new series of 1,3,4-thiadiazole-2-thione derivatives have been prepared and assayed for the inhibition of three physiologically relevant carbonic anhydrase (CA, EC 4.2.1.1) isozymes, the cytosolic human isozymes I and II, and the transmembrane, tumor-associated hCA IX.
  • Against hCA I the investigated thiones, showed inhibition constants in the range of 2.55-222 microM, against hCA II in the range of 2.0-433 microM, and against hCA IX in the range of 1.25-148 microM.
  • Compound 5c, 4-(4,5-dihydro-5-thioxo-1,3,4-thiadiazol-2-yl)-1-(5-nitro-2-oxoindolin-3-ylidene)semicarbazide showed interesting inhibition of the tumor-associated hCA IX with K(I) value of 1.25 microM, being the first non-sulfonamide type inhibitor of such activity.

  • BindingDB. BindingDB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17822907.001).
  • [ISSN] 0968-0896
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 1,3,4-thiadiazole-2-thione; 0 / Carbonic Anhydrase Inhibitors; 0 / Ligands; 0 / Thiadiazoles; 0 / Thiones; EC 4.2.1.- / Carbonic Anhydrase I; EC 4.2.1.- / Carbonic Anhydrase II; EC 4.2.1.- / Carbonic Anhydrase IV
  •  go-up   go-down


Advertisement
4. Fisher SZ, Tu C, Bhatt D, Govindasamy L, Agbandje-McKenna M, McKenna R, Silverman DN: Speeding up proton transfer in a fast enzyme: kinetic and crystallographic studies on the effect of hydrophobic amino acid substitutions in the active site of human carbonic anhydrase II. Biochemistry; 2007 Mar 27;46(12):3803-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Catalysis of the hydration of CO2 by human carbonic anhydrase isozyme II (HCA II) is sustained at a maximal catalytic turnover of 1 mus-1 by proton transfer between a zinc-bound solvent and bulk solution.
  • Correlating these structural variants with kinetic studies suggests that the very efficient proton transfer (approximately 7 micros-1) observed for Y7F HCA II in the dehydration direction, compared with the wild type and other mutants of this study, is due to a combination of three features.
  • Second, in the structure of Y7F HCA II, there is an unbranched chain of hydrogen-bonded waters linking the proton donor His64 and acceptor zinc-bound hydroxide.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • Hazardous Substances Data Bank. Water .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17330962.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM25154
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; 059QF0KO0R / Water; 142M471B3J / Carbon Dioxide; 4QD397987E / Histidine; EC 4.2.1.- / Carbonic Anhydrase II
  •  go-up   go-down


5. Hoban V: HCAs in nursing: what role should they play? Nurs Times; 2008 May 20-26;104(20):18-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCAs in nursing: what role should they play?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18546986.001).
  • [ISSN] 0954-7762
  • [Journal-full-title] Nursing times
  • [ISO-abbreviation] Nurs Times
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


6. Ali K, Lu Y, Christensen C, May T, Hyett C, Griebel R, Fourney D, Meguro K, Resch L, Sharma RK: Fourier transform infrared spectromicroscopy and hierarchical cluster analysis of human meningiomas. Int J Mol Med; 2008 Mar;21(3):297-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fourier transform infrared spectromicroscopy and hierarchical cluster analysis of human meningiomas.
  • Limitations of conventional light microscopy in pathological diagnosis of brain tumors include subjective bias in interpretation and discordance of nomenclature.
  • Spectral datasets were subjected to hierarchical cluster analyses (HCA) using Ward's algorithm for comparison and grouping of similar data groups, and were converted into color-coded digital maps for matching spectra with their respective clusters.
  • False color images of 5 and 6 clusters obtained by HCA identified dominant clusters corresponding to tumor tissue.
  • [MeSH-major] Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / pathology. Meningioma / diagnosis. Meningioma / pathology
  • [MeSH-minor] Aged. Cluster Analysis. Female. Humans. Male. Middle Aged. Spectroscopy, Fourier Transform Infrared

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18288376.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


7. Guo W, He MC, Yang ZF, Lin CY, Quan XC: Occurrence of aliphatic hydrocarbons in water, suspended particulate matter and sediments of Daliao River system, China. Bull Environ Contam Toxicol; 2010 May;84(5):519-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hierarchical cluster analysis (HCA) of aliphatic hydrocarbons is correspondence with hydrocarbons indexes results.
  • [MeSH-major] Air Pollutants / analysis. Alkanes / analysis. Geologic Sediments / chemistry. Industrial Waste / analysis. Particulate Matter / analysis. Rivers / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20411239.001).
  • [ISSN] 1432-0800
  • [Journal-full-title] Bulletin of environmental contamination and toxicology
  • [ISO-abbreviation] Bull Environ Contam Toxicol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Air Pollutants; 0 / Alkanes; 0 / Industrial Waste; 0 / Particulate Matter
  •  go-up   go-down


8. Saito M, Ueno M, Ogino S, Kubo K, Nagata J, Takeuchi M: High dose of Garcinia cambogia is effective in suppressing fat accumulation in developing male Zucker obese rats, but highly toxic to the testis. Food Chem Toxicol; 2005 Mar;43(3):411-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We investigated the ability of Garcinia cambogia extract containing (-)-hydroxycitric acid (HCA) to suppress body fat accumulation in developing male Zucker obese (fa/fa) rats.
  • Diets containing different levels of HCA (0, 10, 51, 102 and 154 mmol/kg diet) were fed to 6-week-old rats for 92 or 93 days.
  • Each diet group was pair-fed to the 154 mmol HCA/kg diet group.
  • The highest dose of HCA-containing Garcinia cambogia (154 mmol HCA/kg diet) showed significant suppression of epididymal fat accumulation in developing male Zucker obese rats, compared with the other groups.
  • However, the diets containing 102 mmol HCA/kg diet and higher (778 and 1244 mg HCA/kg BW/d, respectively) caused potent testicular atrophy and toxicity, whereas diets containing 51 mmol HCA/kg diet (389 mg HCA/kg BW/d) or less did not.
  • Accordingly, 51 mmol HCA/kg diet (389 mg HCA/kg BW/d) was deemed to be the no observed adverse effect level (NOAEL).
  • [MeSH-minor] ATP Citrate (pro-S)-Lyase / metabolism. Animals. Anti-Obesity Agents / toxicity. Dose-Response Relationship, Drug. Leptin / blood. Liver / drug effects. Liver / enzymology. Liver / metabolism. Male. No-Observed-Adverse-Effect Level. Organ Size / drug effects. Random Allocation. Rats. Rats, Zucker. Testosterone / blood

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Food Chem Toxicol. 2005 Nov;43(11):1683-4; author reply 1685-6 [15993998.001]
  • (PMID = 15680676.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Obesity Agents; 0 / Citrates; 0 / Leptin; 0 / Plant Extracts; 3XMK78S47O / Testosterone; 8W94T9026R / hydroxycitric acid; EC 2.3.3.8 / ATP Citrate (pro-S)-Lyase
  •  go-up   go-down


9. Kühnel D, Taugner F, Scholtka B, Steinberg P: Inflammation does not precede or accompany the induction of preneoplastic lesions in the colon of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-fed rats. Arch Toxicol; 2009 Aug;83(8):763-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Heterocyclic aromatic amines (HCAs) are formed in meat cooked at high temperatures for a long time or over an open flame.
  • In this context 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP), the most abundant HCA in cooked meat, has been suggested to be involved in colon and prostate carcinogenesis.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212758.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / 2-amino-1-methyl-6-phenyl-1H-imidazo(4,5-b)pyridine; 0 / Aminopyridines; 0 / Carcinogens; 0 / Imidazoles
  •  go-up   go-down


10. Girard H, Butler LM, Villeneuve L, Millikan RC, Sinha R, Sandler RS, Guillemette C: UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans. Mutat Res; 2008 Sep 26;644(1-2):56-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Glucuronidation by the UDP-glucuronosyltransferase enzymes (UGTs) is one of the primary detoxification pathways of dietary heterocyclic amines (HCAs) and polycyclic aromatic hydrocarbons (PAHs).
  • In a population-based case-control study of 537 cases and 866 controls, we investigated whether colon cancer was associated with genetic variations in UGT1A1 and UGT1A9 genes and we determined if those variations modify the association between colon cancer and dietary HCA and PAH exposure.
  • This finding is also supported by haplotype analyses where the UGT1A1-3279G-allele-bearing haplotype is overrepresented in case group.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1994 May 12;369(6476):154-6 [7909916.001]
  • [Cites] Carcinogenesis. 1994 Aug;15(8):1711-6 [8055653.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6154-9 [7954461.001]
  • [Cites] Cancer Res. 1995 Feb 1;55(3):525-9 [7834621.001]
  • [Cites] Breast Cancer Res Treat. 1995 Jul;35(1):61-4 [7612905.001]
  • [Cites] N Engl J Med. 1995 Nov 2;333(18):1171-5 [7565971.001]
  • [Cites] Epidemiology. 1995 Jul;6(4):455-7 [7548362.001]
  • [Cites] Mol Biol Evol. 1995 Sep;12(5):921-7 [7476138.001]
  • [Cites] Mutat Res. 1997 May 12;376(1-2):195-202 [9202756.001]
  • [Cites] Biochim Biophys Acta. 1998 Jul 1;1407(1):40-50 [9639672.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2407-15 [15319294.001]
  • [Cites] Oncol Rep. 2005 Feb;13(2):185-91 [15643497.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):457-60 [15770010.001]
  • [Cites] Pharmacogenet Genomics. 2005 May;15(5):295-301 [15864130.001]
  • [Cites] World J Gastroenterol. 2005 Jun 7;11(21):3250-4 [15929176.001]
  • [Cites] Chem Res Toxicol. 2004 Aug;17(8):1137-44 [15310245.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1629-37 [15090468.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Am J Epidemiol. 1986 Sep;124(3):453-69 [3740045.001]
  • [Cites] Environ Health Perspect. 1986 Aug;67:17-24 [3757953.001]
  • [Cites] Environ Health Perspect. 1986 Aug;67:5-10 [3530738.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3367-76 [2334931.001]
  • [Cites] Mutat Res. 1991 Mar-Apr;259(3-4):251-61 [2017211.001]
  • [Cites] Am J Epidemiol. 1991 Aug 15;134(4):421-32 [1877602.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Jun 30;185(3):839-44 [1627140.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1626-32 [16030093.001]
  • [Cites] Hepatology. 2005 Aug;42(2):448-57 [15986396.001]
  • [Cites] Pharmacogenet Genomics. 2005 Oct;15(10):713-21 [16141797.001]
  • [Cites] Carcinogenesis. 2005 Nov;26(11):2019-28 [15944213.001]
  • [Cites] Drug Metab Dispos. 2006 Jun;34(6):943-9 [16510539.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Jun;21(6):1036-41 [16724991.001]
  • [Cites] Hum Mutat. 2006 Jul;27(7):717 [16786511.001]
  • [Cites] Clin Pharmacol Ther. 2007 Mar;81(3):392-400 [17339869.001]
  • [Cites] Mutat Res. 2008 Feb 1;638(1-2):162-74 [18022202.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):950-6 [10706110.001]
  • [Cites] Pharm Res. 2000 Jan;17(1):21-6 [10714603.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6921-6 [11156391.001]
  • [Cites] Food Chem Toxicol. 2001 May;39(5):423-36 [11313108.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):439-46 [11352852.001]
  • [Cites] Carcinogenesis. 2001 Jun;22(6):943-50 [11375903.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):1978-86 [11929814.001]
  • [Cites] Drug Metab Rev. 2002 Aug;34(3):625-50 [12214671.001]
  • [Cites] Mutat Res. 2002 Sep 30;506-507:197-204 [12351159.001]
  • [Cites] Pharmacogenetics. 2002 Dec;12(9):725-33 [12464801.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1611-21 [12496052.001]
  • [Cites] Am J Epidemiol. 2003 Mar 1;157(5):434-45 [12615608.001]
  • [Cites] Genet Epidemiol. 2003 Sep;25(2):115-21 [12916020.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Aug;12(8):747-54 [12917206.001]
  • [Cites] Am J Epidemiol. 2003 Nov 15;158(10):951-62 [14607803.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jan;13(1):102-9 [14744740.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1382-8 [15007088.001]
  • [Cites] Environ Mol Mutagen. 2004;44(1):44-55 [15199546.001]
  • [Cites] Pharmacogenetics. 2004 Aug;14(8):501-15 [15284532.001]
  • (PMID = 18675828.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / P30 DK034987; United States / NCI NIH HHS / CA / R01 CA66635; United States / NCI NIH HHS / CA / R01 CA066635; United States / NICHD NIH HHS / HD / K12 HD051958; United States / NIDDK NIH HHS / DK / P30 DK034987-23; United States / NICHD NIH HHS / HD / 5K12HD051958; United States / NCI NIH HHS / CA / R01 CA066635-09; United States / NIDDK NIH HHS / DK / P30 DK34987
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Heterocyclic Compounds; 0 / Polycyclic Hydrocarbons, Aromatic; EC 2.4.1.- / UGT1A1 enzyme; EC 2.4.1.17 / Glucuronosyltransferase; EC 2.4.1.17 / UDP-glucuronosyltransferase 1A9
  • [Other-IDs] NLM/ NIHMS66700; NLM/ PMC2570038
  •  go-up   go-down


11. Sandulescu L, Saftoiu A, Dumitrescu D, Ciurea T: Real-time contrast-enhanced and real-time virtual sonography in the assessment of benign liver lesions. J Gastrointestin Liver Dis; 2008 Dec;17(4):475-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Real-time contrast-enhanced and real-time virtual sonography in the assessment of benign liver lesions.
  • The introduction of second-generation contrast agents and the development of contrast specific techniques have opened new prospects in the detection and characterization of liver lesions.
  • New hybrid imaging techniques that combine in real-time transabdominal ultrasound with other cross-sectional imaging techniques (CT or MR) might add even more valuable information in the cases with focal lesions.
  • The aim of this review is to describe the role of real-time contrast-enhanced and real-time virtual sonography in the assessment of benign liver lesions.
  • [MeSH-major] Liver Diseases / ultrasonography. Ultrasonography / methods
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Contrast Media. Focal Nodular Hyperplasia / diagnosis. Hemangioma / diagnosis. Humans. Image Processing, Computer-Assisted / methods. Liver Neoplasms / diagnosis. Magnetic Resonance Imaging / methods. Practice Guidelines as Topic. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19104714.001).
  • [ISSN] 1841-8724
  • [Journal-full-title] Journal of gastrointestinal and liver diseases : JGLD
  • [ISO-abbreviation] J Gastrointestin Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 15
  •  go-up   go-down


12. Bitencourt Fda S, Figueiredo JG, Mota MR, Bezerra CC, Silvestre PP, Vale MR, Nascimento KS, Sampaio AH, Nagano CS, Saker-Sampaio S, Farias WR, Cavada BS, Assreuy AM, de Alencar NM: Antinociceptive and anti-inflammatory effects of a mucin-binding agglutinin isolated from the red marine alga Hypnea cervicornis. Naunyn Schmiedebergs Arch Pharmacol; 2008 Apr;377(2):139-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antinociceptive and anti-inflammatory effects of a mucin-binding agglutinin isolated from the red marine alga Hypnea cervicornis.
  • The agglutinin from the red marine alga Hypnea cervicornis (HCA) was tested in models of nociception and inflammation.
  • HCA (10(-1), 1, and 10 mg/kg) administered i.v. to mice inhibited writhes induced by acetic acid and, at 10 mg/kg, inhibited the second phase of the formalin test, but did not alter the response latency in the hot-plate test.
  • HCA (1 mg/kg) administered i.v. to rats reduced carrageenan-induced paw edema at 1, 2, and 3 h after challenge, but not edema induced by dextran.
  • The neutrophil migration induced by both N-formyl-methionyl-leucyl-phenylalanine (fMLP) and carrageenan was inhibited by HCA at 10(-1), 1, and 10 mg/kg.
  • The combination of HCA (1 mg/kg) and its ligand mucin reversed the lectin inhibitory effect on carrageenan-induced neutrophil migration and acetic acid-induced writhes.
  • The i.v. treatment of rats with HCA (1 mg/kg) for 7 days did not affect body mass; liver, kidney or heart wet weight; blood leukocyte counts; urea, creatinine or serum transaminase activity; or macroscopy of the organs examined.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Protein Pept Lett. 2004 Apr;11(2):195-200 [15078209.001]
  • [Cites] Pain. 1989 Sep;38(3):347-52 [2478947.001]
  • [Cites] Br J Pharmacol. 1999 Feb;126(3):537-50 [10188959.001]
  • [Cites] Science. 1984 Aug 17;225(4663):743-5 [6087456.001]
  • [Cites] Fitoterapia. 2001 Feb;72(2):131-9 [11223222.001]
  • [Cites] Biochem Cell Biol. 2006 Feb;84(1):49-54 [16462889.001]
  • [Cites] Immunol Rev. 2002 Aug;186:8-18 [12234358.001]
  • [Cites] J Pharm Pharmacol. 2005 Mar;57(3):375-81 [15807994.001]
  • [Cites] Int Arch Allergy Immunol. 1997 Jan;112(1):27-35 [8980461.001]
  • [Cites] Int Immunopharmacol. 2007 Jun;7(6):824-35 [17466916.001]
  • [Cites] Prog Neurobiol. 2001 Jul;64(4):327-63 [11275357.001]
  • [Cites] FASEB J. 1995 Jul;9(10):866-73 [7542213.001]
  • [Cites] Gut. 1994 Jul;35(7):909-15 [8063218.001]
  • [Cites] Neuropharmacology. 1985 Aug;24(8):729-34 [3841806.001]
  • [Cites] Anesth Analg. 2001 Jul;93(1):197-203 [11429365.001]
  • [Cites] Agents Actions. 1988 Jul;24(3-4):377-80 [3051931.001]
  • [Cites] Biochem Cell Biol. 2005 Oct;83(5):659-66 [16234855.001]
  • [Cites] Br J Pharmacol. 1995 Mar;114(5):1069-75 [7780642.001]
  • [Cites] J Pharm Pharmacol. 1979 Sep;31(9):648 [41077.001]
  • [Cites] Brain Res. 1998 Mar 16;787(1):161-4 [9518591.001]
  • [Cites] J Ethnopharmacol. 2001 Dec;78(2-3):151-7 [11694360.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1990 Apr;38(4):1045-8 [2379278.001]
  • [Cites] Br J Pharmacol. 1995 Feb;114(3):578-83 [7537590.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1755-60 [15665080.001]
  • [Cites] Glycoconj J. 1995 Feb;12(1):1-6 [7795408.001]
  • [Cites] J Agric Food Chem. 2002 Jun 19;50(13):3862-6 [12059172.001]
  • [Cites] Pain. 1992 Oct;51(1):5-17 [1454405.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2006 Oct;374(1):1-10 [16957941.001]
  • [Cites] Plant Physiol. 1995 Oct;109(2):347-52 [7480335.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Aug;310(2):710-7 [15075358.001]
  • [Cites] Pak J Pharm Sci. 1993 Jan;6(1):45-51 [16414726.001]
  • [Cites] Braz J Med Biol Res. 2007 Jan;40(1):127-34 [17225005.001]
  • [Cites] J Pharm Pharmacol. 2005 Jul;57(7):919-22 [15969953.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 1;350(4):1050-5 [17045568.001]
  • [Cites] Agents Actions. 1993 Jan;38(1-2):48-54 [8480538.001]
  • [Cites] Braz J Med Biol Res. 2004 Jul;37(7):1071-9 [15264015.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 2007 Jan;374(4):275-82 [17171556.001]
  • [Cites] Mediators Inflamm. 1999;8(2):107-13 [10704148.001]
  • [Cites] Inflamm Res. 2001 Oct;50(10):486-90 [11713900.001]
  • [Cites] J Ethnopharmacol. 1996 Sep;53(3):175-8 [8887026.001]
  • [Cites] Mediators Inflamm. 1997;6(3):201-10 [18472821.001]
  • [Cites] Life Sci. 2001 Nov 2;69(24):2911-9 [11720094.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Dec;35(12):1674-81 [12962707.001]
  • [Cites] J Pharmacol Exp Ther. 1982 Apr;221(1):261-7 [6174730.001]
  • [Cites] Agents Actions. 1985 Oct;17(1):97-103 [4083185.001]
  • [Cites] Protein Sci. 2005 Aug;14(8):2167-76 [16046632.001]
  • [Cites] Br J Pharmacol. 2006 Sep;149(1):14-22 [16865092.001]
  • [Cites] J Pharmacol Exp Ther. 1953 Mar;107(3):385-93 [13035677.001]
  • [Cites] J Urol. 1999 Jun;161(6):1988-93 [10332487.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1805-14 [15914076.001]
  • [Cites] Neuropeptides. 1997 Aug;31(4):381-9 [9308027.001]
  • [Cites] Phytother Res. 2001 May;15(3):224-30 [11351357.001]
  • [Cites] Eur J Pharmacol. 2000 Jan 3;387(1):111-8 [10633169.001]
  • [Cites] Braz J Med Biol Res. 2002 Jun;35(6):713-22 [12045837.001]
  • [Cites] Br J Pharmacol. 1996 Feb;117(3):552-558 [8821548.001]
  • (PMID = 18270688.001).
  • [ISSN] 0028-1298
  • [Journal-full-title] Naunyn-Schmiedeberg's archives of pharmacology
  • [ISO-abbreviation] Naunyn Schmiedebergs Arch. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Agglutinins; 0 / Analgesics; 0 / Anti-Inflammatory Agents; 0 / Lectins; 0 / Mucins
  •  go-up   go-down


13. Galloro V: HCA scores on bond market. First-quarter earnings expected to top $600 million. Mod Healthc; 2009 Apr 20;39(16):12-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA scores on bond market. First-quarter earnings expected to top $600 million.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19422133.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


14. Heppner CW, Schlatter JR: Data requirements for risk assessment of furan in food. Food Addit Contam; 2007;24 Suppl 1:114-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furan is carcinogenic in rats and mice, showing a dose-dependent increase in hepatocellular adenomas and carcinomas.
  • In rats, a dose-dependent increase of mononuclear leukaemia is evident and a very high incidence of cholangiocarcinomas of the liver, even at the lowest dose tested.
  • However, chronic toxicity with secondary cell proliferation may indirectly amplify the tumour response.
  • The European Food Safety Authority's (EFSA) Scientific Panel on Contaminants in the Food Chain (CONTAM) recommended these studies as part of a reliable risk assessment of furan in food.
  • [MeSH-major] Carcinogens, Environmental / analysis. Food Contamination / analysis. Furans / analysis
  • [MeSH-minor] Animals. DNA / drug effects. DNA / genetics. Food Analysis / methods. Gas Chromatography-Mass Spectrometry / methods. Humans. Mice. Mutagenesis / drug effects. Neoplasms, Experimental / chemically induced. Proto-Oncogenes / drug effects. Proto-Oncogenes / genetics. Rats. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Foodborne Illness.
  • Hazardous Substances Data Bank. Furan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17687705.001).
  • [ISSN] 0265-203X
  • [Journal-full-title] Food additives and contaminants
  • [ISO-abbreviation] Food Addit Contam
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens, Environmental; 0 / Furans; 9007-49-2 / DNA; UC0XV6A8N9 / furan
  • [Number-of-references] 34
  •  go-up   go-down


15. Feuerlein S, Pauls S, Juchems MS, Stuber T, Hoffmann MH, Brambs HJ, Ernst AS: Pitfalls in abdominal diffusion-weighted imaging: how predictive is restricted water diffusion for malignancy. AJR Am J Roentgenol; 2009 Oct;193(4):1070-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of our retrospective study was to investigate the specificity of restricted diffusion in differentiation of benign from malignant abdominal disease.
  • Lesions were detected by two blinded readers using only the images with a b value of 1,000 s/mm(2), and representative apparent diffusion coefficients were measured.
  • The 12 benign lesions were liver hemangioma, liver adenoma, autoimmune pancreatitis, pancreatic teratoma, two abscesses, three cases of inflammatory bowel wall thickening due to Crohn's disease, Bartholin cyst, hemorrhagic ovarian cyst, and renal Rosai-Dorfman disease.
  • However, in interpretation of diffusion-weighted images, it should be kept in mind that a number of benign lesions, as many as 22% in our cohort, can exhibit restricted diffusion on images with high b values, thus mimicking malignant lesions.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Artifacts. Diffusion Magnetic Resonance Imaging / methods

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19770331.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Nishimura-Sakurai Y, Sakamoto N, Mogushi K, Nagaie S, Nakagawa M, Itsui Y, Tasaka-Fujita M, Onuki-Karakama Y, Suda G, Mishima K, Yamamoto M, Ueyama M, Funaoka Y, Watanabe T, Azuma S, Sekine-Osajima Y, Kakinuma S, Tsuchiya K, Enomoto N, Tanaka H, Watanabe M: Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells. J Gastroenterol; 2010 May;45(5):523-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of HCV-associated gene expression and cell signaling pathways in cells with or without HCV replicon and in replicon-cured cells.
  • Here, we screened host genes and molecular pathways that are involved in HCV replication by comprehensive analyses using two genotypes of HCV replicon-expressing cells, their cured cells and naïve Huh7 cells.
  • METHODS: Huh7 cell lines that stably expressed HCV genotype 1b or 2a replicon were used.
  • The cured cells were established by treating HCV replicon cells with interferon-alpha.
  • RESULTS: Hierarchical clustering analysis showed that the gene-expression profiles of each cell group constituted clear clusters of naïve, HCV replicon-expressed, and cured cell lines.
  • The pathway process analysis between the replicon-expressing and the cured cell lines identified significantly altered pathways, including MAPK, steroid biosynthesis and TGF-beta signaling pathways, suggesting that these pathways were affected directly by HCV replication.
  • Comparison of cured and naïve Huh7 cells identified pathways, including steroid biosynthesis and sphingolipid metabolism, suggesting that these pathways were required for efficient HCV replication.
  • Cytoplasmic lipid droplets were obviously increased in replicon-expressing and cured cells as compared to naïve cells.
  • CONCLUSION: Comprehensive gene expression and pathway analyses show that lipid biosynthesis pathways are crucial to support proficient virus replication.
  • [MeSH-minor] Cell Culture Techniques. Cell Line. Cluster Analysis. Gene Expression Profiling. Humans. Lipid Metabolism / physiology. Oligonucleotide Array Sequence Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Mol Biol. 2007 May 22;8:38 [17519006.001]
  • [Cites] Mol Pharmacol. 2008 Oct;74(4):952-63 [18599600.001]
  • [Cites] J Gastroenterol. 2006 Aug;41(8):750-7 [16988763.001]
  • [Cites] Hepatology. 2008 Nov;48(5):1396-403 [18830996.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 28;318(2):514-9 [15120631.001]
  • [Cites] Ann Intern Med. 2004 Mar 2;140(5):346-55 [14996676.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2986-91 [15710892.001]
  • [Cites] J Viral Hepat. 2006 Oct;13(10):690-700 [16970601.001]
  • [Cites] DNA Cell Biol. 2000 Feb;19(2):113-20 [10701777.001]
  • [Cites] Virology. 2005 Jan 20;331(2):407-17 [15629783.001]
  • [Cites] Virology. 2008 Feb 5;371(1):71-85 [17949770.001]
  • [Cites] J Virol. 2004 Feb;78(3):1513-24 [14722306.001]
  • [Cites] J Gastroenterol. 2009;44(7):643-9 [19455277.001]
  • [Cites] Cell Host Microbe. 2009 Mar 19;5(3):298-307 [19286138.001]
  • [Cites] Science. 1999 Jul 2;285(5424):110-3 [10390360.001]
  • [Cites] Virology. 2002 Feb 1;293(1):31-43 [11853397.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):311-20 [17241881.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 1;357(2):467-73 [17433261.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D480-4 [18077471.001]
  • [Cites] Virology. 2005 May 10;335(2):264-75 [15840525.001]
  • [Cites] Nat Chem Biol. 2005 Nov;1(6):333-7 [16408072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jun 28;102(26):9294-9 [15939869.001]
  • [Cites] EMBO J. 2006 Oct 18;25(20):5015-25 [17024179.001]
  • [Cites] J Clin Invest. 1999 Jun;103(11):1489-98 [10359558.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 2;313(1):42-7 [14672695.001]
  • [Cites] EMBO Rep. 2003 Jun;4(6):602-8 [12740604.001]
  • [Cites] FEBS Lett. 2009 Sep 3;583(17 ):2720-6 [19631645.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1808-17 [14724833.001]
  • [Cites] J Virol. 2003 May;77(9):5487-92 [12692249.001]
  • [Cites] Virus Res. 2005 Jan;107(1):73-81 [15567036.001]
  • [Cites] J Infect Dis. 2004 Apr 1;189(7):1129-39 [15031779.001]
  • [Cites] J Infect Dis. 2008 Feb 1;197(3):361-70 [18248300.001]
  • [Cites] Hepatology. 1997 Sep;26(3 Suppl 1):62S-65S [9305666.001]
  • [Cites] FEBS Lett. 2006 Aug 7;580(18):4392-400 [16844119.001]
  • [Cites] J Gen Virol. 2001 May;82(Pt 5):1027-41 [11297677.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] J Virol. 2001 Sep;75(18):8516-23 [11507197.001]
  • [Cites] J Biol Chem. 1998 Nov 6;273(45):29577-85 [9792666.001]
  • [Cites] Nat Med. 2005 Jul;11(7):791-6 [15951748.001]
  • [Cites] J Virol. 2002 Aug;76(15):7453-9 [12097557.001]
  • [Cites] Hepatology. 2006 Jul;44(1):117-25 [16799963.001]
  • [Cites] BMC Genomics. 2008 Jun 30;9:309 [18590516.001]
  • [Cites] Am J Gastroenterol. 2008 Jun;103(6):1383-9 [18410471.001]
  • [Cites] Gastroenterology. 2005 Sep;129(3):1031-41 [16143140.001]
  • [Cites] J Virol. 2006 Apr;80(7):3332-40 [16537600.001]
  • [Cites] J Virol. 2002 Dec;76(24):13001-14 [12438626.001]
  • (PMID = 20012654.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


17. Mi J, Apraiz I, Cristobal S: Peroxisomal proteomic approach for protein profiling in blue mussels (Mytilus edulis) exposed to crude oil. Biomarkers; 2007 Jan-Feb;12(1):47-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the study, peroxisome-enriched fractions from digestive gland of M. edulis (L., 1758) were analysed by two-dimensional fluorescence difference electrophoresis (DIGE) and mass spectrometry (MS) after 3 weeks of exposure to crude oil mixtures: crude oil or crude oil spiked with alkylated phenols (AP) and extra polycyclic aromatic hydrocarbons (PAH) in a laboratory flow-through system.
  • The hierarchical clustering analysis succeeded in discriminating the exposed groups from the control groups based on the unique PES.
  • [MeSH-major] Bivalvia / chemistry. Peroxisomes / drug effects. Petroleum / toxicity. Proteins / analysis. Proteomics. Water Pollutants, Chemical / toxicity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17438653.001).
  • [ISSN] 1354-750X
  • [Journal-full-title] Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • [ISO-abbreviation] Biomarkers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Petroleum; 0 / Proteins; 0 / Water Pollutants, Chemical
  •  go-up   go-down


18. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD: Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS Med; 2006 Jan;3(1):e13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling predicts survival in conventional renal cell carcinoma.
  • BACKGROUND: Conventional renal cell carcinoma (cRCC) accounts for most of the deaths due to kidney cancer.
  • Unsupervised hierarchical clustering analysis segregated cRCC into five gene expression subgroups.
  • A semisupervised learning algorithm (supervised principal components analysis) was applied to identify transcripts whose expression was associated with survival in the training set, and the performance of this gene expression-based survival predictor was assessed using the test set.
  • With this method, we identified 259 genes that accurately predicted disease-specific survival among patients in the independent validation group (p < 0.001).
  • In multivariate analysis, the gene expression predictor was a strong predictor of survival independent of tumor stage, grade, and performance status (p < 0.001).
  • [MeSH-major] Carcinoma, Renal Cell / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Kidney Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Algorithms. Cluster Analysis. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Survival Analysis

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] J Mol Diagn. 2005 May;7(2):206-18 [15858144.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9754-9 [11493696.001]
  • [Cites] Genome Res. 2001 Nov;11(11):1861-70 [11691851.001]
  • [Cites] N Engl J Med. 2001 Dec 6;345(23):1655-9 [11759643.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1937-47 [12075054.001]
  • [Cites] N Engl J Med. 2002 Dec 19;347(25):1999-2009 [12490681.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):94-6 [12519956.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):802-11 [12576453.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):925-32 [12598325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 10;100(12):6958-63 [12777628.001]
  • [Cites] J Urol. 2003 Dec;170(6 Pt 1):2225-32 [14634384.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] PLoS Biol. 2004 Apr;2(4):E108 [15094809.001]
  • [Cites] N Engl J Med. 2004 Apr 29;350(18):1828-37 [15115829.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3316-22 [15310775.001]
  • [Cites] Nat Genet. 1994 May;7(1):85-90 [7915601.001]
  • [Cites] N Engl J Med. 1998 Apr 30;338(18):1272-8 [9562581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Lancet. 1998 Nov 21;352(9141):1691-6 [9853456.001]
  • [Cites] J Urol. 2005 Jan;173(1):48-51 [15592023.001]
  • [Cites] N Engl J Med. 2004 Dec 30;351(27):2817-26 [15591335.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] J Pathol. 2005 Feb;205(3):377-87 [15682440.001]
  • [Cites] Science. 2001 Apr 20;292(5516):464-8 [11292862.001]
  • (PMID = 16318415.001).
  • [ISSN] 1549-1676
  • [Journal-full-title] PLoS medicine
  • [ISO-abbreviation] PLoS Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1298943
  •  go-up   go-down


19. Bioulac-Sage P: [Case 1: Hepatocellular adenoma and Case 2: Inflammatory/telangiectasic adenoma]. Ann Pathol; 2007 Apr;27(2):86-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case 1: Hepatocellular adenoma and Case 2: Inflammatory/telangiectasic adenoma].
  • [MeSH-major] Adenoma / pathology. Adenoma, Liver Cell / pathology. Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17909463.001).
  • [ISSN] 0242-6498
  • [Journal-full-title] Annales de pathologie
  • [ISO-abbreviation] Ann Pathol
  • [Language] fre
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Valls C, Iannacconne R, Alba E, Murakami T, Hori M, Passariello R, Vilgrain V: Fat in the liver: diagnosis and characterization. Eur Radiol; 2006 Oct;16(10):2292-308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fat in the liver: diagnosis and characterization.
  • The purpose of this article is to provide an update on imaging techniques useful for detection and characterization of fat in the liver.
  • Imaging findings of liver steatosis, both diffuse steatosis and focal fatty change, as well as focal fatty sparing, are presented.
  • In addition, we will review computed tomography (CT) and magnetic resonance (MR) findings of focal liver lesions with fatty metamorphosis, including hepatocellular carcinoma, hepatocellular adenoma, focal nodular hyperplasia, angiomyolipoma, lipoma, and metastases.
  • [MeSH-major] Diagnostic Imaging. Fatty Liver / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology. Neoplasms, Adipose Tissue / diagnosis. Neoplasms, Adipose Tissue / pathology

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Radiol. 1986;11(2):151-7 [3514355.001]
  • [Cites] AJR Am J Roentgenol. 1988 Oct;151(4):717-20 [2844071.001]
  • [Cites] Abdom Imaging. 2002 Mar-Apr;27(2):180-3 [11847577.001]
  • [Cites] Ann Surg. 2000 Jan;231(1):74-81 [10636105.001]
  • [Cites] Br J Radiol. 1986 Jan;59(697 ):25-8 [3512002.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1227-31 [15100124.001]
  • [Cites] AJR Am J Roentgenol. 1987 Sep;149(3):491-4 [3303875.001]
  • [Cites] Abdom Imaging. 2002 Mar-Apr;27(2):184-7 [11847578.001]
  • [Cites] Abdom Imaging. 2001 Sep-Oct;26(5):487-91 [11503085.001]
  • [Cites] Radiology. 1980 Dec;137(3):727-9 [6934563.001]
  • [Cites] Radiology. 1994 Nov;193(2):507-12 [7972769.001]
  • [Cites] AJR Am J Roentgenol. 2001 Feb;176(2):471-4 [11159098.001]
  • [Cites] Abdom Imaging. 1996 Jul-Aug;21(4):324-8 [8661569.001]
  • [Cites] Radiographics. 2001 Jul-Aug;21(4):877-92; discussion 892-4 [11452062.001]
  • [Cites] Aviat Space Environ Med. 1984 Jan;55(1):59-61 [6696696.001]
  • [Cites] AJR Am J Roentgenol. 1998 Nov;171(5):1391-5 [9798885.001]
  • [Cites] Radiology. 2005 Oct;237(1):159-69 [16100085.001]
  • [Cites] AJR Am J Roentgenol. 2004 Sep;183(3):721-4 [15333361.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jun;180(6):1601-4 [12760927.001]
  • [Cites] Radiology. 2000 Aug;216(2):395-402 [10924560.001]
  • [Cites] Hepatology. 2000 Aug;32(2):213-7 [10915726.001]
  • [Cites] Semin Liver Dis. 2001;21(1):105-13 [11296690.001]
  • [Cites] AJR Am J Roentgenol. 1995 May;164(5):1137-40 [7717220.001]
  • [Cites] Histopathology. 2000 May;36(5):443-50 [10792486.001]
  • [Cites] Radiology. 2004 Jan;230(1):276-80 [14695401.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23(1):34-48 [9888702.001]
  • [Cites] Eur Radiol. 2000;10 (7):1095-100 [11003404.001]
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1103-10 [15788580.001]
  • [Cites] J Gastroenterol. 1994 Feb;29(1):95-105 [8199705.001]
  • [Cites] AJR Am J Roentgenol. 1985 Oct;145(4):753-5 [3898784.001]
  • [Cites] Eur Radiol. 2001;11(8):1389-95 [11519547.001]
  • [Cites] Invest Radiol. 1992 Oct;27(10):865-74 [1399444.001]
  • [Cites] Radiology. 2000 Mar;214(3):861-8 [10715059.001]
  • [Cites] Radiographics. 1998 Nov-Dec;18(6):1465-80 [9821195.001]
  • [Cites] Semin Liver Dis. 2001;21(1):71-80 [11296698.001]
  • [Cites] Clin Radiol. 1992 May;45(5):353-4 [1516352.001]
  • [Cites] J Comput Assist Tomogr. 1983 Dec;7(6):1117-8 [6630652.001]
  • [Cites] AJR Am J Roentgenol. 1995 Aug;165(2):303-8 [7618545.001]
  • [Cites] Semin Diagn Pathol. 1998 Nov;15(4):246-58 [9845426.001]
  • [Cites] J Hepatol. 2000 Aug;33(2):282-9 [10952246.001]
  • (PMID = 16477402.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 41
  •  go-up   go-down


21. Agarwal R, Levinson AW, Schowinsky J, Su LM: Large mixed epithelial and stromal tumor of the kidney masquerading as metastatic renal cell carcinoma. Urology; 2007 Nov;70(5):1008.e17-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large mixed epithelial and stromal tumor of the kidney masquerading as metastatic renal cell carcinoma.
  • We report the case of a 39-year-old woman with a large right renal mass 20 cm in size with heterogeneous solid and cystic components as well as concurrent liver lesions suspicious for metastatic renal cell carcinoma.
  • Surgical extirpation of the renal mass and liver lesions was performed laparoscopically with the pathological analysis revealing a rare renal neoplasm--mixed epithelial and stromal tumor of the kidney--and adenomas of the liver.
  • [MeSH-major] Carcinoma, Renal Cell / pathology. Kidney Neoplasms / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans


22. Gilbert KM, Venanzi CA: Hierarchical clustering analysis of flexible GBR 12909 dialkyl piperazine and piperidine analogs. J Comput Aided Mol Des; 2006 Apr;20(4):209-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hierarchical clustering analysis of flexible GBR 12909 dialkyl piperazine and piperidine analogs.
  • A comprehensive hierarchical clustering study of two GBR 12909 analogs was performed to identify representative conformers for input to three-dimensional quantitative structure-activity relationship studies of closely-related analogs.
  • Two data sets of more than 700 conformers each produced by random search conformational analysis of a piperazine and a piperidine GBR 12909 analog were studied.
  • Several clustering studies were carried out based on different feature sets that include the important pharmacophore elements.
  • The distance maps, the plot of the effective number of clusters versus actual number of clusters, and the novel derived clustering statistic, percentage change in the effective number of clusters, were shown to be useful in determining the appropriate clustering level.
  • This study illustrates the utility of using hierarchical clustering for the classification of conformers of highly flexible molecules in terms of the three-dimensional spatial orientation of key pharmacophore elements.
  • [MeSH-minor] Cluster Analysis. Dopamine Uptake Inhibitors / chemistry. Dopamine Uptake Inhibitors / pharmacology. Fuzzy Logic. Models, Molecular. Molecular Conformation. Molecular Structure. Piperidines / chemistry. Piperidines / pharmacology. Quantitative Structure-Activity Relationship. Thermodynamics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Chem Soc. 2003 Mar 5;125(9):2462-74 [12603134.001]
  • [Cites] J Med Chem. 2004 Jun 17;47(13):3388-98 [15189035.001]
  • [Cites] J Med Chem. 2000 Mar 23;43(6):1085-93 [10737741.001]
  • [Cites] J Med Chem. 1998 Nov 19;41(24):4861-72 [9822555.001]
  • [Cites] J Am Chem Soc. 2003 Mar 12;125(10):3101-7 [12617677.001]
  • [Cites] J Med Chem. 1997 Feb 28;40(5):705-16 [9057857.001]
  • [Cites] J Med Chem. 1996 Feb 2;39(3):749-56 [8576918.001]
  • [Cites] J Med Chem. 1991 Sep;34(9):2719-25 [1895292.001]
  • [Cites] J Med Chem. 2000 Nov 2;43(22):4151-9 [11063611.001]
  • [Cites] J Comput Aided Mol Des. 1998 Jul;12(4):383-96 [9777496.001]
  • [Cites] J Med Chem. 2001 May 10;44(10):1509-15 [11334561.001]
  • [Cites] J Med Chem. 1994 Sep 2;37(18):2865-73 [8071935.001]
  • [Cites] J Med Chem. 1999 Jan 28;42(2):249-59 [9925730.001]
  • [Cites] J Med Chem. 2003 Apr 10;46(8):1293-305 [12672230.001]
  • [Cites] J Med Chem. 2002 Apr 11;45(8):1577-84 [11931612.001]
  • [Cites] Proteins. 1991;11(4):297-313 [1758884.001]
  • [Cites] J Med Chem. 2005 Dec 1;48(24):7773-80 [16302816.001]
  • [Cites] J Biol Chem. 1999 Feb 19;274(8):4876-82 [9988729.001]
  • [Cites] Neuropharmacology. 2005 Nov;49(6):780-90 [16216288.001]
  • [Cites] J Comput Aided Mol Des. 2004 Nov;18(11):719-38 [15865064.001]
  • [Cites] J Med Chem. 1998 Mar 12;41(6):864-76 [9526561.001]
  • [Cites] J Am Chem Soc. 1988 Aug 1;110(18):5959-67 [22148765.001]
  • [Cites] J Mol Biol. 2003 Jan 17;325(3):515-30 [12498800.001]
  • [Cites] J Med Chem. 2003 May 22;46(11):2205-15 [12747792.001]
  • [Cites] J Med Chem. 2002 Sep 12;45(19):4119-27 [12213055.001]
  • [Cites] Pharm Res. 1995 Oct;12(10):1430-4 [8584475.001]
  • [Cites] J Med Chem. 2004 May 6;47(10):2499-510 [15115393.001]
  • [Cites] J Chem Inf Model. 2005 May-Jun;45(3):610-23 [15921451.001]
  • [Cites] Chem Rev. 2000 Mar 8;100(3):925-1024 [11749256.001]
  • [Cites] J Comput Chem. 2006 Apr 15;27(5):609-20 [16470669.001]
  • [Cites] J Comput Aided Mol Des. 1998 Nov;12(6):563-72 [9879504.001]
  • [Cites] J Comput Aided Mol Des. 2000 Mar;14(3):251-64 [10756480.001]
  • [Cites] J Comput Aided Mol Des. 2000 Feb;14(2):135-46 [10721502.001]
  • [Cites] Pharmacol Biochem Behav. 1991 Oct;40(2):387-97 [1839568.001]
  • [Cites] J Med Chem. 2004 Oct 7;47(21):5101-13 [15456254.001]
  • [Cites] J Med Chem. 2004 Dec 2;47(25):6137-43 [15566285.001]
  • [Cites] Synapse. 2001 Feb;39(2):175-81 [11180505.001]
  • [Cites] Trends Neurosci. 1991 Jul;14(7):299-302 [1719677.001]
  • [Cites] Bioorg Med Chem. 2006 Feb 1;14(3):666-75 [16216517.001]
  • [Cites] J Med Chem. 2002 Aug 15;45(17):3649-59 [12166938.001]
  • [Cites] J Med Chem. 2002 Sep 12;45(19):4371-4 [12213078.001]
  • [Cites] J Chem Inf Comput Sci. 1998 May-Jun;38(3):506-10 [9611786.001]
  • [Cites] Bioorg Med Chem. 2001 Jul;9(7):1753-64 [11425577.001]
  • [Cites] J Med Chem. 1999 Sep 9;42(18):3502-9 [10479283.001]
  • [Cites] J Med Chem. 2004 Jan 1;47(1):133-42 [14695827.001]
  • [Cites] Bioorg Med Chem. 1995 Apr;3(4):411-28 [8581425.001]
  • [Cites] Pharmacol Biochem Behav. 1996 Apr;53(4):911-8 [8801597.001]
  • (PMID = 16855855.001).
  • [ISSN] 0920-654X
  • [Journal-full-title] Journal of computer-aided molecular design
  • [ISO-abbreviation] J. Comput. Aided Mol. Des.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA015555; United States / NIDA NIH HHS / DA / DA018153
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Dopamine Uptake Inhibitors; 0 / Piperazines; 0 / Piperidines; 90X28IKH43 / vanoxerine
  •  go-up   go-down


23. Vaahtio M, Peltola T, Hentunen T, Ylänen H, Areva S, Wolke J, Salonen JI: The properties of biomimetically processed calcium phosphate on bioactive ceramics and their response on bone cells. J Mater Sci Mater Med; 2006 Nov;17(11):1113-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The properties of biomimetically processed calcium phosphate on bioactive ceramics and their response on bone cells.
  • This study looks for grounds to alter the chemical composition (phosphate, calcium, silica and carbonate), dissolution properties, structure and nanotopography of the biomimetically processed surfaces on bioactive ceramics to optimize their shown ability to influence bone cell behaviour and production of new bone.
  • The CaP so formed in R-SBF with faster precipitation is more amorphous than the bonelike HCA formed in C-SBF.
  • [MeSH-minor] Animals. Animals, Newborn. Cell Line, Tumor. Cells, Cultured. Humans. Rats

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biomed Mater Res A. 2004 May 1;69(2):314-22 [15058004.001]
  • [Cites] Biomaterials. 2003 Jul;24(16):2711-9 [12711517.001]
  • [Cites] J Biomed Mater Res. 2001 Mar 15;54(4):560-6 [11426602.001]
  • [Cites] J Biomed Mater Res. 2000 Sep 5;51(3):475-83 [10880091.001]
  • [Cites] Clin Chem. 2000 Nov;46(11):1751-4 [11067809.001]
  • [Cites] Biomaterials. 2003 Sep;24(20):3383-93 [12809766.001]
  • [Cites] Biomaterials. 2004 Aug;25(18):3963-72 [15046886.001]
  • [Cites] J Biomed Mater Res. 1990 Jun;24(6):721-34 [2361964.001]
  • [Cites] Biomaterials. 1997 Feb;18(4):295-303 [9068890.001]
  • [Cites] J Bone Miner Res. 1989 Dec;4(6):817-25 [2692403.001]
  • [Cites] Biomaterials. 2002 Jul;23(14):2945-54 [12069336.001]
  • [Cites] J Biomed Mater Res. 1996 Apr;30(4):509-14 [8847359.001]
  • [Cites] J Biomed Mater Res A. 2004 Aug 1;70(2):169-78 [15227661.001]
  • [Cites] J Biomed Mater Res. 1999 May;45(2):140-7 [10397968.001]
  • [Cites] Biomaterials. 1999 Dec;20(23-24):2287-303 [10614935.001]
  • [Cites] Biomaterials. 2004 Jun;25(13):2547-55 [14751740.001]
  • [Cites] J Bone Miner Res. 1998 Oct;13(10):1530-8 [9783541.001]
  • [Cites] Ann Chir Gynaecol. 1999;88(3):237-45 [10532567.001]
  • [Cites] J Biomed Mater Res A. 2003 Feb 1;64(2):339-48 [12522821.001]
  • [Cites] Bone. 1998 Mar;22(3):201-9 [9514212.001]
  • [Cites] J Mater Sci Mater Med. 2001 Aug;12(8):659-64 [15348234.001]
  • [Cites] Endocrinology. 1987 Feb;120(2):602-8 [3467966.001]
  • [Cites] J Biomed Mater Res. 1997 Jul;36(1):109-17 [9212395.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 24;276(2):461-5 [11027497.001]
  • [Cites] Anal Chem. 1999 Jan 1;71(1):149-53 [21662937.001]
  • [Cites] J Mater Sci Mater Med. 1997 Jan;8(1):1-4 [15348834.001]
  • [Cites] J Biomed Mater Res. 2001 May;55(2):151-7 [11255166.001]
  • [Cites] J Biomed Mater Res A. 2003 Dec 15;67(4):1205-18 [14624507.001]
  • [Cites] J Biomed Mater Res. 1999 Jan;44(1):12-21 [10397900.001]
  • [Cites] Biomaterials. 1991 Mar;12(2):155-63 [1878450.001]
  • [Cites] Biomaterials. 2001 Jan;22(2):135-50 [11101158.001]
  • [Cites] J Biomed Mater Res. 1999 Dec 5;47(3):424-33 [10487896.001]
  • [Cites] J Biomed Mater Res. 2001 Aug;56(2):208-15 [11340590.001]
  • [Cites] Exp Cell Res. 2002 May 15;276(1):1-9 [11978003.001]
  • [Cites] J Mater Sci Mater Med. 2003 Sep;14(9):731-8 [15348391.001]
  • [Cites] Biomaterials. 1999 Sep;20(18):1727-41 [10503974.001]
  • (PMID = 17122926.001).
  • [ISSN] 0957-4530
  • [Journal-full-title] Journal of materials science. Materials in medicine
  • [ISO-abbreviation] J Mater Sci Mater Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Phosphates; 85422-94-2 / Glass ceramics; 97Z1WI3NDX / calcium phosphate
  •  go-up   go-down


24. Kadam RU, Roy N: Cluster analysis and two-dimensional quantitative structure-activity relationship (2D-QSAR) of Pseudomonas aeruginosa deacetylase LpxC inhibitors. Bioorg Med Chem Lett; 2006 Oct 1;16(19):5136-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cluster analysis and two-dimensional quantitative structure-activity relationship (2D-QSAR) of Pseudomonas aeruginosa deacetylase LpxC inhibitors.
  • We report herein, the development of cluster analysis-based 2D-QSAR models for LpxC inhibition.
  • Principal component analysis (PCA), hierarchical cluster analysis (HCA), and genetic function approximation (GFA) were employed for the development of the QSAR model.
  • Descriptor-based cluster analysis indicated that the three-structural classes of LpxC inhibitors studied belonged to two clusters.
  • [MeSH-minor] Cluster Analysis. Drug Evaluation, Preclinical / methods. Inhibitory Concentration 50

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879960.001).
  • [ISSN] 0960-894X
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 3.5.- / Amidohydrolases; EC 3.5.1.- / LpxC deacetylase, Pseudomonas
  •  go-up   go-down


25. Zhang YB, Lin HF, Lv L, Hua WG, Tian F, Shen GZ, Xia ZL, Jin XP: [In vitro evaluation of cutaneous allergic reaction induced by chemicals using dendritic cells]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2008 Mar;26(3):147-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [In vitro evaluation of cutaneous allergic reaction induced by chemicals using dendritic cells].
  • OBJECTIVE: To investigate the use of dendritic cells derived from mice bone marrow to evaluate the cutaneous allergic reaction induced by chemical sensitizers.
  • METHODS: Dendritic cells derived from mice bone marrow were cultured and administrated with 2, 4-dinitrochlorobenzene (DNCB), nickel sulfate (NiSO4), sodium dodecyl sulfate (SDS) and hexyl cinnamic aldehyde (HCA), respectively.
  • Cell membrane molecule CD86 and extracellular IL-1 beta, IL-6 and IL-12 were detected after 0, 1, 6, 12, 24, 36, 48 hour's administration, respectively.
  • RESULTS: CD86 expression reached the highest level after exposure to DNCB for 48 h, and increased by about 279% compared with the control (P < 0.05), while it was lower than that of control after administrated with NiSO4 and HCA for 1 h and 6 h, and SDS for 36 h, respectively (P < 0.05).
  • Extracellular IL-1 beta increased greatly after exposure to NiSO4 just for 1 h, with the maximum at 48 h (298 pg/ml, P < 0.05), and after exposure to HCA for 6 h, with maximum at 48 h (84 pg/ml, P < 0.05).
  • After exposure to HCA, extracellular IL-6 reached the maximum at 1 h (1403 pg/ml), and then it was decreased quickly, but still higher than the control (P < 0.05), while it didn't change significantly after treatment with DNCB and SDS, compared with the control (P > 0.05).
  • CONCLUSION: Chemical sensitizer DNCB could induce the high expression of CD86 on DC membrane, and NiSO4 and HCA could induce DC to release IL-1 beta and IL-6.
  • [MeSH-major] Dendritic Cells / drug effects. Dinitrochlorobenzene / pharmacology. Nickel / pharmacology. Sodium Dodecyl Sulfate / pharmacology
  • [MeSH-minor] Animals. Antigens, CD86 / metabolism. Cells, Cultured. Interleukin-12 / metabolism. Interleukin-1beta / metabolism. Interleukin-6 / metabolism. Mice. Mice, Inbred C57BL

  • Hazardous Substances Data Bank. SODIUM LAURYL SULFATE .
  • Hazardous Substances Data Bank. NICKEL, ELEMENTAL .
  • Hazardous Substances Data Bank. NICKEL SULFATE .
  • Hazardous Substances Data Bank. 1-CHLORO-2,4-DINITROBENZENE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18761792.001).
  • [ISSN] 1001-9391
  • [Journal-full-title] Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases
  • [ISO-abbreviation] Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD86; 0 / Interleukin-1beta; 0 / Interleukin-6; 187348-17-0 / Interleukin-12; 368GB5141J / Sodium Dodecyl Sulfate; 4FLT4T3WUN / nickel sulfate; 7OV03QG267 / Nickel; GE3IBT7BMN / Dinitrochlorobenzene
  •  go-up   go-down


26. Culp SJ, Mellick PW, Trotter RW, Greenlees KJ, Kodell RL, Beland FA: Carcinogenicity of malachite green chloride and leucomalachite green in B6C3F1 mice and F344 rats. Food Chem Toxicol; 2006 Aug;44(8):1204-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Female rats exposed to malachite green chloride had increased incidences of thyroid gland follicular cell adenoma or carcinoma and hepatocellular adenoma, and a dose-related increasing trend in mammary gland carcinoma.
  • Female rats fed malachite green chloride and female and male rats fed leucomalachite green had a dose-related decreasing trend in the incidence of mononuclear cell leukemia.
  • In male rats fed leucomalachite green there was a decreasing trend in pituitary gland adenoma and an increasing trend in interstitial cell adenoma of the testis.
  • Female mice fed leucomalachite green had a dose-related increasing trend in the incidence of hepatocellular adenoma or carcinoma, with the incidence being significant in the highest dose group.
  • [MeSH-minor] Animals. Body Weight / drug effects. Carcinogenicity Tests. Eating / drug effects. Female. Male. Mice. Mice, Inbred C57BL. Rats. Rats, Inbred F344. Statistics, Nonparametric. Survival Analysis

  • Hazardous Substances Data Bank. Leucomalachite green .
  • Hazardous Substances Data Bank. MALACHITE GREEN .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554117.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aniline Compounds; 0 / Fungicides, Industrial; 0 / Rosaniline Dyes; 12058M7ORO / malachite green; 8U61G37Z20 / leucomalachite green
  •  go-up   go-down


27. Wang MH, Lee W, Luo YL, Weis MT, Yao HP: Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells. J Pathol; 2007 Dec;213(4):402-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells.
  • The aim of this study was to determine RON expression in various normal epithelial cells and their corresponding tumours by immunohistochemistry.
  • The role of RON in regulating tumourigenic phenotypes was also studied using thyroid cancer cells as a model.
  • RON was almost exclusively expressed at variable levels in normal epithelial cells from the digestive track, lung, kidney, pancreas, liver, breast, bladder, skin, and others.
  • In contrast, limited RON overexpression was observed in cancers from stomach, kidney, brain, liver, ovary, and prostate.
  • Detailed analysis of thyroid tissues showed that RON was hardly detected in normal thyroid cells, moderately expressed in adenoma samples, but overexpressed in about half of papillary and follicular cancer specimens.
  • In cultured thyroid cancer cells, RON was highly expressed, with constitutive phosphorylation.
  • Activation of RON increased cell growth and migration via the MAP kinase and AKT pathways.
  • Silencing RON expression significantly prevented cell growth and increased cell apoptotic death.
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Apoptosis. Cell Division. Cell Transformation, Neoplastic. Disease Progression. Epithelial Cells / metabolism. Female. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Lymphatic Metastasis. Male. Neoplasm Staging. Neoplasms / metabolism. Tissue Array Analysis / methods. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Pathological Society of Great Britain and Ireland
  • (PMID = 17955509.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA91980
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Neoplasm Proteins; EC 2.7.1.- / RON protein; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  •  go-up   go-down


28. Haldenwang PL, Strauch JT, Amann I, Klein T, Sterner-Kock A, Christ H, Wahlers T: Impact of pump flow rate during selective cerebral perfusion on cerebral hemodynamics and metabolism. Ann Thorac Surg; 2010 Dec;90(6):1975-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Although hypothermic selective cerebral perfusion (SCP) is widely used for cerebral protection during aortic surgery, little is known about the ideal pump-flow management during this procedure.
  • After 10 minutes of hypothermic circulatory arrest, the animals were randomly assigned to 60 minutes of SCP at two different pump flow rates: 8 mL·kg(-1)·min(-1) (n = 7) and 18 mL·kg(-1)·min(-1) (n = 7).
  • [MeSH-minor] Animals. Aorta, Thoracic / surgery. Disease Models, Animal. Female. Intracranial Pressure / physiology. Oxygen Consumption. Regional Blood Flow / physiology. Stroke / prevention & control. Swine. Vascular Surgical Procedures / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • [CommentIn] Ann Thorac Surg. 2010 Dec;90(6):1984 [21095349.001]
  • (PMID = 21095348.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


29. Kiralj R, Ferreira MM: Chemometric analysis of the multidrug resistance in strains of Penicillium digitatum. SAR QSAR Environ Res; 2008 Jan-Mar;19(1-2):55-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemometric analysis of the multidrug resistance in strains of Penicillium digitatum.
  • Multidrug resistance activities pECr50 of diverse strains of pathogenic fungus Penicillium digitatum against seven toxicants were studied by Principal Component Analysis (PCA) and Hierarchical Cluster Analysis (HCA).
  • This data set was studied by PCA and HCA, and was correlated with the genome descriptor PCR for expression of gene CYP51 by Partial Least Squares (PLS) regression.
  • Both analyses of pECr50 data and of fungal growth data have identified baseline resistance character, origin and target fruits of the fungal strains.
  • In addition, the analysis of fungal growth data shows that fungal growth morphology is multivariate by nature, meaning that experimental data can be explored more intensely than in usual practice.
  • [MeSH-minor] Cluster Analysis. Cytochrome P-450 Enzyme System / genetics. Fungal Proteins / genetics. Principal Component Analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18311634.001).
  • [ISSN] 1062-936X
  • [Journal-full-title] SAR and QSAR in environmental research
  • [ISO-abbreviation] SAR QSAR Environ Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Fungal Proteins; 0 / Fungicides, Industrial; 9035-51-2 / Cytochrome P-450 Enzyme System
  •  go-up   go-down


31. Satoh J: [Molecular biomarkers for prediction of multiple sclerosis relapse]. Nihon Rinsho; 2008 Jun;66(6):1103-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system white matter mediated by an autoimmune process, whose development is triggered by a complex interplay of multiple genetic, infectious and environmental factors.
  • DNA microarray is a novel technology that allows us to systematically monitor the expression of whole human genome in disease-affected tissues and cells.
  • By using DNA microarray, we have recently studied gene expression profile of peripheral blood T cells isolated from clinically active MS patients and healthy controls, and from MS patients in relapse and during remission.
  • Hierarchical clustering analysis of the discriminator genes established classification of MS subgroups that exhibit distinct gene expression profiles and relapse-specific molecular signatures.
  • [MeSH-major] Biomarkers / analysis. Multiple Sclerosis / diagnosis. Multiple Sclerosis / genetics
  • [MeSH-minor] Humans. Protein Array Analysis. Recurrence

  • Genetic Alliance. consumer health - Multiple Sclerosis.
  • MedlinePlus Health Information. consumer health - Multiple Sclerosis.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540355.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 40
  •  go-up   go-down


32. Yamamoto T, Kikkawa R, Yamada H, Horii I: Investigation of proteomic biomarkers in in vivo hepatotoxicity study of rat liver: toxicity differentiation in hepatotoxicants. J Toxicol Sci; 2006 Feb;31(1):49-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of proteomic biomarkers in in vivo hepatotoxicity study of rat liver: toxicity differentiation in hepatotoxicants.
  • Acetaminophen (APAP), amiodarone (AMD), tetracycline (TC) and carbon tetrachloride (CTC) were administered to male rats by gavages and the liver at 24 hr post-dosing was applied to the proteomic experiment.
  • Protein expression in the liver was investigated by 2-dimensional gel electrophoresis (2DE), and spots showing a significantly different expression in treated versus control group were excised from gels and identified by Q-Tof mass spectrometer.
  • Moreover, hierarchical clustering analysis using 2D-gel spots information revealed the possibility to differentiate the groups based on their toxicity levels such as severity of liver damage.
  • [MeSH-major] Acetaminophen / toxicity. Amiodarone / toxicity. Carbon Tetrachloride / toxicity. Liver / drug effects. Proteins / metabolism. Tetracycline / toxicity


33. Ferrara DE, Weiss D, Carnell PH, Vito RP, Vega D, Gao X, Nie S, Taylor WR: Quantitative 3D fluorescence technique for the analysis of en face preparations of arterial walls using quantum dot nanocrystals and two-photon excitation laser scanning microscopy. Am J Physiol Regul Integr Comp Physiol; 2006 Jan;290(1):R114-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative 3D fluorescence technique for the analysis of en face preparations of arterial walls using quantum dot nanocrystals and two-photon excitation laser scanning microscopy.
  • We studied human coronary arteries (HCAs) and mouse aortas with a modified immunohistochemical (IHC) "en face" method using quantum dot (Qdot) bioconjugates and two-photon excitation laser scanning microscopy (TPELSM).
  • Detailed cell structures, such as the granular appearance of von Willebrand factor (VWF) and the subcellular distribution of endothelial nitric oxide synthase, were visualized using green dots (525 nm), even when the emission maximum of these Qdots overlapped that of tissue autofluorescence (510-520 nm).
  • In addition, sensitive fluorescence quantification of vascular cell adhesion molecule 1 expression at areas of varying hemodynamics (intercostal branches vs. nonbranching areas) was performed in normal C57Bl/6 mice.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16223849.001).
  • [ISSN] 0363-6119
  • [Journal-full-title] American journal of physiology. Regulatory, integrative and comparative physiology
  • [ISO-abbreviation] Am. J. Physiol. Regul. Integr. Comp. Physiol.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / P20 GM072069; United States / NCI NIH HHS / CA / R01 CA108468; United States / PHS HHS / / R-01-L70531; United States / NIH HHS / NH / U0-1-NH-080711
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apolipoproteins E; 0 / Vascular Cell Adhesion Molecule-1
  •  go-up   go-down


34. Gutiérrez NC, López-Pérez R, Hernández JM, Isidro I, González B, Delgado M, Fermiñán E, García JL, Vázquez L, González M, San Miguel JF: Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia; 2005 Mar;19(3):402-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone marrow samples from 43 adult patients with de novo diagnosed acute myeloid leukemia (AML)--10 acute promyelocytic leukemias (APL) with t(15;17), four AML with inv(16), seven monocytic leukemias and 22 nonmonocytic leukemias--were analyzed using high-density oligonucleotide microarrays.
  • Hierarchical clustering analysis segregated APL, AML with inv(16), monocytic leukemias and the remaining AML into separate groups.
  • Quantitative RT-PCR performed for 18 out of these predictor genes confirmed microarray results.
  • AML with inv(16) showed an upregulation of MYH11 and a downregulation of a gene encoding a core-binding factor protein, RUNX3.
  • Genes involved in cell adhesion represented the most altered functional category in monocytic leukemias.
  • In the latter cluster, CD34 upregulation and serine proteases downregulation is consistent with a maturation arrest and lack of granulocytic differentiation.
  • [MeSH-minor] Adolescent. Adult. Aged. Cluster Analysis. Female. Humans. Leukemia, Monocytic, Acute / genetics. Leukemia, Promyelocytic, Acute / genetics. Male. Middle Aged. Phylogeny. Retrospective Studies


35. Rubie C, Frick VO, Wagner M, Schuld J, Gräber S, Brittner B, Bohle RM, Schilling MK: ELR+ CXC chemokine expression in benign and malignant colorectal conditions. BMC Cancer; 2008;8:178
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ELR+ CXC chemokine expression in benign and malignant colorectal conditions.
  • Here, we comparatively analyzed their expression profile in resection specimens from patients with colorectal adenoma (CRA) (n = 30) as well as colorectal carcinoma (CRC) (n = 48) and corresponding colorectal liver metastases (CRLM) (n = 16).
  • METHODS: Chemokine expression was assessed by microdissection, quantitative real-time PCR (Q-RT-PCR), the enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry (IHC).
  • Although a comparative analysis of the CXCL1/CXCL5 protein expression profiles in CRC patients revealed that the absolute expression level of CXCL1 was significantly higher in comparison to CXCL5, mRNA- and protein overexpression of CXCL5 in CRC and CRLM tissues was much more pronounced (80- and 60- fold in CRC tissues, respectively) in comparison to CXCL1 (5- and 3.5- fold in CRC tissues, respectively).
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Chemokines, CXC / biosynthesis. Colorectal Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Amino Acid Sequence. Chemokine CXCL1 / biosynthesis. Chemokine CXCL1 / genetics. Chemokine CXCL5 / biosynthesis. Chemokine CXCL5 / genetics. Chemokine CXCL6 / biosynthesis. Chemokine CXCL6 / genetics. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunohistochemistry. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytokine. 2000 Jan;12(1):78-85 [10623446.001]
  • [Cites] World J Gastroenterol. 2007 Oct 7;13(37):4996-5002 [17854143.001]
  • [Cites] Immunity. 2000 Feb;12(2):121-7 [10714678.001]
  • [Cites] Oncogene. 2000 Jul 20;19(31):3477-86 [10918606.001]
  • [Cites] Eur J Cancer. 2000 Aug;36(13 Spec No):1706-12 [10959056.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] J Immunol. 2000 Nov 1;165(9):5269-77 [11046061.001]
  • [Cites] J Virol. 2001 Jul;75(13):5812-22 [11390582.001]
  • [Cites] J Intern Med. 2001 Aug;250(2):91-104 [11489059.001]
  • [Cites] Scand J Gastroenterol. 2001 Aug;36(8):854-64 [11495082.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Aug;86(8):3968-74 [11502840.001]
  • [Cites] Cytokine Growth Factor Rev. 2001 Dec;12(4):375-91 [11544106.001]
  • [Cites] Am J Pathol. 2001 Oct;159(4):1405-14 [11583968.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10):3298-304 [11595728.001]
  • [Cites] J Leukoc Biol. 2002 Jul;72(1):9-18 [12101257.001]
  • [Cites] J Immunol. 2004 Mar 1;172(5):2853-60 [14978086.001]
  • [Cites] Cancer Res. 2004 Mar 1;64(5):1853-60 [14996749.001]
  • [Cites] Chest. 2004 May;125(5 Suppl):133S [15136463.001]
  • [Cites] Curr Opin Oncol. 1991 Feb;3(1):75-92 [2043698.001]
  • [Cites] J Exp Med. 1991 Dec 1;174(6):1355-62 [1744577.001]
  • [Cites] Cytokines. 1992;4:96-116 [1335322.001]
  • [Cites] J Biol Chem. 1995 Nov 10;270(45):27348-57 [7592998.001]
  • [Cites] Comput Methods Programs Biomed. 1995 Dec;48(3):257-62 [8925653.001]
  • [Cites] J Immunol. 1997 Jun 1;158(11):5257-66 [9164944.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1803-4 [9351551.001]
  • [Cites] J Leukoc Biol. 1997 Nov;62(5):588-97 [9365113.001]
  • [Cites] N Engl J Med. 1998 Feb 12;338(7):436-45 [9459648.001]
  • [Cites] J Clin Invest. 1998 Aug 1;102(3):465-72 [9691082.001]
  • [Cites] J Immunol Methods. 1998 Nov 1;220(1-2):1-17 [9839921.001]
  • [Cites] Am J Pathol. 1999 May;154(5):1503-12 [10329603.001]
  • [Cites] Exp Cell Res. 2005 Feb 15;303(2):331-42 [15652347.001]
  • [Cites] Mol Cell Probes. 2005 Apr;19(2):101-9 [15680211.001]
  • [Cites] Clin Exp Metastasis. 2004;21(7):571-9 [15787094.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3581-4 [16101183.001]
  • [Cites] Dig Dis Sci. 2006 Jan;51(1):173-7 [16416232.001]
  • [Cites] Eur J Cancer. 2006 Apr;42(6):768-78 [16510280.001]
  • [Cites] J Exp Med. 2006 Apr 17;203(4):941-51 [16567391.001]
  • [Cites] Tumour Biol. 2006;27(3):166-74 [16641550.001]
  • [Cites] Scand J Immunol. 2006 Jun;63(6):468-77 [16764701.001]
  • [Cites] Br J Cancer. 2006 Jun 19;94(12):1936-41 [16721367.001]
  • [Cites] Cancer Lett. 2006 Sep 28;241(2):221-7 [16458421.001]
  • [Cites] Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):5951-9 [17062666.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):87-96 [17275174.001]
  • [Cites] J Leukoc Biol. 2000 Jan;67(1):53-62 [10647998.001]
  • (PMID = 18578857.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CXCL1 protein, human; 0 / CXCL5 protein, human; 0 / CXCL6 protein, human; 0 / Chemokine CXCL1; 0 / Chemokine CXCL5; 0 / Chemokine CXCL6; 0 / Chemokines, CXC; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2459188
  •  go-up   go-down


36. Kummerfeld M, Knieriem A, Wohlsein P: [Osteomyelitis and papillary renal adenoma in a red panda (Ailurus fulgens fulgens)]. Dtsch Tierarztl Wochenschr; 2008 Nov;115(11):421-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Osteomyelitis and papillary renal adenoma in a red panda (Ailurus fulgens fulgens)].
  • [Transliterated title] Osteomyelitis und papilläres renales Adenom bei einem Kleinen Pandabären (Ailurus fulgens fulgens).
  • Pathological examination revealed a chronic bacterial ulcerative to necrotizing dermatitis and osteomyelitis at the lower jaw with subsequent pyogranulomatous pneumonia and diffuse hydropic degeneration of the liver.
  • Additionally, in the kidney a papillary renal adenoma was found.
  • [MeSH-major] Carcinoma, Renal Cell / veterinary. Kidney Neoplasms / veterinary. Osteomyelitis / veterinary. Ursidae

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024549.001).
  • [ISSN] 0341-6593
  • [Journal-full-title] DTW. Deutsche tierärztliche Wochenschrift
  • [ISO-abbreviation] DTW. Dtsch. Tierarztl. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


37. Das CJ, Dhingra S, Gupta AK, Iyer V, Agarwala S: Imaging of paediatric liver tumours with pathological correlation. Clin Radiol; 2009 Oct;64(10):1015-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of paediatric liver tumours with pathological correlation.
  • Paediatric hepatic tumours are relatively rare with malignant lesions being twice as frequent as benign neoplasms and are mostly metastases.
  • Imaging has a significant role in the evaluation of most paediatric liver tumours.
  • Differentiating benign from malignant tumours is important as it significantly affects treatment decisions.
  • We present the characteristic radiological and pathological features of the most common paediatric liver tumours.
  • [MeSH-major] Liver Neoplasms / diagnosis. Liver Neoplasms / pathology
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / pathology. Adolescent. Carcinoma, Hepatocellular / diagnosis. Carcinoma, Hepatocellular / pathology. Child. Child, Preschool. Contrast Media. Cysts / diagnosis. Cysts / pathology. Diagnosis, Differential. Female. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / pathology. Hamartoma / diagnosis. Hamartoma / pathology. Hemangioma / diagnosis. Hemangioma / pathology. Hepatoblastoma / diagnosis. Hepatoblastoma / pathology. Humans. Infant. Magnetic Resonance Imaging / methods. Male. Rhabdoid Tumor / diagnosis. Rhabdoid Tumor / pathology. Sarcoma / diagnosis. Sarcoma / pathology. Tomography, X-Ray Computed / methods. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19748008.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 45
  •  go-up   go-down


38. Pavón JL, Peña AG, Pinto CG, Cordero BM: Differentiation of types of crude oils in polluted soil samples by headspace-fast gas chromatography-mass spectrometry. J Chromatogr A; 2006 Dec 22;1137(1):101-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The coupling of a headspace sampler to a fast gas chromatography system with mass spectrometry detection is proposed as a method for the identification of the sources of contamination in soils due to the presence of hydrocarbons derived from petroleum.
  • Chemometric treatments, such as hierarchical cluster analysis (HCA), principal component analysis (PCA), and soft independent modelling of class analogy (SIMCA) were applied to the signals obtained for the different samples.
  • [MeSH-major] Gas Chromatography-Mass Spectrometry / methods. Petroleum / analysis. Soil Pollutants / analysis
  • [MeSH-minor] Pilot Projects. Principal Component Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17056051.001).
  • [ISSN] 0021-9673
  • [Journal-full-title] Journal of chromatography. A
  • [ISO-abbreviation] J Chromatogr A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Petroleum; 0 / Soil Pollutants
  •  go-up   go-down


39. Gasparri F, Cappella P, Galvani A: Multiparametric cell cycle analysis by automated microscopy. J Biomol Screen; 2006 Sep;11(6):586-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiparametric cell cycle analysis by automated microscopy.
  • Cell cycle analysis using flow cytometry (FC) to measure cellular DNA content is a common procedure in drug mechanism of action studies.
  • Although this technique lends itself readily to cell lines that grow in suspension, adherent cell cultures must be resuspended in a cumbersome and potentially invasive procedure that normally involves trypsinization and mechanical agitation of monolayer cultures.
  • High-content analysis (HCA), an automated microscopy-based technology, is well suited to analysis of monolayer cell cultures but provides intrinsically less accurate determination of cellular DNA content than does FC and thus is not the method of choice for cell cycle analysis.
  • Using Cellomics's ArrayScan reader, the authors have developed a 4-color multiparametric HCA approach for cell cycle analysis of adherent cells based on detection of DNA content (4,6-diamidino-2-phenylindole [DAPI] fluorescence), together with the known cell cycle markers bromo-2-deoxyuridine (BrdU) incorporation, cyclin B1 expression, and histone H3 (Ser28) phosphorylation within a single cell population.
  • Considering all 4 markers together, a reliable and accurate quantification of cell cycle phases was possible, as compared with flow cytometric analysis.
  • Using this assay, specific cell cycle blocks induced by treatment with thymidine, paclitaxel, or nocodazole as test drugs were easily monitored in adherent cultures of U-2 OS osteosarcoma cells.
  • [MeSH-major] Cell Cycle / physiology. Flow Cytometry / instrumentation. Microscopy / instrumentation
  • [MeSH-minor] Automation. Bromodeoxyuridine / pharmacology. Cell Division / drug effects. Cells, Cultured. DNA / analysis. Humans

  • Hazardous Substances Data Bank. BROMODEOXYURIDINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844964.001).
  • [ISSN] 1087-0571
  • [Journal-full-title] Journal of biomolecular screening
  • [ISO-abbreviation] J Biomol Screen
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA; G34N38R2N1 / Bromodeoxyuridine
  •  go-up   go-down


40. Pousios D, Velissaris T, Duggan S, Tsang G: Floating intra-aortic thrombus presenting as distal arterial embolism. Interact Cardiovasc Thorac Surg; 2009 Sep;9(3):532-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Floating thrombi in the aorta are a rare finding in the absence of any coagulation abnormality.
  • There was no pre-existing clotting abnormality.
  • Under temporary hypothermic circulatory arrest, the ascending aorta was opened.
  • The lesion was removed along with a rim of aortic wall, circulation was re-established and the aorta was reconnected with use of a synthetic interposition graft.
  • Only a few cases of intra-aortic thrombus without any coagulation abnormality basis are described in literature.
  • [MeSH-minor] Acute Disease. Administration, Oral. Anticoagulants / administration & dosage. Aortography / methods. Blood Vessel Prosthesis Implantation. Cardiopulmonary Bypass. Circulatory Arrest, Deep Hypothermia Induced. Female. Humans. Ischemic Attack, Transient / etiology. Magnetic Resonance Angiography. Middle Aged. Sternum / surgery. Tomography, X-Ray Computed. Treatment Failure

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Blood Clots.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454418.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anticoagulants
  •  go-up   go-down


41. National Toxicology Program: Toxicology and carcinogenesis studies of a binary mixture of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (Cas No. 57465-28-8) and 2,3',4,4',5-pentachlorobiphenyl (PCB 118) (Cas No. 31508-00-6) in female Harlan Sprague-Dawley rats (gavage studies). Natl Toxicol Program Tech Rep Ser; 2006 Nov;(531):1-218
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Toxicology and carcinogenesis studies of a binary mixture of 3,3',4,4',5-pentachlorobiphenyl (PCB 126) (Cas No. 57465-28-8) and 2,3',4,4',5-pentachlorobiphenyl (PCB 118) (Cas No. 31508-00-6) in female Harlan Sprague-Dawley rats (gavage studies).
  • The TEF methodology is a relative potency scheme that ranks the dioxin-like activity of a compound relative to TCDD, which is the most potent congener.
  • This allows for the estimation of the potential dioxin-like activity of a mixture of chemicals, based on a common mechanism of action involving an initial binding of DLCs to the AhR.
  • Hepatic Cell Proliferation Data To evaluate hepatocyte replication, analysis of labeling of replicating hepatocytes with 5-bromo-2'-deoxyuridine was conducted at the 14-, 31-, and 53-week interim evaluations.
  • Hepatic and pulmonary EROD (CYP1A1) activity, hepatic A4H (CYP1A2) activity, and hepatic PROD (CYP2B1) activity were significantly greater in all dosed groups compared to the vehicle controls at weeks 14, 31, and 53.
  • Determinations of PCB 126 and PCB 118 Concentrations in Tissues: The tissue disposition of PCB 126 and PCB 118 was analyzed in the liver, lung, fat, and blood of up to 10 rats in each group at the 14-, 31-, and 53-week interim evaluations, except for the 360 ng TEQ/kg group at 53 weeks.
  • Detectable concentrations of PCB 126 and PCB 118 were observed in the liver, fat, lung, and blood.
  • The highest levels of PCB 126 were seen in the liver whereas the highest levels of PCB 118 were seen in the fat.
  • Hepatic levels of PCB 126 and PCB 118 in the 72 ng TEQ/kg group at the end of the 2-year study were 284 ng/g and 3,769 ng/g, respectively.
  • Pathology and Statistical Analyses: At 14, 31, and 53 weeks, liver weights were significantly increased in treated groups with more pronounced effects occurring in the higher dose groups.
  • Exposure to the PCB mixture led to significant toxicity in the liver.
  • At 31 weeks, most rats in the 216 and 360 ng TEQ/kg groups had multiple hepatic nonneoplastic lesions.
  • At the end of the 2-year study in all dosed groups, there were significantly increased incidences and severity of toxic hepatopathy characterized by hepatocyte hypertrophy, multinucleated hepatocytes, pigmentation, toxic hepatopathy, diffuse fatty change, nodular hyperplasia, centrilobular fibrosis, cholangiofibrosis, oval cell hyperplasia, bile duct cyst, bile duct hyperplasia, and portal fibrosis.
  • The incidences of hepatocellular adenoma were also significantly increased in the 216 and 360 ng TEQ/kg core study groups.
  • In addition, single occurrences of hepatocholangioma, cholangioma, or hepatocellular carcinoma were observed in some dosed groups administered 72 ng TEQ/kg or greater.
  • [MeSH-minor] Animals. Female. Liver / drug effects. Liver / enzymology. Lung / drug effects. Lung / enzymology. Male. Rats. Rats, Sprague-Dawley. Thyroid Hormones / blood

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17342196.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thyroid Hormones; 31508-00-6 / 2,3',4,4',5-pentachlorobiphenyl; DFC2HB4I0K / Polychlorinated Biphenyls; TSH69IA9XF / 3,4,5,3',4'-pentachlorobiphenyl
  •  go-up   go-down


42. Hellin-Meseguer D, Melgarejo-Moreno P, Hostalet E: Carcinoma ex pleomorphic adenoma of the submandibular gland with distant metastases. B-ENT; 2007;3(1):27-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoma ex pleomorphic adenoma of the submandibular gland with distant metastases.
  • A case of metastatic carcinoma ex pleomorphic adenoma (PA) of the submandibular gland is reported.
  • We report a case of a 52-year-old male patient with a history of PA diagnosed ten years previous.
  • Three years post-surgery liver and bony metastases were detected.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma, Pleomorphic / diagnosis. Bone Neoplasms / secondary. Head and Neck Neoplasms / secondary. Liver Neoplasms / secondary. Neoplasms, Multiple Primary / diagnosis. Submandibular Gland Neoplasms / diagnosis
  • [MeSH-minor] Biopsy, Needle. Cell Transformation, Neoplastic / pathology. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neck Dissection. Neoplasm Invasiveness. Submandibular Gland / pathology. Submandibular Gland / surgery. Tomography, X-Ray Computed


43. Elder I, Fisher Z, Laipis PJ, Tu C, McKenna R, Silverman DN: Structural and kinetic analysis of proton shuttle residues in the active site of human carbonic anhydrase III. Proteins; 2007 Jul 1;68(1):337-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Structural and kinetic analysis of proton shuttle residues in the active site of human carbonic anhydrase III.
  • We report the X-ray crystal structures and rate constants for proton transfer in site-specific mutants of human carbonic anhydrase III (HCA III) that place a histidine residue in the active-site cavity: K64H, R67H, and K64H-R67N HCA III.
  • Prior evidence from the exchange of 18O between CO2 and water measured by mass spectrometry shows each mutant to have enhanced proton transfer in catalysis compared with wild-type HCA III.
  • However, His64 in K64H and K64H-R67N HCA III have at most a capacity for proton transfer that is only 13% that of His64 in HCA II.
  • This reduced rate in mutants of HCA III is associated with a constrained side-chain conformation of His64, which is oriented outward, away from the active-site zinc in the crystal structures.
  • This conformation appears stabilized by a prominent pi stacking interaction of the imidazole ring of His64 with the indole ring of Trp5 in mutants of HCA III.
  • This single orientation of His64 in K64H HCA III predominates also in a double mutant K64H-R67N HCA III, indicating that the positive charge of Arg67 does not influence the observed conformation of His64 in the crystal structure.
  • Hence, the structures and catalytic activity of these mutants of HCA III containing His64 account only in small part for the lower activity of this isozyme compared with HCA II.
  • His67 in R67H HCA III was also shown to be a proton shuttle residue, having a capacity for proton transfer that was approximately four times that of His64 in K64H HCA III.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2007 Wiley-Liss, Inc.
  • (PMID = 17427958.001).
  • [ISSN] 1097-0134
  • [Journal-full-title] Proteins
  • [ISO-abbreviation] Proteins
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM 25154
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons; EC 4.2.1.- / Carbonic Anhydrase III
  •  go-up   go-down


44. Mantone J: HCA hits gain-sharing hurdle. Vendor objects to comments on usage levels. Mod Healthc; 2006 Feb 13;36(7):12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA hits gain-sharing hurdle. Vendor objects to comments on usage levels.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515059.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


45. Gitto R, Agnello S, Ferro S, Vullo D, Supuran CT, Chimirri A: Identification of potent and selective human carbonic anhydrase VII (hCA VII) inhibitors. ChemMedChem; 2010 Jun 7;5(6):823-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of potent and selective human carbonic anhydrase VII (hCA VII) inhibitors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20349499.001).
  • [ISSN] 1860-7187
  • [Journal-full-title] ChemMedChem
  • [ISO-abbreviation] ChemMedChem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carbonic Anhydrase Inhibitors; 0 / Protein Isoforms; 0 / Sulfonamides; EC 4.2.1.1 / Carbonic Anhydrases; EC 4.2.1.1 / carbonic anhydrase VI
  •  go-up   go-down


46. Shuhaiber JH: Evaluating the quality of trials of hypothermic circulatory arrest aortic surgery. Asian Cardiovasc Thorac Ann; 2007 Oct;15(5):449-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluating the quality of trials of hypothermic circulatory arrest aortic surgery.
  • The quality of level 1 evidence in reports on deep hypothermic circulatory arrest was assessed, and the confounding factors in surgical management and study design that can prevent meta-analysis formulation were determined.
  • A systematic search of the literature was conducted using categorized nomenclature for randomized controlled trials in adult patients undergoing deep hypothermic circulatory arrest in the last 40 years.
  • Twelve randomized controlled trials (2.3%) were found among 504 publications on deep hypothermic circulatory arrest listed on Medline from 1960; only 4 of them related to adults.
  • One adequately powered study demonstrated reduced blood loss in deep hypothermic circulatory arrest using aprotinin.
  • Existing studies of deep hypothermic circulatory arrest are insufficient and inconsistent in the outcome measured, which explains the lack of a meta-analysis.
  • [MeSH-major] Aortic Diseases / surgery. Cerebrovascular Disorders / etiology. Circulatory Arrest, Deep Hypothermia Induced / adverse effects. Meta-Analysis as Topic. Randomized Controlled Trials as Topic / standards. Vascular Surgical Procedures

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17911080.001).
  • [ISSN] 1816-5370
  • [Journal-full-title] Asian cardiovascular & thoracic annals
  • [ISO-abbreviation] Asian Cardiovasc Thorac Ann
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 17
  •  go-up   go-down


47. Ruebel KH, Leontovich AA, Tanizaki Y, Jin L, Stilling GA, Zhang S, Coonse K, Scheithauer BW, Lombardero M, Kovacs K, Lloyd RV: Effects of TGFbeta1 on gene expression in the HP75 human pituitary tumor cell line identified by gene expression profiling. Endocrine; 2008 Feb;33(1):62-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of TGFbeta1 on gene expression in the HP75 human pituitary tumor cell line identified by gene expression profiling.
  • The pathogenesis of pituitary adenomas and many of the genes influencing growth of these tumors are unknown.
  • TGFbeta is known to inhibit proliferation of cultured anterior pituitary cells and anterior pituitary tumors, but the signal transduction pathways involved in the inhibition of growth are unclear.
  • We treated the human HP75 pituitary cell line with 10(-9) M TGFbeta1 for 4, 24, and 96 h and performed global gene expression profiling by Affymetrix GeneChip microarray analysis.
  • Quantitative PCR validation of specific genes involved in the TGFbeta1-induced regulation of pituitary cell growth was also done.
  • Of the 15,000 genes queried, there were 37 genes up-regulated and 48 genes down-regulated twofold or more after 4 h of TGFbeta1 treatment.
  • There were 121 genes up-regulated and 109 genes down-regulated twofold or more after 24 h of TGFbeta1 treatment and 112 genes up-regulated and 43 genes down-regulated twofold or more after 96 h of TGFbeta1 treatment.
  • These findings highlight the diverse gene networks and pathways through which TGFbeta operates in its effects on pituitary tumor cells.
  • [MeSH-major] Adenoma / genetics. Gene Expression Regulation, Neoplastic / drug effects. Pituitary Neoplasms / genetics. Transforming Growth Factor beta1 / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Gene Expression Profiling. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / analysis

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Oct 17;21(47):7156-63 [12370805.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3535-7 [15867344.001]
  • [Cites] Oncogene. 2003 Oct 2;22(43):6748-63 [14555988.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jan;292(1):G28-38 [16901989.001]
  • [Cites] Endocrine. 2004 Jul;24(2):141-6 [15347840.001]
  • [Cites] Genes Dev. 2005 Dec 1;19(23):2783-810 [16322555.001]
  • [Cites] J Biol Chem. 2005 Mar 4;280(9):8343-50 [15623506.001]
  • [Cites] Am J Pathol. 1999 Mar;154(3):767-74 [10079254.001]
  • [Cites] Cytokine Growth Factor Rev. 2006 Feb-Apr;17(1-2):29-40 [16289860.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):807-21 [14557817.001]
  • [Cites] Nat Rev Cancer. 2006 Jul;6(7):506-20 [16794634.001]
  • [Cites] Endocrinology. 1996 Jul;137(7):3051-60 [8770931.001]
  • [Cites] Int J Cancer. 2000 May 20;89(3):251-8 [10861501.001]
  • [Cites] Nature. 2003 Oct 9;425(6958):577-84 [14534577.001]
  • [Cites] Endocr Pathol. 2001 Summer;12(2):125-36 [11579678.001]
  • [Cites] Mech Dev. 2004 Feb;121(2):183-94 [15037319.001]
  • [Cites] Cancer Res. 1981 Jul;41(7):2842-8 [6265069.001]
  • [Cites] Annu Rev Biochem. 1998;67:753-91 [9759503.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):217-25 [16779673.001]
  • [Cites] J Bone Miner Res. 1999 Oct;14(10):1734-41 [10491221.001]
  • [Cites] Endocrine. 2003 Dec;22(3):285-92 [14709802.001]
  • [Cites] J Bone Miner Res. 2001 Oct;16(10):1837-45 [11585348.001]
  • [Cites] Science. 2006 May 26;312(5777):1228-30 [16728643.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2251-5 [12727847.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10214-22 [16288009.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):509-19 [9250163.001]
  • [Cites] Mol Cell Biol. 2001 Sep;21(17):5935-45 [11486032.001]
  • [Cites] Endocrinology. 2005 Oct;146(10):4179-88 [15961557.001]
  • (PMID = 18401765.001).
  • [ISSN] 1355-008X
  • [Journal-full-title] Endocrine
  • [ISO-abbreviation] Endocrine
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 90249
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Transforming Growth Factor beta1
  •  go-up   go-down


48. Papanikolaou V, Giakoustidis D, Patsiaura K, Imvrios G, Antoniadis N, Ouzounidis N, Nikopolitidis V, Antoniadis A, Takoudas D: Management of a giant ruptured hepatocellular adenoma. Report of a case. Hippokratia; 2007 Apr;11(2):86-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of a giant ruptured hepatocellular adenoma. Report of a case.
  • This report describes a rare case of a young woman with massive intra-abdominal bleeding due to a giant ruptured hepatocellular adenoma.
  • The patient had never used oral contraceptive pills and she was urgently operated for haemorrhage control in another hospital where the left hepatic artery was also ligated.
  • After haemodynamic stabilization in the ICU and because of a complicated postoperative course (signs of intraabdominal sepsis) she was transferred to our hospital and a left lobectomy was performed.
  • We present the case and comment on the preferred treatment modalities of hepatocellular adenomas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ceylon Med J. 1997 Mar;42(1):42-3 [9164033.001]
  • [Cites] Liver Transpl Surg. 1995 Mar;1(2):99-102 [9346548.001]
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1426 [7484578.001]
  • [Cites] Arch Surg. 1994 Jul;129(7):712-7 [7517661.001]
  • [Cites] Br J Surg. 1993 Mar;80(3):380-3 [8472159.001]
  • [Cites] Br J Surg. 2001 Feb;88(2):207-9 [11167868.001]
  • [Cites] Ann Intern Med. 1989 Mar 15;110(6):489-90 [2537593.001]
  • [Cites] Ann Intern Med. 1986 Oct;105(4):547-9 [3019201.001]
  • [Cites] Lancet. 1980 Feb 9;1(8163):273-6 [6101735.001]
  • [Cites] Dig Surg. 2002;19(2):109-13 [11978996.001]
  • [Cites] Surg Gynecol Obstet. 1991 Nov;173(5):426-31 [1658955.001]
  • (PMID = 19582184.001).
  • [ISSN] 1790-8019
  • [Journal-full-title] Hippokratia
  • [ISO-abbreviation] Hippokratia
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Other-IDs] NLM/ PMC2464268
  • [Keywords] NOTNLM ; adenoma / giant / hepatocellular / rupture / surgical
  •  go-up   go-down


49. Mascarenhas NB, Mulcahy MF, Lewandowski RJ, Salem R, Ryu RK: Hepatic abscess after yttrium-90 radioembolization for islet-cell tumor hepatic metastasis. Cardiovasc Intervent Radiol; 2010 Jun;33(3):650-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic abscess after yttrium-90 radioembolization for islet-cell tumor hepatic metastasis.
  • Infectious complications after yttrium-90 (y-90) radioembolization of hepatic tumors are rare.
  • Most reports describe hepatic abscesses as complications of other locoregional therapies, such as transcatheter arterial embolization or chemoembolization.
  • We report a case of hepatic abscess formed immediately after y-90 radioembolization of a hepatic metastasis in a patient who had no history of previous biliary instrumentation.
  • [MeSH-major] Adenoma, Islet Cell / pathology. Embolization, Therapeutic / adverse effects. Liver Abscess / etiology. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688373.001).
  • [ISSN] 1432-086X
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Yttrium Radioisotopes
  •  go-up   go-down


50. Peltz M, Sandoval BA, Jessen ME: Traumatic rupture of a descending thoracic aortic homograft. Ann Thorac Surg; 2005 Aug;80(2):710-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Traumatic rupture of a descending thoracic aortic homograft.
  • My colleagues and I report an unusual case of traumatic aortic injury in an 18-year-old woman who had undergone multiple prior surgical procedures for repair of a type B interrupted aortic arch.
  • Imaging studies revealed rupture of the body of the aortic homograft with formation of a pseudoaneurysm.
  • The injury was successfully repaired with a Dacron graft by using hypothermic circulatory arrest.
  • [MeSH-minor] Accidents, Traffic. Adolescent. Aneurysm, False / diagnosis. Aneurysm, False / surgery. Blood Vessel Prosthesis Implantation. Female. Humans. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039236.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


51. Zboralski D, Warscheid B, Klein-Scory S, Malas MB, Becker H, Böckmann M, Meyer HE, Schmiegel W, Simon-Assmann P, Schwarte-Waldhoff I: Uncoupled responses of Smad4-deficient cancer cells to TNFalpha result in secretion of monomeric laminin-gamma2. Mol Cancer; 2010;9(1):65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncoupled responses of Smad4-deficient cancer cells to TNFalpha result in secretion of monomeric laminin-gamma2.
  • Uncoupled expression of laminin genes, on the other hand, namely overexpression of the laminin-gamma2 chain is an impressive marker at invasive edges of carcinomas where tumor cells are maximally exposed to signals from stromal cell types like macrophages.
  • Here, we address Smad4 dependent effects of the prominent inflammatory cytokine TNFalpha on tumor cells.
  • RESULTS: Smad4-reconstituted colon carcinoma cells like adenoma cells respond to TNFalpha with an increased expression of all three chains encoding laminin-332; coincubation with TGFbeta and TNFalpha leads to synergistic induction and to the secretion of large amounts of the heterotrimer.
  • In contrast, in Smad4-deficient cells TNFalpha can induce expression of the gamma2 and beta3 but not the alpha3 chain.
  • Surprisingly, this uncoupled induction of laminin-332 chains in Smad4-negative cells rather than causing intracellular accumulation is followed by the release of gamma2 into the medium, either in a monomeric form or in complexes with as yet unknown proteins.
  • Soluble gamma2 is associated with increased cell migration.
  • CONCLUSIONS: Loss of Smad4 may lead to uncoupled induction of laminin-gamma2 in response to TNFalpha and may therefore represent one of the mechanisms which underlie accumulation of laminin-gamma2 at the invasive margin of a tumor.
  • The finding, that gamma2 is secreted from tumor cells in significant amounts and is associated with increased cell migration may pave the way for further investigation to better understand its functional relevance for tumor progression.
  • [MeSH-minor] Adenoma / metabolism. Adenoma / secretion. Amino Acid Sequence. Cell Adhesion Molecules / metabolism. Cell Line, Tumor. Cell Movement / physiology. Drug Synergism. Gene Knockdown Techniques. Humans. Mass Spectrometry. Molecular Sequence Data. NF-kappa B / metabolism. Promoter Regions, Genetic. Protein Conformation. Transforming Growth Factor beta / metabolism. Transforming Growth Factor beta / pharmacology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Sep;287(3):G592-8 [15087281.001]
  • [Cites] J Mol Histol. 2004 Mar;35(3):277-86 [15339047.001]
  • [Cites] Proteomics. 2004 Sep;4(9):2541-4 [15352228.001]
  • [Cites] J Biol Chem. 1995 Oct 6;270(40):23496-503 [7559513.001]
  • [Cites] Gut. 1996 Nov;39(5):684-9 [9026483.001]
  • [Cites] Ann N Y Acad Sci. 1998 Nov 17;859:46-64 [9928369.001]
  • [Cites] Oncogene. 1999 May 20;18(20):3152-8 [10340387.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):496-502 [10507776.001]
  • [Cites] Cancer Lett. 2005 Jun 1;223(1):1-10 [15890231.001]
  • [Cites] Genes Dev. 2005 Dec 1;19(23):2783-810 [16322555.001]
  • [Cites] Cancer Sci. 2006 Feb;97(2):91-8 [16441418.001]
  • [Cites] Gastroenterology. 2006 Sep;131(3):830-40 [16952552.001]
  • [Cites] Proteomics. 2006 Sep;6(18):5015-29 [16927432.001]
  • [Cites] Oncogene. 2007 Mar 1;26(10):1417-27 [16953227.001]
  • [Cites] Dev Dyn. 2007 Jul;236(7):1980-90 [17503455.001]
  • [Cites] Int J Biochem Cell Biol. 2008;40(2):199-214 [17855154.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Dec;8(12):970-82 [18000526.001]
  • [Cites] EMBO J. 2008 Jun 18;27(12):1671-81 [18511911.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):7-9 [18598939.001]
  • [Cites] Curr Med Chem. 2008;15(20):1968-75 [18691052.001]
  • [Cites] BMC Cancer. 2008;8:215 [18664273.001]
  • [Cites] J Pathol. 1998 May;185(1):44-52 [9713359.001]
  • [Cites] Electrophoresis. 1999 Dec;20(18):3551-67 [10612281.001]
  • [Cites] Am J Pathol. 2000 Jan;156(1):45-50 [10623652.001]
  • [Cites] Nature. 2000 Feb 17;403(6771):781-5 [10693808.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 18;97(15):8358-63 [10890911.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3545-51 [10999742.001]
  • [Cites] J Bone Joint Surg Am. 2001;83-A Suppl 1(Pt 1):S31-9 [11263663.001]
  • [Cites] Clin Exp Metastasis. 2000;18(6):439-43 [11592300.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8089-93 [11719433.001]
  • [Cites] J Mol Biol. 2001 Dec 7;314(4):751-63 [11733994.001]
  • [Cites] Int J Cancer. 2001 Dec 15;94(6):763-7 [11745475.001]
  • [Cites] Histochem J. 2001 Nov-Dec;33(11-12):629-37 [12197671.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(14):1937-45 [12204677.001]
  • [Cites] Biochem J. 2003 Apr 1;371(Pt 1):211-21 [12519076.001]
  • [Cites] J Cell Biol. 2003 Apr 14;161(1):197-209 [12695504.001]
  • [Cites] Nat Rev Cancer. 2003 Jun;3(6):422-33 [12778132.001]
  • [Cites] Mol Biol Cell. 2003 May;14(5):1790-800 [12802055.001]
  • [Cites] Proteomics. 2004 May;4(5):1324-34 [15188399.001]
  • [Cites] Anal Chem. 2004 Jul 15;76(14):4193-201 [15253663.001]
  • (PMID = 20307265.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / LAMC2 protein, human; 0 / Laminin; 0 / NF-kappa B; 0 / SMAD4 protein, human; 0 / Smad4 Protein; 0 / Transforming Growth Factor beta; 0 / Tumor Necrosis Factor-alpha; 0 / kalinin; 170834-93-2 / laminin alpha 3
  • [Other-IDs] NLM/ PMC2853515
  •  go-up   go-down


52. Heukamp LC, Fischer HP, Schirmacher P, Chen X, Breuhahn K, Nicolay C, Büttner R, Gütgemann I: Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions. Histopathology; 2006 Sep;49(3):242-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Podocalyxin-like protein 1 expression in primary hepatic tumours and tumour-like lesions.
  • AIMS: The differential diagnosis of benign hepatic lesions and well-differentiated hepatocellular carcinomas can be a challenge, especially in small biopsy specimens.
  • Recently, novel proteins expressed by the neovasculature in hepatocellular carcinoma (HCC) have been identified.
  • The aim of this study was to compare the expression of podocalyxin-like protein 1 (PODXL1), a CD34-related sialomucin, in HCC and benign liver tumours or tumour-like lesions.
  • METHODS AND RESULTS: Vascular marker expression was examined using tissue microarrays as well as standard paraffin sections from formalin fixed paraffin-embedded liver tissue samples.
  • PODXL1 is expressed in tumour-associated microvasculature endothelial cells in HCC, as well as in capillarized sinusoidal endothelium of focal nodular hyperplasia (FNH) and hepatic adenoma.
  • CONCLUSIONS: Expression patterns of CD34 and PODXL1 are almost identical in primary hepatic tumours and tumour-like lesions.
  • The presence of CD34+ and PODXL1+ sinusoidal endothelial cells aids in the diagnosis of HCC.
  • Sinusoidal expression of PODXL1 is also seen in a less diffuse pattern in FNH and adenoma.
  • [MeSH-major] Liver Diseases / metabolism. Liver Neoplasms / metabolism. Sialoglycoproteins / biosynthesis
  • [MeSH-minor] Antigens, CD31 / biosynthesis. Antigens, CD34 / biosynthesis. Biomarkers, Tumor / analysis. Diagnosis, Differential. Endothelial Cells / metabolism. Humans. Immunohistochemistry. Protein Array Analysis. von Willebrand Factor / biosynthesis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16918970.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / Sialoglycoproteins; 0 / podocalyxin; 0 / von Willebrand Factor
  •  go-up   go-down


53. Gargano JW, Holzman C, Senagore P, Thorsen P, Skogstrand K, Hougaard DM, Rahbar MH, Chung H: Mid-pregnancy circulating cytokine levels, histologic chorioamnionitis and spontaneous preterm birth. J Reprod Immunol; 2008 Oct;79(1):100-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some spontaneous preterm deliveries (PTD) are caused by occult infections of the fetal membranes (histologic chorioamnionitis [HCA]).
  • High levels of infection-related markers, including some cytokines, sampled from maternal circulation in mid-pregnancy have been linked to PTD, but whether these specifically identify HCA has not been established.
  • We have tested associations between 13 Th1, Th2 and Th17 cytokines and PTD with and without HCA in a prospective cohort study.
  • A panel of cytokines was assessed using a multiplex assay in maternal plasma collected at 15-27 weeks of gestation.
  • Severe HCA was scored by a placental pathologist blinded to clinical variables.
  • Multivariable polytomous logistic regression was used to estimate adjusted odds ratios (OR) per 1 standard deviation (S.D.) increase in cytokine levels using a 5 level outcome variable: PTD <35 weeks with HCA, PTD <35 weeks without HCA, PTD 35-36 weeks with HCA, PTD 35-36 weeks without HCA, and term (referent).
  • Interleukin (IL)-1beta, IL-2, IL-12, interferon-gamma, IL-4, IL-6 and transforming growth factor-beta were all significantly associated with PTD <35 weeks with HCA, with ORs of 1.6-2.3 per S.D. increase.
  • None of these were associated with PTD <35 weeks without HCA or PTD 35-36 weeks with HCA.
  • Although the tissues of origin of circulating cytokines are unclear, the observed elevations across many cytokines among women who later delivered <35 weeks with HCA may represent a robust immune response to infection within gestational tissues.
  • These results suggest that women with HCA could be identified using relatively non-invasive means.

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Preterm Labor.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Reprod Immunol. 2007 Oct;75(2):133-40 [17442403.001]
  • [Cites] Am J Epidemiol. 2007 Oct 1;166(7):786-94 [17625222.001]
  • [Cites] Lancet. 2008 Jan 19;371(9608):261-9 [18207020.001]
  • [Cites] J Obstet Gynaecol Res. 2008 Feb;34(1):7-11 [18226122.001]
  • [Cites] Semin Immunol. 2007 Dec;19(6):362-71 [18035554.001]
  • [Cites] Am J Obstet Gynecol. 2000 Mar;182(3):625-30 [10739519.001]
  • [Cites] Paediatr Perinat Epidemiol. 2001 Jul;15 Suppl 2:136-58 [11520406.001]
  • [Cites] BJOG. 2002 May;109(5):534-9 [12066943.001]
  • [Cites] Paediatr Perinat Epidemiol. 2002 Oct;16(4):297-304 [12445145.001]
  • [Cites] Clin Biochem. 2003 Jul;36(5):323-31 [12849862.001]
  • [Cites] J Reprod Immunol. 2003 Aug;59(2):161-73 [12896820.001]
  • [Cites] Am J Obstet Gynecol. 2003 Aug;189(2):560-7 [14520234.001]
  • [Cites] Int Arch Allergy Immunol. 2004 Jun;134(2):93-119 [15153791.001]
  • [Cites] Am J Clin Nutr. 1987 Nov;46(5):736-48 [3314468.001]
  • [Cites] Am J Obstet Gynecol. 1993 Oct;169(4):1035-44 [8238116.001]
  • [Cites] Obstet Gynecol. 1996 Mar;87(3):360-5 [8598955.001]
  • [Cites] Obstet Gynecol. 1996 May;87(5 Pt 1):656-60 [8677062.001]
  • [Cites] Am J Obstet Gynecol. 1996 Nov;175(5):1356-9 [8942514.001]
  • [Cites] Obstet Gynecol. 1997 Sep;90(3):465-9 [9277663.001]
  • [Cites] Am J Obstet Gynecol. 1998 Mar;178(3):546-50 [9539524.001]
  • [Cites] J Perinat Med. 1998;26(1):17-26 [9595363.001]
  • [Cites] Lancet. 1999 Sep 25;354(9184):1095-6 [10509506.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1854-66 [16081507.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 Oct 1;122(2):136-43 [15893871.001]
  • [Cites] Am J Epidemiol. 2005 Dec 1;162(11):1108-13 [16236995.001]
  • [Cites] Matern Child Health J. 2006 Mar;10(2):127-38 [16400535.001]
  • [Cites] Nat Immunol. 2006 Jun;7(6):557-9 [16715066.001]
  • [Cites] Immunity. 2006 Jun;24(6):677-88 [16782025.001]
  • [Cites] Semin Fetal Neonatal Med. 2006 Oct;11(5):317-26 [16839830.001]
  • [Cites] Trends Immunol. 2006 Aug;27(8):358-61 [16793343.001]
  • [Cites] Obstet Gynecol. 2007 Jan;109(1):121-7 [17197597.001]
  • [Cites] J Reprod Immunol. 2007 Feb;73(1):74-84 [17034864.001]
  • [Cites] Clin Biochem. 2007 Mar;40(5-6):330-5 [17289011.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Mar;92(3):969-75 [17192290.001]
  • [Cites] J Reprod Immunol. 2007 Apr;73(2):158-65 [17074396.001]
  • [Cites] Mol Aspects Med. 2007 Apr;28(2):192-209 [17433431.001]
  • [Cites] Am J Epidemiol. 2007 Aug 1;166(3):323-31 [17504778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12099-104 [17623780.001]
  • [Cites] Acta Obstet Gynecol Scand. 2007;86(9):1103-10 [17712652.001]
  • [Cites] Am J Epidemiol. 2007 Dec 1;166(11):1312-9 [17906337.001]
  • (PMID = 18814919.001).
  • [ISSN] 0165-0378
  • [Journal-full-title] Journal of reproductive immunology
  • [ISO-abbreviation] J. Reprod. Immunol.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD34543; United States / NICHD NIH HHS / HD / HD034543-05A1; United States / NICHD NIH HHS / HD / HD034543-07S1; United States / NICHD NIH HHS / HD / HD034543-08; United States / NCCDPHP CDC HHS / DP / U01 DP000143-01; United States / NICHD NIH HHS / HD / R01 HD034543-07; United States / NICHD NIH HHS / HD / R01 HD034543; United States / NICHD NIH HHS / HD / R01 HD034543-04; United States / NICHD NIH HHS / HD / R01 HD034543-06; United States / NICHD NIH HHS / HD / R01 HD034543-03; United States / NICHD NIH HHS / HD / R01 HD034543-05A1; United States / NICHD NIH HHS / HD / HD034543-06; United States / NCCDPHP CDC HHS / DP / U01 DP000143; United States / NICHD NIH HHS / HD / HD034543-03; United States / NICHD NIH HHS / HD / R01 HD034543-08; United States / NICHD NIH HHS / HD / R01 HD034543-07S1; United States / NICHD NIH HHS / HD / HD034543-04; United States / NICHD NIH HHS / HD / HD034543-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cytokines
  • [Other-IDs] NLM/ NIHMS77538; NLM/ PMC2683663
  •  go-up   go-down


54. Urbanski PP, Lenos A, Lindemann Y, Zacher M, Frank S, Diegeler A: Use of a carotid artery for arterial cannulation: side-related differences. Thorac Cardiovasc Surg; 2010 Aug;58(5):276-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a carotid artery for arterial cannulation: side-related differences.
  • The arterial line was also used for unilateral cerebral perfusion for brain protection during mild hypothermic circulatory arrest.
  • RESULTS: No complications related to the cannulation of a carotid artery were observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) Georg Thieme Verlag KG Stuttgart-New York.
  • [CommentIn] Thorac Cardiovasc Surg. 2010 Dec;58(8):503; author reply 504 [21110280.001]
  • (PMID = 20680903.001).
  • [ISSN] 1439-1902
  • [Journal-full-title] The Thoracic and cardiovascular surgeon
  • [ISO-abbreviation] Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. Schwentner I, Obrist P, Thumfart W, Sprinzl G: Distant metastasis of parotid gland tumors. Acta Otolaryngol; 2006 Apr;126(4):340-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the basis of a clinical case regarding a patient with metastatic parotid gland cancer we present a review of the literature.
  • [MeSH-major] Adenoma, Pleomorphic / pathology. Ileal Neoplasms / secondary. Parotid Neoplasms / pathology
  • [MeSH-minor] Aged. Bone Neoplasms / secondary. Brain Neoplasms / secondary. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / secondary. Carcinoma, Adenoid Cystic / pathology. Carcinoma, Adenoid Cystic / secondary. Carcinoma, Mucoepidermoid / pathology. Carcinoma, Mucoepidermoid / secondary. Fatal Outcome. Humans. Immunohistochemistry. Incidence. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Parotid Gland / pathology. Parotid Gland / surgery. Salivary Ducts / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16608783.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 32
  •  go-up   go-down


56. Rubio CA: Serrated neoplasias and de novo carcinomas in ulcerative colitis: a histological study in colectomy specimens. J Gastroenterol Hepatol; 2007 Jul;22(7):1024-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serrated neoplasias and de novo carcinomas in ulcerative colitis: a histological study in colectomy specimens.
  • BACKGROUND AND AIM: Cancer in ulcerative colitis (UC) originates in dysplastic crypts, adenomatous growths (UCAG), and UC-associated adenomas (UCAD).
  • The aim of the present study was to compare the histological phenotypes between UCAG, UCAD, and sporadic colorectal adenomas in non-colitics (non-UCAD), as well as between UC-associated carcinomas (UCC) and carcinomas in non-colitic patients (non-UCC).
  • Villous and signet ring cell cancer phenotypes were more frequent in UCC (22% and 8%, respectively) than in non-UCC (9% and 0.8%, respectively).
  • Six UCC (5.6%) were de novo carcinomas.
  • The different proportions of histological phenotypes found in UCAG, UCAD, and non-UCAD on the one hand, and UCC and non-UCC on the other, suggest that chronic protracted inflammation might have modified the stem cell receptors that receive the molecular signals that program structural configurations in neoplastic glands.
  • This is the first study reporting the occurrence of serrated and microtubular UCAG and of de novo carcinomas in UC.
  • [MeSH-major] Adenoma / pathology. Adenoma / surgery. Colectomy. Colitis, Ulcerative / pathology. Colitis, Ulcerative / surgery. Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery


57. Saczewski F, Innocenti A, Brzozowski Z, Slawiński J, Pomarnacka E, Kornicka A, Scozzafava A, Supuran CT: Carbonic anhydrase inhibitors. Selective inhibition of human tumor-associated isozymes IX and XII and cytosolic isozymes I and II with some substituted-2-mercapto-benzenesulfonamides. J Enzyme Inhib Med Chem; 2006 Oct;21(5):563-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These derivatives were medium potency hCA I inhibitors (K(I)s in the range of 1.5-5.7 microM), two derivatives were strong hCA II inhibitors (K(I)s in the range of 15-16 nM), whereas the others showed weak activity.
  • These compounds inhibited hCA IX with inhibition constants in the range 160-1950 nM and hCA XII with inhibition constants in the range 1.2-413 nM.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17194028.001).
  • [ISSN] 1475-6366
  • [Journal-full-title] Journal of enzyme inhibition and medicinal chemistry
  • [ISO-abbreviation] J Enzyme Inhib Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbonic Anhydrase Inhibitors; 0 / Isoenzymes; 0 / Sulfonamides
  •  go-up   go-down


58. Ferrucci LM, Cross AJ, Graubard BI, Brinton LA, McCarty CA, Ziegler RG, Ma X, Mayne ST, Sinha R: Intake of meat, meat mutagens, and iron and the risk of breast cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Br J Cancer; 2009 Jul 7;101(1):178-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Comparing the fifth to the first quintile, red meat (HR=1.23; 95% CI=1.00-1.51, P trend=0.22), the heterocyclic amine (HCA), 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx), (HR=1.26; 95% CI=1.03-1.55; P trend=0.12), and dietary iron (HR=1.25; 95% CI=1.02-1.52; P trend=0.03) were positively associated with breast cancer.
  • We observed elevated, though not statistically significant, risks with processed meat, the HCA 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline (DiMeIQx), mutagenic activity, iron from meat, and haem iron from meat.

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2001 Jan 15;91(2):260-3 [11146455.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):905-10 [11008907.001]
  • [Cites] Curr Med Chem. 2001 Jun;8(7):839-49 [11375754.001]
  • [Cites] Am J Epidemiol. 2001 Dec 15;154(12):1089-99 [11744511.001]
  • [Cites] Int J Epidemiol. 2002 Feb;31(1):78-85 [11914299.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):801-8 [12223422.001]
  • [Cites] Mutat Res. 2002 Sep 30;506-507:145-52 [12351154.001]
  • [Cites] Int J Cancer. 2003 Mar 20;104(2):221-7 [12569578.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):19-27 [12708721.001]
  • [Cites] Br J Cancer. 2003 Nov 3;89(9):1672-85 [14583769.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):153-71 [14643418.001]
  • [Cites] Nutr Cancer. 2003;46(2):131-7 [14690788.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):205-12 [14973098.001]
  • [Cites] Cancer Causes Control. 2004 Apr;15(3):295-303 [15090724.001]
  • [Cites] J Am Diet Assoc. 1982 Apr;80(4):307-11 [7061776.001]
  • [Cites] Carcinogenesis. 1991 Jan;12(1):111-4 [1988169.001]
  • [Cites] Crit Rev Food Sci Nutr. 1992;31(4):333-67 [1581009.001]
  • [Cites] Carcinogenesis. 1995 Feb;16(2):431-4 [7859378.001]
  • [Cites] Int J Cancer. 1996 Jan 17;65(2):140-4 [8567108.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):573-81 [9264269.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1757-62 [9328172.001]
  • [Cites] J Epidemiol Community Health. 1998 Feb;52(2):105-10 [9578857.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 18;90(22):1724-9 [9827527.001]
  • [Cites] Int J Cancer. 1999 Jan 5;80(1):13-7 [9935222.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Mar;8(3):233-9 [10090301.001]
  • [Cites] Mol Nutr Food Res. 2005 Jul;49(7):648-55 [15986387.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):717-25 [16614114.001]
  • [Cites] Arch Intern Med. 2006 Nov 13;166(20):2253-9 [17101944.001]
  • [Cites] Br J Cancer. 2007 Apr 10;96(7):1139-46 [17406351.001]
  • [Cites] Epidemiology. 2007 May;18(3):373-82 [17435448.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1306-8 [17548704.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Sep;16(9):1784-94 [17726138.001]
  • [Cites] Cancer Causes Control. 2007 Dec;18(10):1047-53 [17823849.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jan;107(1):123-32 [17431764.001]
  • [Cites] Eur J Cancer Prev. 2008 Feb;17(1):39-47 [18090909.001]
  • [Cites] Nutr Cancer. 2008;60(3):313-24 [18444165.001]
  • [Cites] Int J Cancer. 2008 Oct 1;123(7):1637-43 [18636564.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):2146-51 [18669582.001]
  • [Cites] Nutr Cancer. 2009;61(1):36-46 [19116874.001]
  • [Cites] Int J Cancer. 2009 May 15;124(10):2430-5 [19165862.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):607-15 [10753193.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1352-4 [10944558.001]
  • [Cites] Control Clin Trials. 2000 Dec;21(6 Suppl):273S-309S [11189684.001]
  • (PMID = 19513076.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA105666-01; United States / NCI NIH HHS / CA / TU2 CA105666; United States / Intramural NIH HHS / / Z01 CP010127-12; United States / NCI NIH HHS / CA / TU2 CA105666-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iron, Dietary; 0 / Mutagens
  • [Other-IDs] NLM/ PMC2713710
  •  go-up   go-down


59. Seike M, Kondo T, Fujii K, Okano T, Yamada T, Matsuno Y, Gemma A, Kudoh S, Hirohashi S: Proteomic signatures for histological types of lung cancer. Proteomics; 2005 Jul;5(11):2939-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed proteomic studies on lung cancer cells to elucidate the mechanisms that determine histological phenotype.
  • Thirty lung cancer cell lines with three different histological backgrounds (squamous cell carcinoma, small cell lung carcinoma and adenocarcinoma) were subjected to two-dimensional difference gel electrophoresis (2-D DIGE) and grouped by multivariate analyses on the basis of their protein expression profiles.
  • We found that hierarchical clustering analysis and principal component analysis divided the cell lines according to their original histology.
  • Spot ranking analysis using a support vector machine algorithm and unsupervised classification methods identified 32 protein spots essential for the classification.
  • Next, lung cancer cells isolated from tumor tissue by laser microdissection were classified on the basis of the expression pattern of these 32 protein spots.
  • Based on the expression profile of the 32 spots, the isolated cancer cells were categorized into three histological groups: the squamous cell carcinoma group, the adenocarcinoma group, and a group of carcinomas with other histological types.
  • In conclusion, our results demonstrate the utility of quantitative proteomic analysis for molecular diagnosis and classification of lung cancer cells.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Lung / chemistry. Lung Neoplasms / pathology. Neoplasm Proteins / analysis
  • [MeSH-minor] Adenocarcinoma / pathology. Biomarkers, Tumor. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Small Cell / pathology. Cell Line, Tumor. Electrophoresis, Polyacrylamide Gel. Humans. Microdissection. Multivariate Analysis. Peptide Mapping

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996008.001).
  • [ISSN] 1615-9853
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


60. Lee IJ, Kim SH, Kim DS, Lee JM, Han JK, Choi BI: Intrahepatic extramedullary hematopoiesis mimicking a hypervascular hepatic neoplasm on dynamic- and SPIO-enhanced MRI. Korean J Radiol; 2008 Jul;9 Suppl:S34-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrahepatic extramedullary hematopoiesis mimicking a hypervascular hepatic neoplasm on dynamic- and SPIO-enhanced MRI.
  • We present a rare case of a focal intrahepatic extramedullary hematopoiesis (EMH) that mimicked a hypervascular hepatic neoplasm in a 33-year-old woman with idiopathic myelofibrosis.
  • The lesion did not demonstrate an apparent signal drop on a T2-weighted sequence following administration of a superparamagnetic iron-oxide agent (SHU 555A).
  • A hepatocellular adenoma was the initial radiological diagnosis.
  • To the best of our knowledge, this is the first report of a histopathologically proven intrahepatic EMH evaluated with dynamic- and SPIO-enhanced MRI.
  • [MeSH-major] Adenoma / diagnosis. Hematopoiesis, Extramedullary. Liver / physiology. Liver Neoplasms / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male. Primary Myelofibrosis / physiopathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 1999 Sep;72(861):906-10 [10645201.001]
  • [Cites] Magn Reson Med Sci. 2006 Dec;5(4):191-6 [17332709.001]
  • [Cites] J Korean Med Sci. 2000 Aug;15(4):460-2 [10983698.001]
  • [Cites] Radiology. 2000 Oct;217(1):152-8 [11012438.001]
  • [Cites] J Magn Reson Imaging. 2001 Mar;13(3):397-401 [11241813.001]
  • [Cites] Eur Radiol. 2001;11(11):2319-31 [11702180.001]
  • [Cites] AJR Am J Roentgenol. 2004 Apr;182(4):1031-2 [15039182.001]
  • [Cites] AJR Am J Roentgenol. 1987 Dec;149(6):1171-2 [3318340.001]
  • [Cites] J Clin Ultrasound. 1989 May;17(4):280-2 [2497146.001]
  • [Cites] AJR Am J Roentgenol. 1990 Apr;154(4):900-1 [2107698.001]
  • [Cites] Radiology. 1990 May;175(2):489-93 [2326474.001]
  • [Cites] Surgery. 1990 Jun;107(6):704-7 [2353310.001]
  • [Cites] Acta Cytol. 1990 Jul-Aug;34(4):567-9 [2375226.001]
  • [Cites] J Comput Assist Tomogr. 1991 Jul-Aug;15(4):683-5 [2061490.001]
  • [Cites] Abdom Imaging. 1999 Jul-Aug;24(4):366-8 [10390558.001]
  • [Cites] Eur Radiol. 2006 Sep;16(9):1887-97 [16547707.001]
  • [Cites] Cancer Imaging. 2006;6:182-5 [17208673.001]
  • [Cites] Abdom Imaging. 2000 Mar-Apr;25(2):184-6 [10675463.001]
  • (PMID = 18607123.001).
  • [ISSN] 1229-6929
  • [Journal-full-title] Korean journal of radiology
  • [ISO-abbreviation] Korean J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2627188
  •  go-up   go-down


61. Ikota H, Kinjo S, Yokoo H, Nakazato Y: Systematic immunohistochemical profiling of 378 brain tumors with 37 antibodies using tissue microarray technology. Acta Neuropathol; 2006 May;111(5):475-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our TMA consisted of a grid of 1.5-mm cores that were extracted from individual donor blocks.
  • We used hierarchical clustering analysis to interpret these data, which resulted in separation of all the brain tumors into seven groups.
  • Although there were some exceptions, cases with the same histological diagnosis were generally grouped together.
  • We then carried out statistical analyses to find the most useful antibodies for grouping of brain tumors.
  • Six antibodies [EMA, AE1/AE3, TUJ1, nestin, neurofilament protein-MH (NF-MH) and perivascular cells GP-1] showed significant differences between high-grade and low-grade gliomas.
  • [MeSH-major] Antibodies / immunology. Astrocytoma / immunology. Brain Neoplasms / immunology. Immunohistochemistry / methods. Oligodendroglioma / immunology. Protein Array Analysis / methods
  • [MeSH-minor] Aquaporin 4 / immunology. Aquaporin 4 / metabolism. Basic Helix-Loop-Helix Transcription Factors / immunology. Basic Helix-Loop-Helix Transcription Factors / metabolism. Biomarkers, Tumor / immunology. Biomarkers, Tumor / metabolism. Cluster Analysis. Diagnosis, Differential. Glial Fibrillary Acidic Protein / immunology. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / immunology. Intermediate Filament Proteins / metabolism. Mucin-1 / immunology. Mucin-1 / metabolism. Nerve Tissue Proteins / immunology. Nerve Tissue Proteins / metabolism. Nestin. Prognosis. Vimentin / immunology. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16598485.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / AQP4 protein, human; 0 / Antibodies; 0 / Aquaporin 4; 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Mucin-1; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / OLIG2 protein, human; 0 / Vimentin; 0 / alpha-internexin
  •  go-up   go-down


62. Chia WK, Sharifah NA, Reena RM, Zubaidah Z, Clarence-Ko CH, Rohaizak M, Naqiyah I, Srijit D, Hisham AN, Asmiati A, Rafie MK: Fluorescence in situ hybridization analysis using PAX8- and PPARG-specific probes reveals the presence of PAX8-PPARG translocation and 3p25 aneusomy in follicular thyroid neoplasms. Cancer Genet Cytogenet; 2010 Jan 1;196(1):7-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization analysis using PAX8- and PPARG-specific probes reveals the presence of PAX8-PPARG translocation and 3p25 aneusomy in follicular thyroid neoplasms.
  • At the present time, the differentiation between follicular thyroid carcinoma (FTC) and adenoma can be made only postoperatively and is based on the presence of capsular or vascular invasion.
  • The ability to differentiate preoperatively between the malignant and benign forms of follicular thyroid tumors assumes greater importance in any clinical setting.
  • In this study, a group of 60 follicular thyroid neoplasms [18 FTC, 1 Hurthle cell carcinoma (HCC), 24 follicular thyroid adenomas (FTA), 5 Hurthle cell adenomas (HCA), and 12 follicular variants of papillary thyroid carcinomas (FV-PTC)] were analyzed to determine the prevalence of the PAX8-PPARG translocation by fluorescence in situ hybridization.
  • In addition, 2/18 (11.1%) FTC and 1/5 (20%) HCA showed 3p25 aneusomy only.

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19963130.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Molecular Probes; 0 / PAX8 protein, human; 0 / PPAR gamma; 0 / Paired Box Transcription Factors
  •  go-up   go-down


63. Davis RA, Innocenti A, Poulsen SA, Supuran CT: Carbonic anhydrase inhibitors. Identification of selective inhibitors of the human mitochondrial isozymes VA and VB over the cytosolic isozymes I and II from a natural product-based phenolic library. Bioorg Med Chem; 2010 Jan 1;18(1):14-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have investigated the enzyme inhibition characteristics of a natural product (NP)-based phenolic library against a panel of human carbonic anhydrases (hCAs, EC 4.2.1.1) which included hCAs I and II (cytosolic) and hCA VA/VB (mitochondrial isoforms).
  • Most of these compounds were weak, micromolar inhibitors of the two cytosolic hCAs (K(I)s >10 microM) but showed good hCA VA/VB inhibitory activity with inhibition constants in the range of 70-125 nM.
  • The selectivity ratios for inhibiting the mitochondrial over the cytosolic isoforms for these phenol derivatives were in the range of 120-3800, making them the most isoform-selective compounds for inhibiting hCA VA/VB known to date.
  • Thus the NP inhibitors identified during these studies are excellent leads for obtaining even more effective compounds that selectively target mitochondrial hCAs, and also have the potential to be used as tools for understanding the physiological processes that are regulated by the two mitochondrial CA isoforms.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19962903.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbonic Anhydrase Inhibitors; 0 / Isoenzymes; 0 / Phenols; EC 4.2.1.- / Carbonic Anhydrase I; EC 4.2.1.- / Carbonic Anhydrase II; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


64. Mehrabi M, Ghobadi S, Khodarahmi R: Spectroscopic study on the interaction of celecoxib with human carbonic anhydrase II: thermodynamic characterization of the binding process. J Photochem Photobiol B; 2009 Dec 2;97(3):161-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effect of celecoxib, a sulfonamide drug, on the structure and function of human carbonic anhydrase II (hCA II) was investigated by various spectroscopic techniques such as UV-Vis, fluorescence and circular dichroism (CD) spectroscopy and differential scanning calorimetry (DSC), in 20 mM Tris, pH 7.75 at 27 degrees C.
  • Kinetic results revealed that celecoxib inhibits the esterase activity of hCA II in a linear competitive manner with K(i) = 61.61 + or -3.05 nM.
  • Stern-Volmer analysis of quenching data at different temperatures elucidated that the quenching of intrinsic fluorescence of hCA II is occurred through a static quenching mechanism.
  • Analysis of the thermodynamic parameters of binding showed that hydrogen bonding and hydrophobic interactions play the major role in stabilization of the enzyme-drug complex.
  • The Job's plot confirmed the existence of one binding site for celecoxib in hCA II.
  • The far- and near-UV CD experiments indicated that celecoxib causes a little increment in alpha-helicity content of hCA II whereas its flexibility is decreased somewhat upon celecoxib binding.

  • Hazardous Substances Data Bank. CELECOXIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Photochem Photobiol B. 2010 Mar 8;98(3):225
  • (PMID = 19879770.001).
  • [ISSN] 1873-2682
  • [Journal-full-title] Journal of photochemistry and photobiology. B, Biology
  • [ISO-abbreviation] J. Photochem. Photobiol. B, Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anilino Naphthalenesulfonates; 0 / Cyclooxygenase 2 Inhibitors; 0 / Fluorescent Dyes; 0 / Pyrazoles; 0 / Sulfonamides; 82-76-8 / 1-anilino-8-naphthalenesulfonate; EC 4.2.1.- / Carbonic Anhydrase II; JCX84Q7J1L / Celecoxib
  •  go-up   go-down


65. Brennan G, McSherry R: Exploring the transition and professional socialisation from health care assistant to student nurse. Nurse Educ Pract; 2007 Jul;7(4):206-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Minimal research is available examining the socialisation process from the perspective of students with health care knowledge who prior to undertaking their training worked as a health care assistant (HCA).
  • The transition and professional socialisation process undertaken by students is an important factor in contributing to the successful completion of a pre-registration nursing programme.
  • OBJECTIVE: The studies aim was to determine the transitional processes associated with moving from a HCA to Student Nurse.
  • POPULATION, SAMPLE, SETTING: A homogeneous sample of 14 students with previous experience as a HCA within the field of adult nursing was used.
  • ] thematic content analysis.
  • Equally a new concept is introduced from the findings, that of 'the comfort zone', which explores the intentional reversal into the HCA role by the participants of the study.
  • From the findings a framework for the transition and professional socialisation from HCA to student nurse is provided.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17689446.001).
  • [ISSN] 1873-5223
  • [Journal-full-title] Nurse education in practice
  • [ISO-abbreviation] Nurse Educ Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. He F, Lin L, Zhao S, Zhao S, Chen S, Wang X: [Fast formation of biomimetic apatite coatings on pure porous titanium implant's surface]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2007 Aug;24(4):806-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to elaborate a dense, strong and thin calcium-phosphate coating on commercial porous pure titanium implant surface in the light of a fast biomimetic procedure.
  • A thin calcium-phosphate coating was deposited on all the specimens of the two groups, the surface consisted of well-formed crystals, which were proved to be the mixture of hydroxycarbonated apatite (HCA) and octacalcium phosphate (OCP); the coating's Ca/P rate was 1.51.

  • Hazardous Substances Data Bank. TITANIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17899750.001).
  • [ISSN] 1001-5515
  • [Journal-full-title] Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi
  • [ISO-abbreviation] Sheng Wu Yi Xue Gong Cheng Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Calcium Phosphates; 0 / Coated Materials, Biocompatible; D1JT611TNE / Titanium
  •  go-up   go-down


67. Loewy EH: Age discrimination at its best: should chronological age be a prime factour in medical decision making? Health Care Anal; 2005 Jun;13(2):101-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper briefly reviews the papers in this special section of HCA and makes the point--a point which should be obvious--that statistics are useful only as guidelines but tell one nothing about the individual patient in front of you.
  • To ration on the basis of age alone is unfair to the individual denied treatment and damaging to the community because it disturbs the solidarity which comes about because most members of the community feel that the community has obligations beyond those of not directly harming them; indeed, what produces solidarity is the feeling that members of a community will do their best to come to each others help.
  • It is pointed out that what matters is a patient's disease and not his/her age.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16013524.001).
  • [ISSN] 1065-3058
  • [Journal-full-title] Health care analysis : HCA : journal of health philosophy and policy
  • [ISO-abbreviation] Health Care Anal
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] KIE/ 123470
  • [Keywords] KIE ; Analytical Approach / Health Care and Public Health
  • [General-notes] KIE/ 20 fn.; KIE/ KIE Bib: patien care/aged; resource allocation; selection for treatment
  •  go-up   go-down


68. Popescu I, Vasile S, Sgarbură O: [The Pringle maneuver in laparoscopic hepatic surgery: is it useful? Analysis of a series of 38 cases]. Chirurgia (Bucur); 2007 Sep-Oct;102(5):521-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The Pringle maneuver in laparoscopic hepatic surgery: is it useful? Analysis of a series of 38 cases].
  • [Transliterated title] Este utilă manevra Pringle în chirurgia hepatică prin abord laparoscopic? Analiza unei serii de 38 cazuri.
  • The Pringle maneuver is the most feasible method to control bleeding in hepatic resections in both open and laparoscopic approach.
  • This is a retrospective cohort study that includes all hepatic laparoscopic resections performed in our department between 1998-2007 and excludes all exploratory laparoscopies and all cases in which conversion to open procedure was imposed after the lesion assessment and in the absence on any intraoperative event.
  • 38 hepatic laparoscopic resections were performed for both benign lesions (20 out of which 13 hemangiomas, 2 focal nodular hyperplasia, 1 liver cell adenoma, 2 hydatic cysts, 2 inflammatory lesions) and malignant lesions (18 out of which 8 metastases, 9 hepatocellular carcinoma, 1 cholangiocarcinoma).
  • There were 2 conversions to open procedures due to bleeding from hepatic veins collaterals.
  • Pringle maneuver did not prove to be useful in our series because, on one hand, we performed only limited laparoscopic hepatic resections and, on the other hand, intraoperative bleeding was mainly due to lesions of the hepatic veins collaterals which cannot be influenced by clamping the hepatic pedicle.
  • Even if there is no consensus, major laparoscopic hepatic resections may benefit from Pringle maneuver.
  • [MeSH-major] Hepatectomy / methods. Laparoscopy. Liver Diseases / surgery
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Humans. Liver Neoplasms / surgery. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18018350.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


69. Carestiato FN, Silva KC, Dimetz T, Oliveira LH, Cavalcanti SM: Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay. Braz J Infect Dis; 2006 Oct;10(5):331-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of human papillomavirus infection in the genital tract determined by hybrid capture assay.
  • Recently developed, the second generation of the hybrid capture test (HCA II) is a non-radioactive, relatively rapid, hybridization assay, designed to detect 18 HPV types divided into high and low-risk groups.
  • We evaluated 7,314 patients (5,833 women and 1,481 men) for HPV infection by HCA II.
  • Because of high costs, the HCA II test cannot be recommended for routine mass screening for cervical infection in poor countries.
  • These findings point to the need for close and careful management of patients, thereby reducing overtreatment, allowing analysis of both sexual partners and finally contributing to the control of genital infections associated with a risk for cancer.
  • [MeSH-minor] Adolescent. Adult. Aged. Brazil / epidemiology. Child. DNA, Viral / analysis. Female. Humans. Male. Middle Aged. Prevalence. Risk Factors. Viral Load

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17293921.001).
  • [ISSN] 1413-8670
  • [Journal-full-title] The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
  • [ISO-abbreviation] Braz J Infect Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


70. Tustian W: Allowing HCAs to develop is good for patients and nurses. Nurs Stand; 2006 Sep 20;21(2):30-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allowing HCAs to develop is good for patients and nurses.
  • As a former HCA about to begin my second year of nurse training, I was disappointed to read David Salvage's views on caring responsibilities (reflections August 30).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28086506.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


71. Ananiadou OG, Drossos GE, Bibou KN, Palatianos GM, Johnson EO: Acute regional neuronal injury following hypothermic circulatory arrest in a porcine model. Interact Cardiovasc Thorac Surg; 2005 Dec;4(6):597-601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute regional neuronal injury following hypothermic circulatory arrest in a porcine model.
  • OBJECTIVES: Although deep hypothermic circulatory arrest (HCA) is routinely used to interrupt normal perfusion of the brain and prevent subsequent cerebral ischemic injury during cardiac surgery, it is associated with various forms of neurologic disturbances.
  • Neurologic sequelae after prolonged HCA include motor, memory and cognitive deficits.
  • The present study was designed to assess acute regional neuronal injury after HCA in an animal model.
  • METHODS: Six piglets underwent 75 min of HCA at 18 degrees C.
  • Regional patterns of neuronal apoptosis after HCA was characterized by in situ DNA fragmentation using terminal deoxyneucleotidyl-transferase-mediated biotin-dUTP nick end-labeling (TUNEL) histochemistry.
  • Hematoxylin and eosin histology was used to characterize cell damage morphologically.
  • TUNEL-positive cells were scored on a scale of 0 to 5.
  • Grade 0: no TUNEL-positive cells; Grade 1: <10%, Grade 2: 10-25%, Grade 3: 25-50%, Grade 4: 50-75%; and Grade 5: >75%.
  • RESULTS: TUNEL-positive cells indicating DNA-fragmentation were scored in the precentral gyrus (motor neocortex), postcentral gyrus (sensory neocortex), hippocampus, cerebellum, thalamus and ventral medulla of HCA treated animals and were significantly greater than in normal controls (P<or=0.05).
  • Significantly higher concentrations of TUNEL-positive cells were observed in the sensory and motor neocortex and hippocampus, compared to the cerebellum, thalamus and medulla, indicating an increased selective vulnerability of these brain subregions (P<or=0.05).
  • Despite significant DNA fragmentation indicated by high-concentrations TUNEL-positive cells, no morphologic evidence of apoptosis or necrosis was observed in this acute model.
  • CONCLUSION: The data indicate that sensory and motor neocortex and hippocampal neurons are selectively vulnerable to neurologic injury after HCA as indicated by elevated levels of TUNEL-positive cells in these brain regions.
  • The absence of morphological evidence of apoptosis or necrosis with high levels of TUNEL-positive cells, strongly suggests activation of the apoptotic mechanisms at this early stage.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17670490.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


72. Larsen BT, Bubolz AH, Mendoza SA, Pritchard KA Jr, Gutterman DD: Bradykinin-induced dilation of human coronary arterioles requires NADPH oxidase-derived reactive oxygen species. Arterioscler Thromb Vasc Biol; 2009 May;29(5):739-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Hydrogen peroxide (H2O2) is an endothelium-derived hyperpolarizing factor in human coronary arterioles (HCAs).
  • Superoxide and H2O2 production was assayed in HCAs and human coronary artery endothelial cells (HCAECs) using dihydroethidium and dichlorodihydrofluorescein histofluorescence, respectively.
  • Diameter changes of HCAs were measured by videomicroscopy.
  • NADPH oxidase subunits Nox1, Nox2, Nox4, p22, p47, and p67 were each expressed in HCA endothelium.
  • In HCAs or HCAECs incubated with dihydroethidium and dichlorodihydrofluorescein, BK induced superoxide and H2O2 formation, which was inhibited by gp91ds-tat or apocynin but not by gp91scram-tat or rotenone.
  • HPLC analysis confirmed that BK specifically induced superoxide production.
  • CONCLUSION: We conclude that endothelial NADPH oxidase is a functionally relevant source of H2O2 that mediates agonist-induced dilation in the human heart.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hypertension. 2000 Aug;36(2):270-5 [10948089.001]
  • [Cites] J Clin Invest. 2000 Dec;106(12):1521-30 [11120759.001]
  • [Cites] Circ Res. 2001 Jan 19;88(1):44-51 [11139472.001]
  • [Cites] Circulation. 2001 Apr 17;103(15):1992-8 [11306529.001]
  • [Cites] Circ Res. 2001 Aug 31;89(5):408-14 [11532901.001]
  • [Cites] Hypertension. 2001 Nov;38(5):1162-6 [11711515.001]
  • [Cites] Circ Res. 2002 May 17;90(9):1028-36 [12016270.001]
  • [Cites] Eur J Clin Invest. 2002 Oct;32(10):732-7 [12406020.001]
  • [Cites] Hypertension. 2002 Nov;40(5):755-62 [12411473.001]
  • [Cites] Antioxid Redox Signal. 2002 Dec;4(6):899-914 [12573139.001]
  • [Cites] Circ Res. 2003 Feb 7;92(2):e31-40 [12574154.001]
  • [Cites] Free Radic Biol Med. 2003 Jun 1;34(11):1359-68 [12757846.001]
  • [Cites] J Renin Angiotensin Aldosterone Syst. 2003 Jun;4(2):51-61 [12806586.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Aug;285(2):R277-97 [12855411.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2003 Jul 1;23(7):1224-30 [12763764.001]
  • [Cites] Trends Pharmacol Sci. 2003 Sep;24(9):471-8 [12967772.001]
  • [Cites] Circ Res. 2003 Sep 19;93(6):573-80 [12919951.001]
  • [Cites] Pharmacol Rev. 1995 Mar;47(1):25-49 [7784479.001]
  • [Cites] J Clin Invest. 1996 Apr 15;97(8):1916-23 [8621776.001]
  • [Cites] J Biol Chem. 1996 Sep 20;271(38):23317-21 [8798532.001]
  • [Cites] Circulation. 1997 Nov 18;96(10):3570-8 [9396457.001]
  • [Cites] Circulation. 1999 Jun 22;99(24):3132-8 [10377076.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5727-32 [15824309.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2005 May;25(5):995-1001 [15718491.001]
  • [Cites] Cardiovasc Res. 2005 Oct 1;68(1):26-36 [16009356.001]
  • [Cites] Cell Signal. 2006 Jan;18(1):69-82 [15927447.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H491-9 [16258029.001]
  • [Cites] Antioxid Redox Signal. 2006 Sep-Oct;8(9-10):1609-19 [16987015.001]
  • [Cites] Trends Pharmacol Sci. 2007 Jan;28(1):32-8 [17150260.001]
  • [Cites] Circ Res. 2008 Jan 4;102(1):59-67 [17975109.001]
  • (PMID = 19213944.001).
  • [ISSN] 1524-4636
  • [Journal-full-title] Arteriosclerosis, thrombosis, and vascular biology
  • [ISO-abbreviation] Arterioscler. Thromb. Vasc. Biol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL68769; United States / NHLBI NIH HHS / HL / R01 HL080704; United States / NHLBI NIH HHS / HL / R01 HL080704-04; United States / NHLBI NIH HHS / HL / P01 HL068769; United States / NHLBI NIH HHS / HL / HL080704-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] BBX060AN9V / Hydrogen Peroxide; EC 1.6.3.1 / NADPH Oxidase; S8TIM42R2W / Bradykinin
  • [Other-IDs] NLM/ NIHMS126047; NLM/ PMC2727937
  •  go-up   go-down


73. Gil MV, Calvo LF, Blanco D, Sánchez ME: Assessing the agronomic and environmental effects of the application of cattle manure compost on soil by multivariate methods. Bioresour Technol; 2008 Sep;99(13):5763-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multivariate analysis was used for interpreting data from a pot experiment using samples of three Spanish soils.
  • Hierarchical cluster analysis (HCA) and principal component analysis (PCA) were used; they perfectly differentiated sample groups both as a function of the treatment applied and by sampling date.
  • Multivariate methods may therefore be useful for the analysis and interpretation of a large number of data in soil research.
  • [MeSH-minor] Animals. Cattle. Cluster Analysis. Environmental Monitoring / methods. Multivariate Analysis. Spain

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036814.001).
  • [ISSN] 0960-8524
  • [Journal-full-title] Bioresource technology
  • [ISO-abbreviation] Bioresour. Technol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Manure; 0 / Soil
  •  go-up   go-down


74. Li W, Gomez E, Zhang Z: Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. J Exp Clin Cancer Res; 2007 Dec;26(4):527-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma.
  • Angiogenesis is an essential process for progression of hepatocellular carcinoma (HCC).
  • The alpha-chemokine stromal cell-derived factor-1 (SDF-1) and its receptor CXCR4 have been recognized for their roles in regulating neoangiogenesis.
  • Formalin-fixed paraffin-embedded tissue sections of 28 HCC, 7 hepatocellular adenoma (HA), 26 cirrotic nodules (CN) and 16 normal liver tissues (NLT) were immunostained for SDF-1 and CXCR4.
  • SDF-1 and CXCR4 are detected in sinusoidal endothelial cells in HCC tissue, and their expressions are significantly higher than in non-HCC tissues.
  • Overexpressions of SDF-1 and CXCR4 in sinusoidal endothelial cells in HCC suggest that the SDF-1/CXCR4 pathway plays a possible role in HCC progression through neoangiogenesis.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Chemokine CXCL12 / metabolism. Liver Neoplasms / metabolism. Receptors, CXCR4 / metabolism
  • [MeSH-minor] Endothelial Cells / metabolism. Humans. Immunohistochemistry. Neovascularization, Pathologic. Signal Transduction

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18365549.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Chemokine CXCL12; 0 / Receptors, CXCR4
  •  go-up   go-down


75. Waldkirch E, Uckert S, Schultheiss D, Geismar U, Bruns C, Scheller F, Jonas U, Becker AJ, Stief CG, Hedlund P: Non-genomic effects of androgens on isolated human vascular and nonvascular penile erectile tissue. BJU Int; 2008 Jan;101(1):71-5; discussion 75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate non-genomic effects of testosterone and dihydrotestosterone (DHT) on isolated human cavernosal arteries (HCA) and corpus cavernosum (HCC) using organ-bath studies and radio-immunoassays (RIA), as non-genomic effects of androgens are reported for vascular smooth musculature and there is evidence that the relaxant response involves a modulation of cyclic nucleotide tissue levels.
  • MATERIALS AND METHODS: The relaxation induced by the cumulative addition of testosterone and DHT (0.01-10 microm) was studied using circular segments of HCA and strip preparations of HCC.
  • CONCLUSION: Rapid androgen-induced relaxation of HCA and HCC occurs via non-genomic mechanisms.

  • Hazardous Substances Data Bank. TESTOSTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868421.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 08J2K08A3Y / Dihydrotestosterone; 3XMK78S47O / Testosterone; E0399OZS9N / Cyclic AMP; H2D2X058MU / Cyclic GMP
  •  go-up   go-down


76. Bicknell DC, Bodmer WF: A mutated HLA-A*0101 allele in the colorectal cell line HCA-7. Tissue Antigens; 2005 Sep;66(3):231-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A mutated HLA-A*0101 allele in the colorectal cell line HCA-7.
  • The colorectal cell line HCA-7 expresses surface human leucocyte antigen-A*0201 (HLA-A*0201), but lacks expression of HLA-A*0101 whilst the normal B-cell line (EVA-1224), derived from the same individual, expresses both surface HLA-A1 and HLA-A2.
  • Amplification refractory mutation system-polymerase chain reaction analysis, using sequence-specific primers, suggested that HCA-7 has a mutation in a 7 base pair (bp) cytosine repeat sequence located at the beginning of Exon 4 (bp 621-627).
  • Cloning and sequencing revealed HCA-7 to have eight cytosine residues in this repeat sequence.
  • Analysis of the mRNA for HLA-A*010 using reverse trancriptase-polymerase chain reaction (RT-PCR), with an allele-specific 5' primer in exon 2 (bp 253-271) and a series of 3' primers in exons 3, 4 and 7 and in the 3'untranslated region, revealed that HCA-7 contained a shortened message terminating in the region of the exon 3/4 boundary.
  • The insertion of an extra cytosine in this region, which is only two bases from the exon 3/4 splice site, is presumed to lead to a splicing defect between exons 3 and 4 resulting in the lack of expression of a functional HLA-A*0101 product.
  • HCA-7 is mismatch repair (MMR) defective due to lack of expression of hMLH1 resulting from hypermethylation of the promoter region.
  • [MeSH-minor] 3' Untranslated Regions. Alleles. Base Pair Mismatch. Cell Line, Tumor. Cloning, Molecular. Cytosine. DNA / metabolism. DNA Primers / genetics. DNA Repair. Exons. Gene Frequency. HLA-A1 Antigen. HLA-A2 Antigen. Humans. Isoelectric Focusing. Polymerase Chain Reaction. Promoter Regions, Genetic. RNA / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101834.001).
  • [ISSN] 0001-2815
  • [Journal-full-title] Tissue antigens
  • [ISO-abbreviation] Tissue Antigens
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / DNA Primers; 0 / HLA-A Antigens; 0 / HLA-A*01:01 antigen; 0 / HLA-A*02:01 antigen; 0 / HLA-A1 Antigen; 0 / HLA-A2 Antigen; 63231-63-0 / RNA; 8J337D1HZY / Cytosine; 9007-49-2 / DNA
  •  go-up   go-down


77. Galloro V: HCA initiates Texas two-step. Allegations spur Baylor joint-venture investigations. Mod Healthc; 2006 May 15;36(20):8-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA initiates Texas two-step. Allegations spur Baylor joint-venture investigations.

  • MedlinePlus Health Information. consumer health - Health Fraud.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752858.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] Legal Cases; News
  • [Publication-country] United States
  •  go-up   go-down


78. Galloro V: LifePoint rethinks HCA deal. Renegotiations are under way for five hospitals. Mod Healthc; 2006 Apr 10;36(15):8-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LifePoint rethinks HCA deal. Renegotiations are under way for five hospitals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16671188.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


79. Shirley Law. Nurs Older People; 2009 Mar 11;21(2):16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Shirley is currently seconded to the Dementia Services Development Centre (DSDC) at the University of Stirling where she is project manager for an innovative RCN-accredited study programme for healthcare assistants (HCAs) working in hospitals and care homes.
  • By the end of its first year, 800 HCAs had undertaken the programme throughout the UK.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27745086.001).
  • [ISSN] 1472-0795
  • [Journal-full-title] Nursing older people
  • [ISO-abbreviation] Nurs Older People
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


80. Becker C: HCA's private ambitions. What twists could the industry expect this time? Mod Healthc; 2006 Jul 31;36(30):8-9, 16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA's private ambitions. What twists could the industry expect this time?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16913009.001).
  • [ISSN] 0160-7480
  • [Journal-full-title] Modern healthcare
  • [ISO-abbreviation] Mod Healthc
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] United States
  •  go-up   go-down


81. Ueda Y: What is the best method for brain protection in surgery of the aortic arch? Retrograde cerebral perfusion. Cardiol Clin; 2010 May;28(2):371-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The technical simplicity of retrograde cerebral perfusion (RCP) together with a highly favorable effect upon stroke rates and survival after aortic arch surgery justifies continued clinical use of RCP in patients requiring hypothermic circulatory arrest (HCA), in particular patients with dissecting or atheromatous arch branches.
  • In clinical practice, using RCP can provide effective brain protection in HCA for about 40 to 60 minutes, although there is a time limitation.
  • [MeSH-major] Aorta, Thoracic / surgery. Aortic Aneurysm, Thoracic / surgery. Cerebrovascular Circulation / physiology. Circulatory Arrest, Deep Hypothermia Induced / adverse effects. Perfusion / methods. Stroke / prevention & control. Vascular Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Stroke.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [CommentIn] Cardiol Clin. 2010 May;28(2):403-4 [20452559.001]
  • (PMID = 20452556.001).
  • [ISSN] 1558-2264
  • [Journal-full-title] Cardiology clinics
  • [ISO-abbreviation] Cardiol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 39
  •  go-up   go-down


82. Seki A, Inoue T, Maegaki Y, Sugiura C, Toyoshima M, Akaboshi S, Ohno K: [Polycystic ovary syndrome and hepatocellular adenoma related to long-term use of sodium valproate in a young woman]. No To Hattatsu; 2006 May;38(3):205-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Polycystic ovary syndrome and hepatocellular adenoma related to long-term use of sodium valproate in a young woman].
  • We report the case of a 28 year-old epileptic female taking VPA, who developed PCOS and later hepatocellular adenoma.
  • At the age of 22 years, she suffered spontaneous rupture of a liver tumor that was diagnosed as hepatocellular adenoma.
  • It is known that abnormality in the sex hormones contributes to the onset of hepatocellular adenoma.
  • Therefore, we speculate that hyperandrogenemia due to VPA contributed to the development of hepatocellular adenoma in this case.
  • [MeSH-major] Adenoma, Liver Cell / chemically induced. Liver Neoplasms / chemically induced. Polycystic Ovary Syndrome / chemically induced. Valproic Acid / adverse effects

  • Genetic Alliance. consumer health - Young syndrome.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16715935.001).
  • [ISSN] 0029-0831
  • [Journal-full-title] No to hattatsu. Brain and development
  • [ISO-abbreviation] No To Hattatsu
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


83. Ao L, Liu JY, Liu WB, Gao LH, Hu R, Fang ZJ, Zhen ZX, Huang MH, Yang MS, Cao J: Comparison of gene expression profiles in BALB/c 3T3 transformed foci exposed to tumor promoting agents. Toxicol In Vitro; 2010 Mar;24(2):430-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, cDNA microarrays were used to analyze gene expression and discern chemical-associated profiles induced by a variety of tumor promoting agents in transformed cells.
  • Two-stage transformation model of BALB/c 3T3 cells was established with MNNG as initiator, and 12-O-tetradecanoylphorbol-13-acetate (TPA), okadaic acid (OA), or cadmium chloride (CdCl(2)) as tumor promoters.
  • Nine morphologically transformed foci were isolated and the anchorage-independent growth of transformed cells was verified.
  • Unsupervised hierarchical clustering analysis revealed that the nine foci were classified into three groups in concordance with the promoters used to induce them and characteristic clusters of genes were identified.
  • Moreover, common gene expression alterations were also observed in foci, including upregulated genes associated with cell proliferation and downregulated genes associated with extracellular matrix.
  • Our results demonstrate the presence of unique gene expression profiles in transformed cells which reflect the etiological chemicals and indicate the importance of characteristic molecular alterations as potential biomarkers of exposure to tumor promoters.
  • [MeSH-minor] Animals. BALB 3T3 Cells. Cell Proliferation / drug effects. Extracellular Matrix. Mice. Protein Array Analysis. Reproducibility of Results. Reverse Transcriptase Polymerase Chain Reaction

  • Hazardous Substances Data Bank. CADMIUM CHLORIDE .
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. OKADAIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ltd. All rights reserved.
  • (PMID = 19840844.001).
  • [ISSN] 1879-3177
  • [Journal-full-title] Toxicology in vitro : an international journal published in association with BIBRA
  • [ISO-abbreviation] Toxicol In Vitro
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 1W21G5Q4N2 / Okadaic Acid; J6K4F9V3BA / Cadmium Chloride; NI40JAQ945 / Tetradecanoylphorbol Acetate
  •  go-up   go-down


84. Franco LM, Krishnamurthy V, Bali D, Weinstein DA, Arn P, Clary B, Boney A, Sullivan J, Frush DP, Chen YT, Kishnani PS: Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis; 2005;28(2):153-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma in glycogen storage disease type Ia: a case series.
  • We present a series of 8 patients (6 males, 2 females) with hepatocellular carcinoma (HCC) and glycogen storage disease type Ia (GSD Ia).
  • Hepatic masses were first detected at an age range of 13-45 years (mean 28.1 years).
  • Age at diagnosis of HCC ranged from 19 to 49 years (mean 36.9 years).
  • Duration between the diagnosis of liver adenomas and the diagnosis of HCC ranged from 0 to 28 years (mean 8.8 years, SD = 11.5).
  • Current guidelines recommend abdominal ultrasonography with AFP and CEA levels every 3 months once patients develop hepatic lesions.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Glycogen Storage Disease Type I / complications. Liver Neoplasms / etiology
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / etiology. Adult. Aged. Aged, 80 and over. Biomarkers. Carcinoembryonic Antigen / blood. Child. Child, Preschool. Female. Humans. Male. Prognosis. Tomography, X-Ray Computed. Ultrasonography. alpha-Fetoproteins / metabolism

  • Genetic Alliance. consumer health - Glycogen Storage Disease.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15877204.001).
  • [ISSN] 0141-8955
  • [Journal-full-title] Journal of inherited metabolic disease
  • [ISO-abbreviation] J. Inherit. Metab. Dis.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Carcinoembryonic Antigen; 0 / alpha-Fetoproteins
  •  go-up   go-down


85. Maoz D, Sharon E, Chen Y, Grief F: Spontaneous hepatic rupture: 13-year experience of a single center. Eur J Gastroenterol Hepatol; 2010 Aug;22(8):997-1000
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous hepatic rupture: 13-year experience of a single center.
  • BACKGROUND: Spontaneous hepatic rupture is a rare clinical event associated with various pathologies of the liver.
  • Most series to date reported the incidence and characteristics of a single etiology.
  • METHODS: Data were collected for all patients admitted with spontaneous hepatic rupture from 1995 to 2007.
  • Hepatocellular adenoma was the cause of the rupture in six female patients, in their second to fourth decade.
  • In the remaining patients, the ruptures were because of hepatocellular carcinoma in two, metastatic gastrointestinal stromal tumor in one, and HELLP syndrome (hemolysis, elevated liver enzymes, and low platelet count) in one.
  • CONCLUSION: Spontaneous hepatic rupture requires a high index of suspicion for a correct and timely diagnosis.
  • [MeSH-major] Adenoma, Liver Cell / complications. Gastrointestinal Stromal Tumors / complications. HELLP Syndrome / physiopathology. Liver Neoplasms / complications. Rupture, Spontaneous / diagnosis. Rupture, Spontaneous / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Hepatocellular / complications. Female. Humans. Male. Middle Aged. Pregnancy. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20555270.001).
  • [ISSN] 1473-5687
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


86. Wang D, Lagerstrom R, Sun C, Bishof L, Valotton P, Götte M: HCA-vision: Automated neurite outgrowth analysis. J Biomol Screen; 2010 Oct;15(9):1165-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HCA-vision: Automated neurite outgrowth analysis.
  • Automating the analysis of neurons in culture represents a key aspect of the search for neuroactive compounds.
  • A number of commercial neurite analysis software packages tend to measure some basic features such as total neurite length and number of branching points.
  • The authors have developed a suite of image analysis tools that will allow researchers to produce quality analyses at primary screening rates.
  • In mixed cell populations, neurons can be filtered and separated from other brain cell types so that neurite analysis can be performed only on neurons.
  • It supports batch processing with a built-in database to store the batch-processing results, a batch result viewer, and an ad hoc query builder for users to retrieve features of interest.
  • The suite of tools has been deployed into a software package called HCA-Vision.
  • The free version of the software package is available at http://www.hca-vision.com.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20855562.001).
  • [ISSN] 1552-454X
  • [Journal-full-title] Journal of biomolecular screening
  • [ISO-abbreviation] J Biomol Screen
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Brain-Derived Neurotrophic Factor
  •  go-up   go-down


87. Sato S, Rai T, Ohira H, Abe K, Saito H, Takahashi A, Sakamoto N, Hoshi N, Suzuki E, Sato Y: Hepatic adenomatous hyperplasia with hyperattenuation on CT during arterial portography: a case report. Fukushima J Med Sci; 2005 Dec;51(2):87-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic adenomatous hyperplasia with hyperattenuation on CT during arterial portography: a case report.
  • We report a 72-year-old man who was admitted to our department with multiple nodules of hepatocellular carcinoma (HCC) in a cirrhotic liver because of HCV infection.
  • Unlike most of the nodules, one in segment 2 (S2) showed hypoattenuation on computed tomography (CT) during hepatic arteriography (CTA), and hyperattenuation on CT during arterial portography (CTAP).
  • Fine needle aspiration biopsy of the nodule established the diagnosis of hepatic adenomatous hyperplasia.
  • Two possibilities are considered: i) greater portal blood flow into the nodule than into the surrounding cirrhotic parenchyma, ii) existence of a period during the course of hepatocarcinogenesis when the portal blood flow into the nodule is higher in density on CTAP.
  • [MeSH-major] Adenoma, Liver Cell / radiography. Liver Neoplasms / radiography
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Carcinoma, Hepatocellular / blood supply. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / radiography. Humans. Hyperplasia. Male. Portography. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16555629.001).
  • [ISSN] 0016-2590
  • [Journal-full-title] Fukushima journal of medical science
  • [ISO-abbreviation] Fukushima J Med Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


88. Blonski W, Reddy KR: Evaluation of nonmalignant liver masses. Curr Gastroenterol Rep; 2006 Feb;8(1):38-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of nonmalignant liver masses.
  • Nonmalignant liver masses are increasingly being recognized with the widespread use of imaging modalities such as ultrasonography, computed tomography, and magnetic resonance imaging.
  • Based on the radiologic appearance, benign lesions can be categorized as solid or cystic, single or multiple, hypervascular or hypovascular.
  • Based on histologic characteristics, they are classified as of hepatocellular, biliary, or mesenchymal origin.
  • In the majority of patients, a proper diagnosis can be made based on these characteristics on imaging modalities alone.
  • This review discusses the various characteristics of the most common benign liver lesions and recommends a practical approach.
  • [MeSH-major] Adenoma, Liver Cell / diagnosis. Focal Nodular Hyperplasia / diagnosis. Hemangioma, Cavernous / diagnosis. Liver / pathology. Liver Neoplasms / diagnosis
  • [MeSH-minor] Cysts / diagnosis. Humans. Hyperplasia. Liver Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Radiol. 2001;11(9):1578-93 [11511877.001]
  • [Cites] Gut. 2002 Jun;50(6):877-80 [12010893.001]
  • [Cites] Radiology. 1991 Jul;180(1):25-30 [2052704.001]
  • [Cites] Radiographics. 2001 Jul-Aug;21(4):895-910 [11452064.001]
  • [Cites] Radiology. 2004 Aug;232(2):420-30 [15286314.001]
  • [Cites] Gut. 2005 Jul;54(7):1021-3 [15951553.001]
  • [Cites] Scand J Gastroenterol Suppl. 2002;(236):81-6 [12408510.001]
  • [Cites] Ultrasound Q. 2004 Dec;20(4):155-69 [15602218.001]
  • [Cites] Abdom Imaging. 1996 Mar-Apr;21(2):117-9 [8661756.001]
  • [Cites] AJR Am J Roentgenol. 1987 Apr;148(4):711-5 [3030082.001]
  • [Cites] Scand J Gastroenterol. 2004 Jan;39(1):67-73 [14992564.001]
  • [Cites] Eur Radiol. 2002 Mar;12 (3):537-44 [11870467.001]
  • [Cites] J Am Coll Surg. 2001 Jul;193(1):36-45 [11442252.001]
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1403-6 [7484574.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):705-12 [10701613.001]
  • [Cites] Eur Radiol. 1999;9(3):428-35 [10087111.001]
  • [Cites] Hepatology. 1992 Oct;16(4):1069-83 [1398487.001]
  • [Cites] J Clin Gastroenterol. 2002 Apr;34(4):463-71 [11907365.001]
  • [Cites] Abdom Imaging. 1999 May-Jun;24(3):262-6 [10227890.001]
  • [Cites] Radiology. 2001 Jun;219(3):699-706 [11376257.001]
  • [Cites] Br J Radiol. 1989 Apr;62(736):335-7 [2653548.001]
  • [Cites] Radiology. 2001 Apr;219(1):61-8 [11274535.001]
  • [Cites] Eur Radiol. 2001;11(2):202-12 [11218015.001]
  • [Cites] Gastroenterology. 2000 Mar;118(3):560-4 [10702207.001]
  • [Cites] J Hepatol. 1985;1(6):573-8 [2997324.001]
  • [Cites] Radiology. 1994 Feb;190(2):387-92 [8284385.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):3-17; discussion 18-9 [14730031.001]
  • [Cites] Ultrasound Med Biol. 2004 Sep;30(9):1089-97 [15550313.001]
  • [Cites] Radiographics. 2000 Mar-Apr;20(2):379-97 [10715338.001]
  • [Cites] Radiology. 1990 Jan;174(1):161-3 [2294544.001]
  • [Cites] Hepatology. 1999 Oct;30(4):889-93 [10498639.001]
  • [Cites] Radiographics. 2001 Jul-Aug;21(4):877-92; discussion 892-4 [11452062.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1441-54 [10584697.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):17-42, v [11218914.001]
  • [Cites] Clin Liver Dis. 2001 Feb;5(1):1-15, v [11218909.001]
  • [Cites] J Ultrasound Med. 1999 Jul;18(7):445-51; quiz 453-4 [10400046.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 1997 Mar;24(3):276-9 [9138172.001]
  • [Cites] Eur J Radiol. 1999 Oct;32(1):52-60 [10580322.001]
  • [Cites] Curr Probl Diagn Radiol. 2004 Nov-Dec;33(6):239-53 [15549050.001]
  • [Cites] J Clin Gastroenterol. 2005 May-Jun;39(5):401-12 [15815209.001]
  • [Cites] Radiol Clin North Am. 1998 Mar;36(2):319-31 [9520985.001]
  • [Cites] Radiology. 2000 Aug;216(2):395-402 [10924560.001]
  • [Cites] J Hepatol. 1991 Jan;12(1):94-9 [2007779.001]
  • [Cites] Eur Radiol. 2005 Aug;15(8):1643-9 [15712000.001]
  • [Cites] Br J Surg. 2001 Jun;88(6):808-13 [11412249.001]
  • [Cites] Lancet. 1973 Oct 27;2(7835):926-9 [4126557.001]
  • [Cites] Gastroenterology. 1983 May;84(5 Pt 1):994-1002 [6299876.001]
  • [Cites] J Comput Assist Tomogr. 2000 Jan-Feb;24(1):61-6 [10667661.001]
  • [Cites] Med Clin North Am. 1975 Jul;59(4):995-1013 [167242.001]
  • [Cites] Radiology. 2000 Jun;215(3):746-51 [10831693.001]
  • [Cites] Radiographics. 1999 Mar-Apr;19(2):431-51 [10194789.001]
  • [Cites] Ann Surg. 1970 Aug;172(2):239-45 [5433290.001]
  • [Cites] AJR Am J Roentgenol. 1998 Feb;170(2):391-5 [9456952.001]
  • [Cites] Gastroenterology. 1985 Nov;89(5):1132-8 [2412930.001]
  • [Cites] J Am Coll Surg. 2000 Sep;191(3):311-21 [10989905.001]
  • [Cites] AJR Am J Roentgenol. 1995 Mar;164(3):625-9 [7863883.001]
  • [Cites] J Clin Gastroenterol. 1990 Aug;12(4):460-5 [1975817.001]
  • [Cites] AJR Am J Roentgenol. 2002 Oct;179(4):1053-7 [12239064.001]
  • [Cites] J Am Coll Surg. 2003 Sep;197(3):392-402 [12946794.001]
  • [Cites] Abdom Imaging. 2000 May-Jun;25(3):255-8 [10823445.001]
  • [Cites] JAMA. 1979 Aug 17;242(7):644-8 [221698.001]
  • [Cites] Am J Obstet Gynecol. 2002 Feb;186(2):195-7 [11854634.001]
  • [Cites] J Clin Ultrasound. 1993 Feb;21(2):115-8 [8381130.001]
  • [Cites] Hepatology. 1995 Sep;22(3):983-93 [7657307.001]
  • [Cites] Semin Liver Dis. 2001 May;21(2):237-49 [11436575.001]
  • [Cites] Radiology. 2000 Mar;214(3):861-8 [10715059.001]
  • [Cites] Arch Surg. 1994 Jul;129(7):712-7 [7517661.001]
  • [Cites] Semin Roentgenol. 1995 Oct;30(4):324-46 [8539643.001]
  • [Cites] Magn Reson Imaging Clin N Am. 1997 May;5(2):241-53 [9113674.001]
  • [Cites] Abdom Imaging. 2001 Sep-Oct;26(5):500-6 [11503088.001]
  • [Cites] Eur Radiol. 1997;7(5):654-8 [9166561.001]
  • [Cites] Clin Liver Dis. 2002 Feb;6(1):119-45 [11933585.001]
  • [Cites] N Engl J Med. 1976 Feb 26;294(9):470-2 [173996.001]
  • [Cites] Adv Surg. 1997;31:127-48 [9408491.001]
  • [Cites] Am Surg. 2001 Feb;67(2):173-8 [11243545.001]
  • [Cites] Radiology. 1995 Aug;196 (2):465-9 [7617862.001]
  • [Cites] Arch Surg. 2001 Sep;136(9):1033-8 [11529826.001]
  • [Cites] Hepatology. 1985 Nov-Dec;5(6):1194-200 [4065824.001]
  • [Cites] Liver Transpl Surg. 1997 Mar;3(2):160-5 [9346730.001]
  • (PMID = 16510033.001).
  • [ISSN] 1522-8037
  • [Journal-full-title] Current gastroenterology reports
  • [ISO-abbreviation] Curr Gastroenterol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 81
  •  go-up   go-down


89. Güzel O, Innocenti A, Hall RA, Scozzafava A, Mühlschlegel FA, Supuran CT: Carbonic anhydrase inhibitors. The nematode alpha-carbonic anhydrase of Caenorhabditis elegans CAH-4b is highly inhibited by 2-(hydrazinocarbonyl)-3-substituted-phenyl-1H-indole-5-sulfonamides. Bioorg Med Chem; 2009 Apr 15;17(8):3212-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some of these sulfonamides also showed a good selectivity profile for the inhibition of the nematode over the human isozymes CA I and II (selectivity ratios in the range of 1.78-4.95 for the inhibition of ceCA over hCA II).

  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • BindingDB. BindingDB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19201197.001).
  • [ISSN] 1464-3391
  • [Journal-full-title] Bioorganic & medicinal chemistry
  • [ISO-abbreviation] Bioorg. Med. Chem.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0601049; United Kingdom / Biotechnology and Biological Sciences Research Council / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbonic Anhydrase Inhibitors; 0 / Hydrazines; 0 / Indoles; 0 / Isoenzymes; 0 / Sulfonamides; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


90. Lee BH, Seong J, Kim UJ, Won R, Kim J: Behavioral characteristics of a mouse model of cancer pain. Yonsei Med J; 2005 Apr 30;46(2):252-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Behavioral characteristics of a mouse model of cancer pain.
  • Murine hepatocarcinoma cells, HCa-1, were inoculated unilaterally into the thigh or the dorsum of the foot of male C3H/HeJ mice.
  • Bone invasion by the tumor commenced from 7 days after inoculation of tumor cells and was evident from 14 days after inoculation.
  • These results suggest that carcinoma cells injected into the foot of mice may develop severe chronic pain related to cancer.
  • [MeSH-minor] Animals. Bone and Bones / pathology. Carcinoma, Hepatocellular / pathology. Cell Line, Tumor. Cold Temperature. Disease Models, Animal. Foot. Liver Neoplasms / pathology. Male. Mice. Mice, Inbred C3H. Neoplasm Invasiveness. Neoplasm Transplantation. Pain Threshold. Physical Stimulation. Thigh

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res. 1990 Feb 5;508(2):329-32 [2306625.001]
  • [Cites] Cancer Res. 1974 Jan;34(1):61-71 [4809463.001]
  • [Cites] Pain. 1990 Nov;43(2):205-18 [1982347.001]
  • [Cites] Exp Brain Res. 1993;92(3):441-52 [8454008.001]
  • [Cites] Pain. 1993 Nov;55(2):267-73 [8309714.001]
  • [Cites] J Neurosci. 1994 May;14(5 Pt 1):2708-23 [8182437.001]
  • [Cites] Lancet. 1999 May 15;353(9165):1695-700 [10335806.001]
  • [Cites] Pain. 1999 Apr;80(3):521-31 [10342413.001]
  • [Cites] Pain. 1999 Sep;82(3):263-74 [10488677.001]
  • [Cites] J Neurosci. 2001 Dec 1;21(23):9355-66 [11717369.001]
  • [Cites] J Neurosci. 2001 Dec 1;21(23):9367-76 [11717370.001]
  • [Cites] J Neurosci. 1999 Dec 15;19(24):10886-97 [10594070.001]
  • [Cites] Neuroreport. 2000 Mar 20;11(4):657-61 [10757496.001]
  • [Cites] Neuroscience. 2000;98(3):585-98 [10869852.001]
  • [Cites] Yonsei Med J. 2000 Jun;41(3):354-61 [10957890.001]
  • [Cites] Yonsei Med J. 2001 Feb;42(1):30-40 [11293499.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4038-47 [11358823.001]
  • [Cites] Pain. 2002 Mar;96(1-2):129-40 [11932069.001]
  • [Cites] Yonsei Med J. 2002 Jun;43(3):370-6 [12089747.001]
  • [Cites] Int J Cancer. 2003 May 1;104(5):550-8 [12594809.001]
  • [Cites] Pain. 1990 May;41(2):235-51 [2164179.001]
  • (PMID = 15861499.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2823022
  •  go-up   go-down


91. Fioole B, Kokke M, van Hillegersberg R, Rinkes IH: Adequate symptom relief justifies hepatic resection for benign disease. BMC Surg; 2005;5:7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adequate symptom relief justifies hepatic resection for benign disease.
  • BACKGROUND: The purpose of this study was to evaluate the long-term results of partial liver resection for benign liver lesions.
  • METHODS: All patients operated on for benign liver lesions from 1991 to 2002 were included.
  • The diagnosis was haemangioma in 8 patients, FNH in 6, HCA in 13 and angiomyolipoma in 1.
  • CONCLUSION: Long-term follow up after liver surgery for benign liver lesions shows considerable symptom relief and patient satisfaction.
  • [MeSH-major] Angiomyolipoma / surgery. Focal Nodular Hyperplasia / surgery. Hemangioma / surgery. Liver / surgery. Liver Neoplasms / surgery. Postoperative Complications

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 2000 Jul;191(1):38-46 [10898182.001]
  • [Cites] Langenbecks Arch Surg. 1999 Aug;384(4):313-27 [10473851.001]
  • [Cites] Arch Surg. 2001 Sep;136(9):1033-8 [11529826.001]
  • [Cites] Ned Tijdschr Geneeskd. 2002 Feb 2;146(5):210-3 [11851082.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):397-406; discussion 406-7 [12368667.001]
  • [Cites] J Nucl Med. 2003 Feb;44(2):213-21 [12571212.001]
  • [Cites] Ann Surg. 1988 Aug;208(2):190-5 [2840865.001]
  • [Cites] Gut. 1991 Jun;32(6):677-80 [2060877.001]
  • [Cites] Am J Gastroenterol. 1991 Nov;86(11):1645-9 [1951244.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):13-8 [7740799.001]
  • [Cites] World J Surg. 1995 Jan-Feb;19(1):19-24 [7740805.001]
  • [Cites] Ned Tijdschr Geneeskd. 1996 Jan 6;140(1):18-22 [8569904.001]
  • [Cites] Br J Surg. 1996 Jul;83(7):915-8 [8813773.001]
  • [Cites] Br J Surg. 1997 Mar;84(3):314-6 [9117293.001]
  • [Cites] Arch Surg. 1998 May;133(5):510-5; discussion 515-6 [9605913.001]
  • [Cites] Ned Tijdschr Geneeskd. 1998 Nov 7;142(45):2459-63 [10028326.001]
  • [Cites] Ned Tijdschr Geneeskd. 1998 Nov 7;142(45):2463-8 [10028327.001]
  • [Cites] Arch Surg. 1999 Apr;134(4):407-11 [10199314.001]
  • [Cites] Br J Surg. 2001 Jun;88(6):808-13 [11412249.001]
  • (PMID = 15804352.001).
  • [ISSN] 1471-2482
  • [Journal-full-title] BMC surgery
  • [ISO-abbreviation] BMC Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1087495
  •  go-up   go-down


92. Zhang YZ, Shen Y, Wang LF, Ding WY, Xu JX, He J: Magnetic resonance T2 image signal intensity ratio and clinical manifestation predict prognosis after surgical intervention for cervical spondylotic myelopathy. Spine (Phila Pa 1976); 2010 May 1;35(10):E396-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The means of quantizing SI ratio for the disease has not been discussed.
  • All patients had been divided into 3 groups by hierarchical clustering analysis with SI ratio (Group 1: low SI ratio, Group 2: middle SI ratio, and Group 3: high SI ratio).
  • Statistical analyses were performed with SPSS 11.0.
  • RESULTS: There are significant differences between 3 groups by comparing the recovery rate (P < 0.001), age (P = 0.003), duration of disease (P = 0.001), Babinski sign (P < 0.001), preoperative JOA score (P = 0.006), and postoperative JOA score (P < 0.001).
  • By using the multiple comparison analysis, the above results are further shown.
  • CONCLUSION: Patients with low SI ratio who were not too old and had a shorter duration of disease experienced a good surgical outcome.

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20393392.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


93. Smaine FZ, Pacchiano F, Rami M, Barragan-Montero V, Vullo D, Scozzafava A, Winum JY, Supuran CT: Carbonic anhydrase inhibitors: 2-substituted-1,3,4-thiadiazole-5-sulfamides act as powerful and selective inhibitors of the mitochondrial isozymes VA and VB over the cytosolic and membrane-associated carbonic anhydrases I, II and IV. Bioorg Med Chem Lett; 2008 Dec 15;18(24):6332-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The new compounds showed weak inhibitory activity against hCA I (K(I)s of 102 nM-7.42 microM), hCA II (K(I)s of 0.54-7.42 microM) and hCA IV (K(I)s of 4.32-10.05 microM) but were low nanomolar inhibitors of hCA VA and hCA VB, with inhibition constants in the range of 4.2-32 nM and 1.3-74 nM, respectively.

  • COS Scholar Universe. author profiles.
  • BindingDB. BindingDB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18990571.001).
  • [ISSN] 1464-3405
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbonic Anhydrase Inhibitors; 0 / Isoenzymes; 0 / Thiadiazoles; EC 4.2.1.- / Carbonic Anhydrase I; EC 4.2.1.- / Carbonic Anhydrase II; EC 4.2.1.- / Carbonic Anhydrase IV; EC 4.2.1.- / Carbonic Anhydrase V
  •  go-up   go-down


94. Maupin CM, Voth GA: Preferred orientations of His64 in human carbonic anhydrase II. Biochemistry; 2007 Mar 20;46(11):2938-47
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histidine at position 64 (His64) in human carbonic anhydrase II (HCA II) is believed to be the proton acceptor in the hydration direction and the proton donor in the dehydration direction for the rate-limiting proton transfer (PT) event.
  • X-ray data of HCA II suggests that His64 can adopt either an "in" or "out" orientation.
  • In the present work, classical molecular dynamics simulations have been conducted to elucidate the role that the His64 orientation may play in its ability to act as a proton donor/acceptor in HCA II.

  • Hazardous Substances Data Bank. (L)-HISTIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 2001 Feb 13;40(6):1741-8 [11327835.001]
  • [Cites] J Phys Chem B. 2006 Apr 6;110(13):6458-69 [16570942.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2003 Jan;59(Pt 1):93-104 [12499545.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):117-22 [14691245.001]
  • [Cites] Physiol Rev. 1967 Oct;47(4):595-781 [4964060.001]
  • [Cites] Nat New Biol. 1972 Feb 2;235(57):131-7 [4621826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1973 Sep;70(9):2505-8 [4200327.001]
  • [Cites] J Biol Chem. 1976 Sep 25;251(18):5457-63 [823150.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Jan;79(1):101-5 [6948294.001]
  • [Cites] CRC Crit Rev Biochem. 1983;14(3):207-55 [6313293.001]
  • [Cites] Ann N Y Acad Sci. 1984;429:49-60 [6430186.001]
  • [Cites] Bioessays. 1989 Jun;10(6):186-92 [2500929.001]
  • [Cites] Proteins. 1988;4(4):274-82 [3151019.001]
  • [Cites] Biochemistry. 1989 Sep 19;28(19):7913-8 [2514797.001]
  • [Cites] Adv Protein Chem. 1991;42:281-355 [1793007.001]
  • [Cites] J Mol Biol. 1992 Oct 20;227(4):1192-204 [1433293.001]
  • [Cites] J Mol Graph. 1996 Feb;14(1):33-8, 27-8 [8744570.001]
  • [Cites] Biochemistry. 1997 Dec 16;36(50):15758-64 [9398305.001]
  • [Cites] Biophys J. 1998 Jun;74(6):3182-9 [9635771.001]
  • [Cites] Proteins. 1998 Oct 1;33(1):119-34 [9741850.001]
  • [Cites] Biochemistry. 2005 Feb 1;44(4):1097-105 [15667203.001]
  • [Cites] Acc Chem Res. 2006 Feb;39(2):143-50 [16489734.001]
  • [Cites] Biochemistry. 2002 Mar 5;41(9):3235-42 [11863462.001]
  • (PMID = 17319695.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / 1 S10 RR17214-01; United States / NIGMS NIH HHS / GM / R01 GM053148; United States / NIGMS NIH HHS / GM / GM053148-13; United States / NIGMS NIH HHS / GM / GM53148; United States / NIGMS NIH HHS / GM / R01 GM053148-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 4QD397987E / Histidine; EC 4.2.1.- / Carbonic Anhydrase II
  • [Other-IDs] NLM/ NIHMS61946; NLM/ PMC2569863
  •  go-up   go-down


95. Elder I, Tu C, Ming LJ, McKenna R, Silverman DN: Proton transfer from exogenous donors in catalysis by human carbonic anhydrase II. Arch Biochem Biophys; 2005 May 1;437(1):106-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the site-specific mutant of human carbonic anhydrase in which the proton shuttle His64 is replaced with alanine, H64A HCA II, catalysis can be activated in a saturable manner by the proton donor 4-methylimidazole (4-MI).
  • From 1H NMR relaxivities, we found 4-MI bound as a second-shell ligand of the tetrahedrally coordinated cobalt in Co(II)-substituted H64A HCA II, with 4-MI located about 4.5 A from the metal.
  • Binding constants of 4-MI to H64A HCA II were estimated from:.
  • (1) NMR relaxation of the protons of 4-MI by Co(II)-H64A HCA II, (2) the visible absorption spectrum of Co(II)-H64A HCA II in the presence of 4-MI, (3) the inhibition by 4-MI of the catalytic hydration of CO2, and (4) from the catalyzed exchange of 18O between CO2 and water.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • Hazardous Substances Data Bank. COBALT, ELEMENTAL .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15820222.001).
  • [ISSN] 0003-9861
  • [Journal-full-title] Archives of biochemistry and biophysics
  • [ISO-abbreviation] Arch. Biochem. Biophys.
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM 25154
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Imidazoles; 0 / Protons; 142M471B3J / Carbon Dioxide; 3G0H8C9362 / Cobalt; EC 4.2.1.- / Carbonic Anhydrase II; Q64GF9FV4I / 4-methylimidazole; S88TT14065 / Oxygen
  •  go-up   go-down


96. Heiken JP: Distinguishing benign from malignant liver tumours. Cancer Imaging; 2007;7 Spec No A:S1-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinguishing benign from malignant liver tumours.
  • Liver masses are very common and most are benign.
  • It is therefore important to avoid unnecessary interventions for benign lesions, while at the same time ensuring accurate diagnosis of hepatic malignancies.
  • Many cancer patients, like the general population, have incidental benign liver lesions.
  • In planning treatment for cancer patients, it is critical to avoid inappropriate treatment decisions based on misdiagnosis of a benign lesion as a metastasis or primary liver malignancy.
  • This article describes the salient imaging features of the common benign liver masses and outlines a general approach to distinguishing between benign and malignant hepatic lesions.
  • [MeSH-major] Liver Neoplasms / diagnosis
  • [MeSH-minor] Adenoma, Liver Cell / diagnosis. Adenoma, Liver Cell / pathology. Diagnosis, Differential. Focal Nodular Hyperplasia / diagnosis. Focal Nodular Hyperplasia / pathology. Hemangioma / diagnosis. Hemangioma / pathology. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 1995 Jul-Aug;19(4):665-7 [7622710.001]
  • [Cites] AJR Am J Roentgenol. 1995 Oct;165(4):1016-7 [7676959.001]
  • [Cites] Abdom Imaging. 1995 Sep-Oct;20(5):459-61 [7580785.001]
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1403-6 [7484574.001]
  • [Cites] AJR Am J Roentgenol. 1995 Dec;165(6):1407-13 [7484575.001]
  • [Cites] Semin Roentgenol. 1995 Oct;30(4):375-95 [8539646.001]
  • [Cites] Lancet. 1998 Apr 25;351(9111):1251-2 [9643751.001]
  • [Cites] Radiology. 1998 Aug;208(2):543-8 [9680590.001]
  • [Cites] Liver Transpl Surg. 1998 Sep;4(5):388-98 [9724476.001]
  • [Cites] AJR Am J Roentgenol. 1998 Nov;171(5):1433-4 [9798902.001]
  • [Cites] Lancet. 1998 Nov 21;352(9141):1679-80 [9853447.001]
  • [Cites] Am J Gastroenterol. 1998 Dec;93(12):2568-72 [9860429.001]
  • [Cites] Eur Radiol. 1999;9(3):444-9 [10087113.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jun;172(6):1547-54 [10350287.001]
  • [Cites] Eur Radiol. 1999;9(8):1535-42 [10525860.001]
  • [Cites] Radiology. 2005 Feb;234(2):468-78 [15591431.001]
  • [Cites] Radiographics. 2005 Mar-Apr;25(2):321-31 [15798052.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):341-7 [1712664.001]
  • [Cites] Am J Surg Pathol. 1999 Dec;23(12):1441-54 [10584697.001]
  • [Cites] Radiology. 2000 Jan;214(1):167-72 [10644118.001]
  • [Cites] J Comput Assist Tomogr. 2000 Jan-Feb;24(1):61-6 [10667661.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):705-12 [10701613.001]
  • [Cites] Radiographics. 2000 Mar-Apr;20(2):379-97 [10715338.001]
  • [Cites] Radiology. 2000 Mar;214(3):861-8 [10715059.001]
  • [Cites] Radiology. 2000 Aug;216(2):395-402 [10924560.001]
  • [Cites] AJR Am J Roentgenol. 2000 Sep;175(3):687-92 [10954451.001]
  • [Cites] Radiology. 2001 Apr;219(1):69-74 [11274536.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jun;176(6):1493-8 [11373219.001]
  • [Cites] Radiographics. 2001 Jul-Aug;21(4):877-92; discussion 892-4 [11452062.001]
  • [Cites] Radiology. 2001 Dec;221(3):731-9 [11719669.001]
  • [Cites] Radiology. 2002 Jan;222(1):73-80 [11756708.001]
  • [Cites] Radiology. 2002 Mar;222(3):667-73 [11867783.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jul;179(1):81-5 [12076909.001]
  • [Cites] J Comput Assist Tomogr. 2002 Sep-Oct;26(5):815-7 [12439320.001]
  • [Cites] J Magn Reson Imaging. 2003 May;17(5):593-602 [12720270.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):809-17 [12933487.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):3-17; discussion 18-9 [14730031.001]
  • [Cites] N Engl J Med. 1976 Feb 26;294(9):470-2 [173996.001]
  • [Cites] Ann Intern Med. 1976 Aug;85(2):203-4 [942141.001]
  • [Cites] Ann Intern Med. 1977 Feb;86(2):180-2 [835939.001]
  • [Cites] Gastroenterology. 1977 Aug;73(2):386-94 [194813.001]
  • [Cites] Cancer. 1977 Oct;40(4):1765-70 [198106.001]
  • [Cites] Medicine (Baltimore). 1978 May;57(3):223-37 [205759.001]
  • [Cites] AJR Am J Roentgenol. 1979 Mar;132(3):379-87 [106640.001]
  • [Cites] J Comput Assist Tomogr. 1996 May-Jun;20(3):349-55 [8626888.001]
  • [Cites] Radiographics. 1996 Mar;16(2):369-88 [8966294.001]
  • [Cites] Magn Reson Imaging Clin N Am. 1997 May;5(2):255-88 [9113675.001]
  • [Cites] Abdom Imaging. 1997 May-Jun;22(3):274-6 [9107649.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jul;169(1):137-40 [9207513.001]
  • [Cites] AJR Am J Roentgenol. 1998 Feb;170(2):391-5 [9456952.001]
  • [Cites] Gastroenterology. 1985 Nov;89(5):1132-8 [2412930.001]
  • [Cites] AJR Am J Roentgenol. 1985 Dec;145(6):1195-9 [3904370.001]
  • [Cites] Hepatology. 1985 Nov-Dec;5(6):1194-200 [4065824.001]
  • [Cites] J Clin Pathol. 1986 Feb;39(2):183-8 [3950039.001]
  • [Cites] AJR Am J Roentgenol. 1986 Jun;146(6):1149-53 [3518366.001]
  • [Cites] Radiology. 1986 Jul;160(1):53-8 [3520655.001]
  • [Cites] AJR Am J Roentgenol. 1986 Oct;147(4):711-9 [3489370.001]
  • [Cites] Ann Intern Med. 1986 Oct;105(4):547-9 [3019201.001]
  • [Cites] Eur J Radiol. 1991 May-Jun;12(3):228-33 [1855518.001]
  • [Cites] Br J Radiol. 1991 Nov;64(767):1019-22 [1742582.001]
  • [Cites] Radiology. 1992 Feb;182(2):545-8 [1732978.001]
  • [Cites] Radiology. 1992 Sep;184(3):699-703 [1509052.001]
  • [Cites] Radiology. 1993 Jan;186(1):133-8 [8416554.001]
  • [Cites] J Magn Reson Imaging. 1993 Jan-Feb;3(1):51-8 [8381314.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):159-63 [10882267.001]
  • [Cites] AJR Am J Roentgenol. 2000 Jul;175(1):165-70 [10882268.001]
  • [Cites] Cancer. 1979 Oct;44(4):1481-9 [227566.001]
  • [Cites] Gastroenterology. 1979 Dec;77(6):1319-25 [499719.001]
  • [Cites] Lancet. 1980 Feb 9;1(8163):273-6 [6101735.001]
  • [Cites] Radiology. 1980 Oct;137(1 Pt 1):149-55 [7422836.001]
  • [Cites] AJR Am J Roentgenol. 1981 Nov;137(5):983-90 [6975026.001]
  • [Cites] J Comput Assist Tomogr. 1982 Feb;6(1):67-71 [6950959.001]
  • [Cites] AJR Am J Roentgenol. 1982 May;138(5):965-6 [6979189.001]
  • [Cites] Semin Liver Dis. 1981 May;1(2):116-28 [6287645.001]
  • [Cites] J Comput Assist Tomogr. 1983 Feb;7(1):83-9 [6298290.001]
  • [Cites] Gastroenterology. 1983 May;84(5 Pt 1):994-1002 [6299876.001]
  • [Cites] AJR Am J Roentgenol. 1983 May;140(5):953-7 [6301252.001]
  • [Cites] J Comput Assist Tomogr. 1983 Oct;7(5):899-901 [6684129.001]
  • [Cites] Radiology. 1985 May;155(2):417-20 [3983393.001]
  • [Cites] Radiology. 1985 May;155(2):421-3 [2984719.001]
  • [Cites] Radiology. 1985 Sep;156(3):593-5 [3895291.001]
  • [Cites] AJR Am J Roentgenol. 1985 Aug;145(2):213-22 [2992250.001]
  • [Cites] Arch Pathol Lab Med. 1987 Feb;111(2):166-9 [3545138.001]
  • [Cites] AJR Am J Roentgenol. 1987 Apr;148(4):711-5 [3030082.001]
  • [Cites] Am J Surg Pathol. 1987 Mar;11(3):191-6 [3030147.001]
  • [Cites] J Comput Assist Tomogr. 1987 May-Jun;11(3):455-60 [3571588.001]
  • [Cites] AJR Am J Roentgenol. 1987 Jun;148(6):1105-8 [3034012.001]
  • [Cites] J Comput Assist Tomogr. 1987 Jul-Aug;11(4):651-4 [3597890.001]
  • [Cites] Radiology. 1987 Aug;164(2):353-6 [3037591.001]
  • [Cites] AJR Am J Roentgenol. 1987 Nov;149(5):953-7 [3314430.001]
  • [Cites] AJR Am J Roentgenol. 1987 Dec;149(6):1167-70 [3500603.001]
  • [Cites] Hepatology. 1988 May-Jun;8(3):531-7 [2453430.001]
  • [Cites] Radiology. 1988 Sep;168(3):621-3 [2841716.001]
  • [Cites] Radiology. 1988 Nov;169(2):409-15 [3174988.001]
  • [Cites] Ann Surg. 1988 Nov;208(5):558-64 [3190282.001]
  • [Cites] AJR Am J Roentgenol. 1989 Jan;152(1):63-72 [2535770.001]
  • [Cites] AJR Am J Roentgenol. 1989 Mar;152(3):493-9 [2536996.001]
  • [Cites] AJR Am J Roentgenol. 1989 Mar;152(3):505-7 [2536997.001]
  • [Cites] Radiology. 1989 May;171(2):323-6 [2539605.001]
  • [Cites] AJR Am J Roentgenol. 1989 May;152(5):977-83 [2539710.001]
  • [Cites] AJR Am J Roentgenol. 1989 Jun;152(6):1221-6 [2718858.001]
  • [Cites] J Comput Assist Tomogr. 1989 Sep-Oct;13(5):910-2 [2778153.001]
  • [Cites] J Comput Assist Tomogr. 1990 Jan-Feb;14(1):143-5 [2298982.001]
  • [Cites] J Comput Assist Tomogr. 1990 Mar-Apr;14(2):223-8 [2312850.001]
  • [Cites] Radiology. 1990 Jul;176(1):103-6 [2162066.001]
  • [Cites] Radiology. 1990 Jul;176(1):95-101 [2191377.001]
  • [Cites] AJR Am J Roentgenol. 1990 Jul;155(1):55-9 [2112864.001]
  • [Cites] Radiology. 1991 Jul;180(1):25-30 [2052704.001]
  • [Cites] Radiology. 1996 Mar;198(3):881-7 [8628887.001]
  • [Cites] Radiology. 1996 Mar;198(3):889-92 [8628888.001]
  • [Cites] Abdom Imaging. 1993;18(1):32-8 [8431691.001]
  • [Cites] Radiology. 1993 Jul;188(1):53-9 [8390072.001]
  • [Cites] Radiology. 1993 Dec;189(3):863-70 [8234717.001]
  • [Cites] J Nucl Med. 1993 Dec;34(12):2105-10 [8254396.001]
  • [Cites] Radiology. 1994 Jan;190(1):49-52 [8259426.001]
  • [Cites] J Comput Assist Tomogr. 1994 Mar-Apr;18(2):301-4 [8126288.001]
  • [Cites] Radiology. 1994 Apr;191(1):111-3 [8134554.001]
  • [Cites] AJR Am J Roentgenol. 1994 May;162(5):1113-7 [8165993.001]
  • [Cites] AJR Am J Roentgenol. 1994 Jul;163(1):113-6 [8010195.001]
  • [Cites] Arch Surg. 1994 Jul;129(7):712-7 [7517661.001]
  • [Cites] Radiology. 1994 Oct;193(1):43-7 [8090920.001]
  • [Cites] Radiology. 1994 Oct;193(1):49-57 [8090921.001]
  • [Cites] Radiology. 1994 Nov;193(2):507-12 [7972769.001]
  • [Cites] Radiology. 1994 Dec;193(3):665-9 [7972805.001]
  • [Cites] AJR Am J Roentgenol. 1995 Mar;164(3):625-9 [7863883.001]
  • [Cites] J Comput Assist Tomogr. 1995 May-Jun;19(3):412-8 [7790551.001]
  • [Cites] Radiology. 1995 Aug;196(2):465-9 [7617862.001]
  • [Cites] AJR Am J Roentgenol. 1995 Aug;165(2):303-8 [7618545.001]
  • (PMID = 17921080.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 132
  • [Other-IDs] NLM/ PMC2727979
  •  go-up   go-down


97. Herszényi L, Sipos F, Galamb O, Solymosi N, Hritz I, Miheller P, Berczi L, Molnár B, Tulassay Z: Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon. Pathol Oncol Res; 2008 Mar;14(1):31-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon.
  • We determined protein expression of matrix metalloproteinase-9 (MMP-9) in colorectal cancer (CRC), corresponding normal mucosa and colorectal adenomas.
  • For confirmation of immunohistochemical results MMP-9 TaqMan RT-PCR analysis was performed.
  • Expression of MMP-9 was determined on paraffin embedded biopsy sections by immunohistochemistry in 31 CRC patients (from cancer tissue and corresponding normal mucosa) and in 30 patients with adenoma (nine adenomas with high grade of dysplasia).
  • For Taqman RT-PCR analyses normal mucosa (n = 5), adenoma without (n = 6) and with high grade dysplasia (n = 7) and CRC (n = 10) were investigated.
  • Statistical analysis with ANOVA, LSD test and correlation analysis were performed.
  • The MMP-9 expression in CRC was significantly higher compared to adenomas or the normal mucosa (P = 0.001).
  • Significantly higher expression of MMP-9 has been observed in adenomas with high grade dysplasia compared to other adenomas or normal colon (P < 0.001).
  • Diffuse strong MMP-9 expression was present in tumor as well as in stromal cells.
  • In adenoma samples, dysplastic epithelial cells showed moderate intensive cytoplasmic MMP-9 expression, with a clear-cut differentiation between dysplastic and non-dysplastic areas.
  • We demonstrate a significantly higher expression of MMP-9 in adenoma with high grade dysplasia-CRC sequence as compared to normal tissue.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenoma / metabolism. Colon / metabolism. Colorectal Neoplasms / metabolism. Intestinal Mucosa / metabolism. Matrix Metalloproteinase 9 / metabolism
  • [MeSH-minor] Aged. Analysis of Variance. Female. Humans. Immunohistochemistry / methods. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Scand J Clin Lab Invest. 2007;67(5):545-52 [17763191.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):527-31 [16739314.001]
  • [Cites] J Pathol. 2003 Jul;200(4):448-64 [12845612.001]
  • [Cites] Int J Cancer. 2000 Apr 1;86(1):24-9 [10728590.001]
  • [Cites] Dig Liver Dis. 2005 Aug;37(8):584-92 [15869913.001]
  • [Cites] Br J Surg. 2000 Sep;87(9):1215-21 [10971431.001]
  • [Cites] Cancer. 1995 Aug 1;76(3):367-75 [8625115.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2A):489-94 [15152948.001]
  • [Cites] Br J Cancer. 2002 Jun 17;86(12):1876-83 [12085179.001]
  • [Cites] J Surg Oncol. 2002 Jun;80(2):105-10 [12173379.001]
  • [Cites] Am J Gastroenterol. 1997 May;92(5):843-7 [9149198.001]
  • [Cites] J Clin Oncol. 1996 Dec;14(12):3133-40 [8955659.001]
  • [Cites] Mol Cancer Res. 2007 Feb;5(2):153-63 [17314273.001]
  • [Cites] Mol Carcinog. 2008 Jan;47(1):1-8 [17620311.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4293-7 [8183903.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1876-82 [16551873.001]
  • [Cites] Br J Cancer. 2001 Jun 15;84(12):1664-70 [11401321.001]
  • [Cites] Br J Cancer. 1996 Aug;74(3):413-7 [8695357.001]
  • [Cites] Int J Oncol. 2007 Apr;30(4):985-92 [17332939.001]
  • [Cites] World J Gastroenterol. 2006 Mar 7;12(9):1458-62 [16552821.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1135-49 [10694567.001]
  • [Cites] J Clin Pathol. 2002 Oct;55(10):758-62 [12354802.001]
  • [Cites] Carcinogenesis. 1996 Dec;17(12):2581-7 [9006092.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1355-60 [12651627.001]
  • [Cites] Thromb Haemost. 2005 Apr;93(4):676-81 [15841311.001]
  • [Cites] World J Gastroenterol. 2007 Feb 7;13(5):676-82 [17278189.001]
  • [Cites] Cancer. 2001 Nov 15;92(10):2680-91 [11745204.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8229-34 [15623598.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3193-9 [15833850.001]
  • [Cites] Curr Cancer Drug Targets. 2005 May;5(3):203-20 [15892620.001]
  • [Cites] Cell Biochem Funct. 2007 Jul-Aug;25(4):433-41 [16615041.001]
  • [Cites] Surg Endosc. 2006 Mar;20(3):482-6 [16432654.001]
  • [Cites] Mol Cancer Res. 2006 May;4(5):293-302 [16687484.001]
  • [Cites] Br J Cancer. 2007 Nov 19;97(10):1425-31 [17923875.001]
  • [Cites] Clin Exp Metastasis. 1997 Jul;15(4):418-25 [9219730.001]
  • [Cites] BMC Cancer. 2006 Aug 18;6:211 [16916471.001]
  • [Cites] Cancer. 1999 Oct 1;86(7):1135-42 [10506696.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):177-203 [12784996.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8706-12 [16314630.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2091-9 [17404091.001]
  • [Cites] Clin Colorectal Cancer. 2002 Feb;1(4):208-19 [12450419.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):156-64 [11801553.001]
  • [Cites] J Cell Biol. 1999 Jul 26;146(2):517-29 [10427102.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3387-91 [16101153.001]
  • [Cites] Thromb Haemost. 1997 Jul;78(1):497-500 [9198203.001]
  • [Cites] Science. 2002 Mar 29;295(5564):2387-92 [11923519.001]
  • [Cites] Clin Cancer Res. 2007 Jul 15;13(14 ):4117-22 [17634538.001]
  • [Cites] Int J Clin Pharmacol Ther. 2005 Jun;43(6):282-93 [15968885.001]
  • [Cites] Biochim Biophys Acta. 2004 Dec 17;1705(2):69-89 [15588763.001]
  • [Cites] Scand J Gastroenterol. 2008 Mar;43(3):289-98 [18938767.001]
  • [Cites] Curr Opin Chem Biol. 1998 Aug;2(4):466-71 [9736919.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4A):1863-7 [17649785.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18 Suppl):5054s-5059s [1884381.001]
  • [Cites] Dis Colon Rectum. 2000 Mar;43(3):389-95 [10733122.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):577-83 [16133529.001]
  • [Cites] Ann Surg. 1967 Sep;166(3):420-7 [6039601.001]
  • [Cites] Inflamm Bowel Dis. 2006 Nov;12(11):1025-35 [17075343.001]
  • [Cites] Tumour Biol. 2001 Nov-Dec;22(6):383-9 [11786732.001]
  • [Cites] Carcinogenesis. 2005 May;26(5):892-9 [15695237.001]
  • [Cites] Anticancer Res. 2007 Jan-Feb;27(1B):583-8 [17348445.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1161-7 [8883399.001]
  • (PMID = 18347934.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


98. Sakurai A, Katai M, Yamashita K, Mori J, Fukushima Y, Hashizume K: Long-term follow-up of patients with multiple endocrine neoplasia type 1. Endocr J; 2007 Apr;54(2):295-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whether early surgical treatment of non-functioning pancreas islet cell tumor (NFPT) provides a favorable quality of life and life expectancy in patients with multiple endocrine neoplasia type 1 (MEN1) remains controversial.
  • Furthermore, these small NFPTs did not metastasize to regional lymph nodes or the liver.
  • [MeSH-major] Adenoma, Islet Cell / etiology. Adenoma, Islet Cell / surgery. Multiple Endocrine Neoplasia Type 1 / complications. Pancreatic Neoplasms / etiology. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adult. Asian Continental Ancestry Group. Diabetes Mellitus / etiology. Disease Progression. Female. Follow-Up Studies. Glucose Intolerance / etiology. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasms, Second Primary / radiography. Pancreas / physiopathology. Pancreatectomy / adverse effects. Pancreatectomy / methods. Tomography, X-Ray Computed


99. Barreiro CJ, Williams JA, Fitton TP, Lange MS, Blue ME, Kratz L, Barker PB, Degaonkar M, Gott VL, Troncoso JC, Johnston MV, Baumgartner WA: Noninvasive assessment of brain injury in a canine model of hypothermic circulatory arrest using magnetic resonance spectroscopy. Ann Thorac Surg; 2006 May;81(5):1593-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive assessment of brain injury in a canine model of hypothermic circulatory arrest using magnetic resonance spectroscopy.
  • BACKGROUND: Studies have confirmed the neuroprotective effect of diazoxide in canines undergoing hypothermic circulatory arrest (HCA).
  • We demonstrated that noninvasive measurement of NAA:Cho with magnetic resonance spectroscopy facilitates assessment of neuronal injury after HCA and allows for evaluation of neuroprotective strategies.
  • METHODS: Canines underwent 2 hours of HCA at 18 degrees C and were observed for 24 hours.
  • Animals were divided into three groups (n = 15 in each group): normal (unoperated), HCA (HCA only), and HCA+diazoxide (pharmacologic treatment before HCA).
  • The NAA:Cho ratios were obtained 24 hours after HCA by spectroscopy.
  • Separate cohorts of HCA (n = 16) and HCA+diazoxide (n = 23) animals were kept alive for 72 hours for daily neurologic assessment.
  • RESULTS: Cortical NAA:Cho ratios were significantly decreased in HCA versus normal animals (1.01 +/- 0.29 versus 1.31 +/- 0.23; p = 0.004), consistent with severe neurologic injury.
  • Diazoxide pretreatment limited neurologic injury versus HCA alone, reflected in a preserved NAA:Cho ratio (1.21 +/- 0.27 versus 1.01 +/- 0.29; p = 0.05).
  • A significant decrease in cortical NAA was observed in HCA versus normal (7.07 +/- 1.9 versus 8.54 +/- 2.1 micromol/g; p = 0.05), with maintenance of normal NAA levels after diazoxide pretreatment (9.49 +/- 1.1 versus 7.07 +/- 1.9 micromol/g; p = 0.0002).
  • Clinical neurologic scores were significantly improved in the HCA+diazoxide group versus HCA at all time points.
  • CONCLUSIONS: Neurologic injury remains a significant complication of cardiac surgery and is most severe after HCA.
  • [MeSH-major] Circulatory Arrest, Deep Hypothermia Induced. Hypoxia, Brain / diagnosis. Magnetic Resonance Spectroscopy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-ASPARTIC ACID .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631640.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R37NS31238-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Vasodilator Agents; 30KYC7MIAI / Aspartic Acid; 997-55-7 / N-acetylaspartate; N91BDP6H0X / Choline; O5CB12L4FN / Diazoxide
  •  go-up   go-down


100. Colli A, Fraquelli M, Massironi S, Colucci A, Paggi S, Conte D: Elective surgery for benign liver tumours. Cochrane Database Syst Rev; 2007;(1):CD005164
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elective surgery for benign liver tumours.
  • BACKGROUND: Benign liver tumours (haemangioma, focal nodular hyperplasia, and hepatic adenoma) have different prevalence and prognosis.
  • Spontaneous rupture and malignant transformation can complicate hepatic adenoma.
  • Elective surgery is controversial, and indications are represented by uncertain diagnosis, presence of symptoms, and prevention of major complications.
  • OBJECTIVES: To assess the beneficial and harmful effects of elective surgery of benign liver tumours.
  • A further search included the proceedings of major hepatological and surgical congresses (Annual Meetings of the American Association for the Study of the Liver (AASLD) and European Association for the Study of the Liver (EASL)), and examination of the references of relevant papers and reference lists of the identified studies.
  • SELECTION CRITERIA: Randomised clinical trials in adult patients with benign liver tumours without indications for emergency surgery in which elective surgery (resection) versus no intervention or sham operation are compared.
  • DATA COLLECTION AND ANALYSIS: All trials identified through searches were evaluated for eligibility for inclusion.
  • We intended to extract relevant data in order to analyse the outcomes as per our published protocol using intention-to-treat analysis.
  • AUTHORS' CONCLUSIONS: We were unable to find evidence supporting or refuting elective surgery for patients with benign liver tumours.
  • [MeSH-major] Adenoma, Liver Cell / surgery. Elective Surgical Procedures. Focal Nodular Hyperplasia / surgery. Hemangioma / surgery. Liver Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17253542.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down






Advertisement